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Abstract 
 
Title: Human GINS, a conserved DNA replication factor and candidate cancer marker 
Nina Marinšek, St John’s College, Cambridge 
The GINS complex (a heterotetramer of Sld5, Psf1, Psf2 and Psf3) is a highly conserved 
DNA replication factor required for the initiation and elongation of DNA replication. GINS 
is believed to associate with Cdc45 and MCM proteins on replicating DNA. The interaction 
between GINS and MCM is also conserved in archaea. 
In my thesis, I explore the subcellular localisation of the GINS complex in relation to the 
MCM proteins and sites of DNA replication by high-resolution confocal microscopy. For 
these studies, I generated and carefully validated purified rabbit polyclonal and mouse 
monoclonal antibodies; these show a specific staining pattern by immunohistochemistry, 
immunoblotting and immunofluorescence. At high-resolution, all GINS antibodies produced 
a focal nuclear pattern, similar to that seen for the MCMs. However, confusingly, 
colocalisation between GINS and MCMs and between the GINS subunits themselves is 
poor. Investigations are continuing to understand this conundrum.  
Given the value of MCM proteins as specific and sensitive markers for cancer screening, I 
investigated whether GINS subunits also have potential diagnostic value. Sld5 and Psf3 
expression is restricted to the proliferative compartment in normal tissue, but is found in the 
majority of cells in a wide range of dysplastic and malignant tissues, including cervix, colon 
and bladder. In vitro studies of tissue culture cells and cell lysates incubated in urine suggest 
that Sld5 protein is more stable than Mcm2 in harsh extracellular environments. In an 
ongoing pilot clinical study of Sld5 protein as a potential biomarker, Sld5 is readily and 
specifically detectable in the cellular fraction of the samples from prostate and bladder 
cancer patients. Work is ongoing to evaluate Sld5 protein levels in the supernatant portion 
of those same urine samples as an easy-to-screen diagnostic/prognostic marker for male 
urogenital cancers. Owing to their stability, GINS proteins hold promise as independent or 
complementary markers to the MCM proteins for cancer screening in harsh extracellular 
environments such as urine.  
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Chapter 1 Introduction 
1.1 Cell cycle 
The cell division cycle is the reproductive cycle of the cell. In eukaryotes, one cycle (or the 
time between two cell divisions) is further divided into multiple temporally distinct stages 
(Figure 1.1) to accommodate various key processes that must take place before a cell can 
physically divide again, including growth, replenishment of energy levels and faithful 
replication of the genetic material. The process of eukaryotic DNA replication occurs in the 
S phase of the cell cycle. This is separated from the process of chromosome segregation and 
cell division (M phase) by two gap phases, G1 and G2. This separation of processes of 
chromosomal replication and mitosis and the underlying molecular mechanisms or 
checkpoints in each cell cycle phase play an important role in maintaining genomic stability, 
i.e. in ensuring that cell division does not occur before all of the DNA has been faithfully 
replicated, and that further cell division does not occur until the next cycle, thus keeping the 
copy number of all genomic loci within normal levels (between 1 and 2) (Takeda & Dutta, 
2005). Over-replication could lead to amplification of oncogenes (if the region encoding an 
oncogene is included in the DNA being replicated more than once). Alternatively, 
unreplicated DNA, even in minute amounts, could lead to chromosome breakage at the next 
cell division (Laskey, 2005). 
Cells almost invariably decide whether to divide or not at the start of every cycle, during G1 
phase. The decision is influenced by external stimuli such as presence of growth hormones, 
cell-to-cell and cell-to-substrate interactions and suitable environmental conditions (such as 
nutrient supply), as well as the obvious internal factors (such as the correct size of the cell 
and absence of significant DNA damage). The decision point is known as the start point in 
yeast and restriction point in higher eukaryotes. Once a cell is beyond the start point, it is 
committed to completing the remainder of the cell cycle (subject to numerous further 
internal checkpoints), even if the favourable external stimuli are subsequently removed.  
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Figure 1.1 Phases of the cell division cycle in a proliferating eukaryotic cell. Growth occurs throughout 
the interphase (G1, S and G2 phases). Chromosomal replication is restricted to S phase, whilst mitosis occurs 
in the M phase. The pie chart size depicted for each phase roughly corresponds to the duration of that phase in 
a typical metazoan cell. See text for further details.  
In a typical metazoan somatic cell, the DNA replication period (S phase) is at least several 
hours in length, and the entire cell cycle takes roughly 24h to complete. This is in stark 
contrast to the early embryos. For example, Drosophila early embryos take around 8min to 
undergo one round of cell division, but do not incorporate gap phases (Edgar et al., 1986). 
On the other hand, in some populations of somatic cells (for instance, in a tissue), the cell 
cycle often takes a lot longer than 24h to complete, with cells arresting for days or months 
before the restriction point. If the arrested cells downregulate a set of key replication 
proteins in the process, they are said to be in a G0 arrest or in a state of replicative 
quiescence (Figure 1.1). This state is fully reversible when environmental conditions 
become favourable again, whereas cells that exit the cell cycle during G1 to differentiate 
cannot enter back into the cell cycle without global reprogramming. Molecular events of 
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quiescence and re-entry into the cell cycle are targeted by many oncogenes and tumour 
suppressor genes (Blow & Gillespie, 2008). 
1.2 DNA replication in the three domains of life 
DNA replication is a complex and tightly regulated process that is essential for all 
proliferating cells. Understanding the replication process and the controls and checkpoints 
involved can therefore not only increase our appreciation of this crucial mechanism, but also 
further our understanding of cancer, where cells proliferate outside of the normal restraints 
of the cell cycle. Studies of DNA replication have already proved useful in the discovery of 
new methods of cancer detection and therapy (Gonzalez et al., 2005). 
DNA replication is carried out by the multiprotein complex termed the replisome, which is 
assembled at specific DNA sites or origins of replication. The assembly and firing of the 
replisome is a multi-step process, involving an analogous set of proteins in all three domains 
of life (Johnson & O'Donnell, 2005). As summarised in Table 1-i, all living organisms 
contain an origin-binding protein, which defines the origin of replication and serves as a 
landing pad for other molecular building blocks in the process of initiation of DNA 
replication. Helicase loaders recruit the replicative helicase to the origin of replication 
through their interaction with the origin-binding protein. In eukaryotes and possibly in 
archaea, further activation of the replicative helicase has to take place before initiation of 
DNA replication is complete. This activation is achieved through highly regulated assembly 
of further initiation factors at the origin.  
When the helicase is fully activated, it unwinds the DNA duplex in an ATP-dependent 
manner, allowing separation of the two complementary DNA strands to form a replication 
bubble. The primase enzyme synthesises a short RNA primer to initiate the DNA replication 
reaction on both strands. Primers are then extended by DNA polymerases, which are 
tethered to the DNA by a sliding clamp, which is in turn loaded by a clamp loader. The 
leading strand is extended in a single continuous 5’ to 3’ reaction, whereas the lagging 
strand is synthesised discontinuously as Okazaki fragments (several thousand nucleotides, 
but only a few hundred nucleotides long in prokaryotes and eukaryotes, respectively) due to 
the unidirectionality of DNA polymerases. Any exposed single stranded DNA (ssDNA) is 
stabilised by binding of a ssDNA-binding protein. Topoisomerase enzyme is recruited to the 
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sites ahead of the replisome in order to relieve the torsional stress imposed by passing of the 
replication fork. 
As an origin fires, two replication forks (each involving both a leading and lagging strand 
synthesis reaction) move bidirectionally away from each other until they meet another 
replication fork and termination ensues. Replication fork proteins are believed to form one 
big multiprotein complex that coordinates the reactions at the progressing fork, possibly 
involving over 100 proteins in eukaryotic cells (Kelly & Stillman, 2006).  
As summarised in Table 1-i, the key molecular players needed to replicate DNA are 
analogous in all domains of life, hinting at the importance of this fundamental molecular 
mechanism. Importantly, whilst bacterial and eukaryotic machineries are only analogous, 
those of eukaryotes and archaea are actually evolutionary related, allowing us to gain 
valuable insight about the more complex eukaryotic DNA replication by performing 
experiments on the simple archaeal organisms.  
 Eukaryotes Archaea Bacteria 
Initiation    
   Origin-binding protein Orc1–6 (6) DnaA 
   Helicase loaders Cdc6, Cdt1 Orc1/Cdc6
a 
DnaA, DnaC 
   Replicative helicase Mcm2–7 (6) MCM (6e×1) DnaB (6×1) 
   Origin activation GINS (4) Gins15, Gins23b (2×2) 
Gins15c (4×1?) 
N/A 
 Cdc45, Sld2, Sld3, Dpb11 N/A? N/A 
Elongation    
   Primase Polα/primase (4) PriS, PriL (2) DnaG (1) 
   ssDNA-binding protein RPA (3) SSB/RPA (1 or 3)f SSB (4×1) 
   Processive polymerase Polδ (4), Polε (4) PolB (?), PolDh (2) DNA pol III (3) 
   Processive helicase CMG MCM, GINS?g DnaB (6×1) 
   Clamp loader Rfc1–5 (5) RFC (1+(4×1)) γ-complex (5) 
   Sliding clamp PCNA (3×1) PCNA1–3d (3) β-clamp (2×1) 
a single protein that is thought to function both as an origin-binding protein and a helicase loader  
b in more ancient archaeal orders, including Sulfolobus and Pyrococcus lineages 
c in most euryarchaea, including the methanogenic archaea, haloarchaea and nanoarchaea 
d in Crenarchaeota 
e dodecamer (i.e. double hexamer) in some species, such as Methanobacterium thermoautotrophicum 
f remarkable heterogeneity: either a single-subunit or heterotrimeric complex, depending on the species 
g biochemical evidence for GINS stimulation of MCM helicase activity only available for Pyrococcus furiosus 
(Yoshimochi et al., 2008) 
h in Euryarchaeota 
(N): hetero-N-meric complex; (N×1): homo-N-meric complex 
?: insufficient data to make a firm conclusion 
CMG: Cdc45, MCM and GINS 
 
Table 1-i Conserved eukaryotic/archaeal DNA replication machinery compared to bacterial analogues 
(adapted from Johnson & O’Donnell, 2005; Grabowski & Kelman, 2003; Duggin & Bell, 2006; MacNeill, 
2010). 
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Based on the rRNA sequence analysis, archaea constitute the third domain of life (Woese & 
Fox, 1977). Their domain is divided into at least three phyla: Crenarcheota 
(hyperthermophyles), Euryarcheota and Thaumarcheota (previously mesophylic 
geochemical Crenarcheota) (Brochier-Armanet et al., 2008). These peculiar prokaryotes 
share certain features, including gross genomic organisation and metabolic pathways, with 
bacteria, but resemble eukaryotes in the processes of DNA replication, transcription and 
translation (Grabowski & Kelman, 2003). Sequence similarity and the related properties of 
replication proteins (Table 1-i) suggest that the DNA replication apparatuses of archaea and 
eukaryotes are derived from a common ancestor (McGeoch & Bell, 2005, Barry & Bell, 
2006). Owing perhaps to their prokaryotic unicellular mode of life (organisational 
simplicity), the archaeal replication machinery represents a core version of that found in 
eukaryotes. Archaea can therefore provide a powerful model system for the study of basic 
principles underlying eukaryotic DNA replication (Bell & Dutta, 2002, Kelman & Kelman, 
2003, Duggin & Bell, 2006). 
Whilst prokaryotes and viruses have been instrumental in increasing our understanding of 
the basic mechanism of DNA replication, they are of limited use when it comes to shedding 
light onto the regulatory mechanisms underlying the process, including origin activation. 
The regulation of eukaryotic DNA replication is significantly more complex than the 
prokaryotic control of the process, given that bacteria and most archaea only posses a single 
origin of replication and initiate further rounds of DNA replication from that single origin 
before the previous round has been completed (Remus & Diffley, 2009). It is therefore not 
surprising that eukaryotes have developed new molecular mechanisms to enable them to 
fully complete one and only one round of DNA replication per cell cycle, and deal with 
replication at a much larger scale, from multiple origins of replication. These molecular 
players are not evolutionarily related to their prokaryotic counterparts, or are indeed more 
often than not apparently absent from the prokaryotic domains of life (for example, see 
Cdc45, Mcm10 in Table 1-i). Our understanding of eukaryotic regulation of DNA 
replication has therefore generally focused on the use of eukaryotic model organisms, such 
as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Xenopus laevis, Drosophila 
melanogaster and mammalian tissue culture cell lines. 
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1.3 Replication origins 
In 1964, Jacob, Brenner and Cuzin postulated that DNA replication control involves 
sequence elements (termed replicators) that initiate replication. This hypothesis was soon 
tested and confirmed in bacteria and viruses, where the origin sequences are precisely 
defined. In eukaryotes, the budding yeast origins also appear to be directly defined by the 
underlying sequence, whereas for fission yeast and especially for metazoans, other factors 
such as the local chromatin structure and other DNA binding proteins appear to play a more 
critical role in defining the origins of replication (Kelly & Stillman, 2006). 
In budding yeast, origins were also successfully defined by screening the genomic library 
for sequences that would allow an origin-less plasmid encoding an essential metabolic 
enzyme to replicate and therefore allow colony formation on restrictive medium. Budding 
yeast replicators were termed autonomously replicating sequence (ARS) elements, and are 
composed of AT-rich sequences of approximately 150bp. Systematic analysis of deletion 
constructs suggests that ARS elements include essential units that act to identify the origin 
and bind ORC, exclude nucleosomes and help with the initial unwinding of the DNA 
(Aladjem et al., 2006b). The ‘A element’ is the most highly conserved and also the most 
essential unit, responsible for ORC binding (together with a non-essential but also 
ubiquitous ‘B1 element’). Point mutations in the consensus sequence of the A element 
reduce or inactivate ARS function, origin activity and ORC binding in vitro (Bell, 2002, 
Aladjem et al., 2006b).  
Search for origins of replication in Schizosaccharomyces pombe was performed using the 
same screen as the one used in Saccharomyces cerevisiae. However, upon sequencing, the 
identified stretches of fission yeast DNA showed no obvious sequence conservation, 
although the regions were generally rich in A and T residues (Dubey et al., 1994, Clyne & 
Kelly, 1995). The minimum regions required to support initiation of DNA replication were 
generally much larger than in budding yeast (500-1000bp) and composed of multiple AT-
rich elements, which could generally be replaced by other AT-rich sequences and still 
function as replication origins (Okuno et al., 1997). These observation can largely be 
explained by the finding that fission yeast Orc4 contains multiple copies of a DNA-binding 
motif called the AT hook, which binds short AT tracts of a few nucleotides in length 
(Remus & Diffley, 2009). Fission yeast origins are therefore largely defined by the high 
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concentration of AT tracts over a relatively extended stretch of DNA, which is a 
significantly more stochastic picture than in budding yeast and prokaryotes (Kelly & 
Stillman, 2006). 
In metazoans, origin specification appears to be even less dependent on DNA sequence. 
Replicator sequences cannot be easily identified by extrachromosomal assays, such as the 
ones used in yeast (Aladjem et al., 2006b). Furthermore, when DNA is injected into 
Xenopus laevis unfertilised eggs, replication initiates independently of the underlying DNA 
sequence (Harland & Laskey, 1980). In fact, injected DNA replicates with the same 
efficiency even when using a bacterial cloning vector without any eukaryotic sequences or 
when using similarly-sized fragments of animal viral DNA lacking the viral origin of 
replication (Harland & Laskey, 1980, Mechali & Kearsey, 1984). It was later shown that 
DNA replication is independent of DNA sequence only during the first 12 rapid cell cycles 
of the amphibian embryonic development (Hyrien & Mechali, 1993, Hyrien et al., 1995). 
After the mid-blastula transition, the pattern of initiation becomes more widely spaced, 
origins fire asynchronously and the cell cycle slows down to incorporate gap phases 
(Newport & Kirschner, 1982).  
However, it is still not clear what, if any, sequence defines an origin of replication on a 
metazoan chromosome. Various mechanisms have been proposed. For example, before the 
mid-blastula transition initiation is excluded from highly transcribed regions, such as the 
rDNA repeats, suggesting that pattern of initiation adjusts according to the expression 
pattern of genetic loci to avoid frequent collisions between DNA replication and 
transcription machinery (Laskey, 2005). This agrees with the observation that very little 
transcription takes place during the first 12 cell cycles (Newport & Kirschner, 1982) when 
origin definition is independent of DNA sequence and chromatin properties. Transcription 
also affects the timing of origin firing. Genome-wide microarray studies have shown that 
chromosomal regions, which are high in actively transcribed genes replicate early in the S 
phase, whereas heterochromatic regions devoid of actively transcribed genes tend to 
replicate late (MacAlpine et al., 2004). Moreover, studies of the DHFR locus in Chinese 
hamster ovary cells and other experimental systems indicate that a specific origin does not 
fire during every cell cycle, further supporting the current view that metazoan origins, like 
those of fission yeast, consist of relatively simple sequence elements whose usage depends 
on epigenetic factors (Kelly & Stillman, 2006). This hypothesis is consistent with the 
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observation that purified human and fruit fly ORC binds AT-rich DNA with no strong 
preference for any particular DNA sequence but possibly with a higher affinity for 
negatively supercoiled DNA (Vashee et al., 2003, Remus et al., 2004, Kelly & Stillman, 
2006). 
1.4 Initiation of DNA replication 
Origins of replication in all eukaryotes serve as landing pads for the assembly of the 
replication machinery. This reaction is termed the initiation of DNA replication and spans 
both G1 and early S phases of the cell cycle. Control of initiation of DNA replication in the 
context of the cell cycle is especially important in ensuring that the genomic material is 
replicated once and only once per cell division. As such, the mechanism and the key 
molecular players are conserved throughout eukaryotes. Eukaryotic initiation involves an 
ordered multi-step assembly of replication factors (DePamphilis et al., 2006, Bell & Dutta, 
2002, Remus & Diffley, 2009). This assembly is in turn regulated by a set of cyclin-
dependent kinases (CDK) and Cdc7-Dbf4-dependent kinase (DDK). I will discuss each of 
these two groups of proteins in turn, mainly in the context of budding yeast, which has been 
the most extensively studied model organism. The initiation reaction in fission yeast and 
metazoans follows the same principle, although the roles of some molecular players, 
especially Sld2-Sld3-Dpb11 homologues that ultimately do not form part of the RPC, differ 
slightly or still remain to be fully elucidated, as reviewed in detail elsewhere (Labib, 2010).  
As illustrated in Figure 1.2, in early G1 phase of the cell cycle, an ordered and highly 
regulated assembly of the pre-RC takes place at the origins, where the origin-binding 
complex (ORC) binds the origin and through the interaction between Cdc6 and Cdt1 loads 
the MCM:Cdt1 complex. ORC and Cdc6 belong to the AAA+ family of ATP binding 
proteins, a family that commonly forms ring- or spiral-shaped structures (Evrin et al., 2009). 
ATP hydrolysis by Cdc6 is required for MCM loading, and ATP hydrolysis by Orc1 
facilitates the release of MCM from ORC, thus completing the loading (Bowers et al., 2004, 
Randell et al., 2006), possibly similarly to the way that the spiral-shaped structure of RFC 
AAA+ proteins destabilises the PCNA ring during DNA loading (Bowman et al., 2004, 
Trakselis & Bell, 2004). Multiple MCM complexes are loaded at each ORC-bound origin. 
Once loaded, they are thought to slide bidirectionally away from the origin along the DNA 
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duplex (Remus et al., 2009, Evrin et al., 2009). This reaction licenses the origins for 
replication, but does not activate the MCM.  
In late G1/S phase, another set of initiator proteins including Mcm10, Sld2 (RecQL4 in 
metazoa), Sld3 (possibly Treslin/Ticrr in metazoa) (Sanchez-Pulido et al., 2010), Cdc45, 
GINS and Dpb11/Cut5/Mus101/TopBP associates with the origins to form the pre-initiation 
complex (pre-IC). The assembly of the pre-IC is regulated by S-phase CDKs and DDK. In 
yeast, CDKs phosphorylate Sld2 and Sld3, which promotes their binding to the C- and N-
terminal BRCA1 C-terminus (BRCT) repeats of Dpb11, respectively (Zegerman & Diffley, 
2007, Tanaka et al., 2007, Botchan, 2007). From other work in budding yeast, it has been 
proposed that the main role of DDK is to phosphorylate the MCM loaded at origins (Sheu & 
Stillman, 2006, Francis et al., 2009). The main targets of DDK appear to be the unordered 
N-termini of Mcm2, Mcm4 and Mcm6 (Labib, 2010). In the case of Mcm4, this 
phosphorylation relieves the replication-inhibiting activity of the N-terminal tail (Sheu & 
Stillman, 2010).  
The assembly of the pre-IC intermediate ultimately leads to activation of the MCM helicase, 
local DNA unwinding and recruitment of the polymerases and a multitude of other proteins 
that form part of the replisome progression complex (RPC) (Gambus et al., 2006). This 
completes the initiation of DNA replication, which is illustrated in Figure 1.2. 
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Figure 1.2 Initiation of DNA replication at a budding yeast origin (adapted from Marinsek et al., 2006, 
Botchan, 2007, Labib, 2010 and Remus & Diffley, 2009). MCMs are loaded onto the origins (surrounding 
dsDNA) in G1 phase, mediated by the concerted action of Cdt1, Cdc6 and ORC. MCMs appear to be loaded 
as a double hexamer, and multiple MCMs can be loaded per origin. Cdc45:Sld3 is recruited to early origins in 
G1 phase (and to later origins in S phase just before they fire), but a stable association between Cdc45 and 
MCM is only detected after pre-IC formation. During G1/S transition the protein kinase activity is 
upregulated. Importantly, DDK is thought to act on N-termini of Mcm2-4-6 in situ and CKD phosphorylates 
Sld2-3, which in their phosphorylated state display an increased affinity for BRCT repeats of Dpb11. 
Phosphorylated Sld3 bound at the origins therefore helps to recruit the pre-LC (association of Sld2, Dpb11, 
GINS and Pol ε) to form a stable CMG complex. This ultimately leads to the activation of MCM helicase and 
recruitment of DNA polymerases and various other factors that are essential for the elongation reaction of 
DNA replication and together form the RPC. Only the most relevant members of the RPC are depicted here for 
simplicity. 
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When the origins fire, re-initiation of replication is prevented by inactivation of certain pre-
RC factors, the exact mechanism of which depends on the organism (reviewed in Arias & 
Walter, 2007). In yeast, one mechanism through which this is achieved is through 
phosphorylation of all pre-RC components and the export of MCM proteins from the 
nucleus (Labib et al., 1999). In metazoa, this is achieved through a combination of (a) 
CyclinA:Cdk2 activity, which seems to phosphorylate the MCM complex and thus prevent 
rebinding to origins until mitosis, when dephosphorylation occurs; and (b) the presence of 
geminin protein, which binds Cdt1 during S, G2 and M phases, preventing further MCM 
loading (McGarry & Kirschner, 1998, Tada et al., 2001, Wohlschlegel et al., 2000, 
Hodgson et al., 2002).  
The underlying theme of various molecular mechanisms that prevent re-initiation of 
replication is the temporal and spatial separation of the loading and activation of the 
replicative helicase (MCM), as illustrated in Figure 1.3. Loading of an inactive MCM 
complex occurs in G1 phase whereas the activation can only take place in S phase 
specifically for MCM complexes loaded at origins. Once S phase is initiated and MCM 
proteins are displaced from the chromatin by the passage of replication forks, cells are 
unable to load further MCM complexes onto the DNA because hyper-phosphorylation 
prevents re-binding (Todorov et al., 1995, Coverley et al., 1998). This ensures that MCM 
loading does not occur until the metaphase-to-anaphase transition in mitosis, when CDK 
activity is abolished and MCM phosphorylation is reversed. The end result is that 
chromosomal replication at each origin initiates only once during the cell cycle. The two-
step ‘lock and load’ mechanism of assembly is also important for coordinating the processes 
of DNA replication with cell growth and extracellular signals (Remus & Diffley, 2009). The 
same behaviour of MCM proteins is observed when cells enter quiescence. Namely, MCMs 
appear to be displaced from chromatin within the first few days after cells enter quiescence 
and are then gradually degraded, consistent with their essential role as replication licensing 
factors (Stoeber et al., 2001). 
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Figure 1.3 DNA licensing reaction (adapted from Laskey, 2005). Regulation of MCM protein complex 
at different stages of the cell cycle to ensure one and only one round of DNA replication per cell division. In 
G1 phase, MCM proteins are loaded onto the origins of replication with the help of ORC, Cdt1 and Cdc6 
proteins. This is the only part of the cell cycle when cells are competent to perform the licensing reaction 
(LRC). During S phase, MCM proteins are displaced from the replicated chromatin as the replication forks 
progress. De novo binding to nascent chromatin is prevented until the next G1 phase by various mechanisms, 
depending on the organism, as detailed in the text. During quiescence (G0), MCMs are rapidly displaced from 
chromatin and more slowly degraded. Cyclin E is required to load MCM during escape from quiescence 
(Coverley et al., 2002, Geng et al., 2003). 
Cyclin-dependent kinases (CDKs) and Dbf4-dependent kinase (DDK) are the master drivers 
of cell-cycle progression (Blow & Dutta, 2005) together with the proteolysis-marking 
activity of the anaphase promoting complex (APC). In short, the cell cycle is divided into 
two functional states (Figure 1.4). The first one is limited to G1 phase and is marked by low 
kinase activity and high APC activity, which promotes pre-RC assembly or origin licensing. 
The second state encompasses S, G2 and M phases and is marked by high kinase and low 
APC activity. This promotes origin firing but at the same time prevents further pre-RC 
assembly (Arias & Walter, 2007). The concerted action of CDKs, DDK and APC ensures 
that DNA is replicated once and only once during each cell cycle. Whilst CDKs and DDK 
drive the cell-cycle progression, cell cycle checkpoint mechanisms act as decision points to 
override the action of CDKs/DDK/APC and stop further cell cycle progression when 
problems, such as DNA damage or collapsed forks during replication, arise (Figure 1.4). For 
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example, the checkpoint that controls entry into mitosis remains active until such a time that 
all DNA replication is completed including any proof-reading steps. This ensures that only 
compete and faithful genomes are passed on to the two daughter cells. 
 
Figure 1.4 Cell cycle drivers and checkpoints (adapted from Arias & Walter, 2007). 
1.5 MCM protein complex 
The eukaryotic MCM (minichromosome maintenance) protein complex consists of 
evolutionarily conserved subunits Mcm2-7. As reviewed by Bochman and Schwacha 
(Bochman & Schwacha, 2009), MCM2, MCM3 and MCM5 genes were first identified in 
Saccharomyces cerevisiae in a screen for genes responsible for faithful segregation of 
plasmids (i.e. minichromosomes), giving the protein family its name (Maine et al., 1984). 
Similarly, mcm6 was initially isolated in Schizosaccharomyces pombe as a chromosome 
segregation mutant mis5 (Takahashi et al., 1994). Mcm4 and Mcm7 identified in 
Saccharomyces cerevisiae were initially named Cdc54 and Cdc47 (cell-division-cycle), 
respectively (Hennessy et al., 1991, Moir et al., 1982). Homologues of yeast MCM proteins 
were very soon characterised in higher eukaryotes under a variety of names, including 
BM28 as the human homologue of Mcm2 (Todorov et al., 1994), P1 protein as the human 
homologue of Mcm3 (Thommes et al., 1992) and Cdc46 as the murine homologue of Mcm5 
(Kimura et al., 1995). Based on their sequence homology, the MCM protein family 
nomenclature was later simplified to Mcm2-7 in all eukaryotic species (Chong et al., 1996).  
Importantly, MCM protein family does not include Mcm1 or Mcm10, which were identified 
in the same budding yeast screen (Maine et al., 1984), but do not show any sequence 
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homology to Mcm2-7 (Bell & Dutta, 2002). Mcm10 is also an essential DNA replication 
factor that interacts with the MCM and Polα (Zhu et al., 2007), whereas Mcm1 is a 
transcription factor. On the other hand, MCM protein family includes Mcm8 and Mcm9, 
which were only identified more recently in humans based on sequence homology to the 
other MCM proteins (Johnson et al., 2003, Lutzmann et al., 2005, Gozuacik et al., 2003, 
Yoshida, 2005). Unlike Mcm2-7, Mcm8 and Mcm9 are not universally conserved in 
eukaryotes, but their interlinked pattern of presence or absence suggests that they might 
have related functions (Liu et al., 2009). Recent publications seem to propose a function for 
Mcm9 in pre-RC formation (Lutzmann & Mechali, 2008), whereas Mcm8 binds to DNA 
specifically during S-phase and is only required for processive DNA synthesis during 
elongation but not for replication licensing during G1 (Maiorano et al., 2005). This suggests 
that the main functions of these two proteins, if related, are temporarily distinct, but clearly 
more work is needed to better define the relationship between Mcm8 and Mcm9, and 
between these two proteins and the conserved Mcm2-7. 
MCM complex is thought to form a heterohexamer with a ring structure made up of one 
molecule each of Mcm2-7 subunits (Adachi et al., 1997, Sato et al., 2000). Each subunit has 
a highly conserved C-terminus, which shows sequence homology to hexameric DNA 
helicases and includes an ATPase motif (Blow & Dutta, 2005). ATPase motifs are located at 
the interface between subunits, with the Walker A motif from one subunit interacting with 
the arginine finger from the adjacent subunit to make up the ATPase active site (Davey et 
al., 2003). The single archaeal homologue (Table 1-i) has a similar structure of either 
homohexameric or homo-dodecameric tertiary structure, depending on the species, and 
shows in vitro helicase activity (Barry & Bell, 2006). The MCM complex has therefore long 
been considered as the best candidate for the eukaryotic replicative helicase. 
Clear biochemical data supporting the MCM helicase hypothesis has been lacking. 
Historically, one of the initial reasons that hampered the biochemical studies of the MCM 
complex was that SV40 viral DNA replication, which was one of the first DNA replication 
systems to be extensively studied, uses its own (large T antigen) viral helicase (which also 
acts as an origin recognition complex), whilst hijacking other pre-RC components from the 
host cell’s proteome (Stillman, 2005). However, even when MCM was purified and studied 
biochemically, helicase activity could not be detected and MCM purification methods often 
resulted in a very heterogeneous population, containing multiple subcomplexes ranging 
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from monomers to very large complexes (Evrin et al., 2009). Interestingly, certain MCM 
subcomplexes, such as Mcm4-6-7, display in vitro helicase activity (Ishimi, 1997, Sato et 
al., 2000). However, only the heterohexamer that contains all six MCM subunits can 
support replication in Xenopus egg extracts (Prokhorova & Blow, 2000), suggesting that 
these in vitro studies of MCM subcomplexes might not have a direct in vivo link. In recent 
years, significant progress has been made in explaining this conundrum. Firstly, Bochman 
and Schwacha observed a weak Mcm2-7 in vitro helicase activity that is very heavily anion-
dependent (Bochman & Schwacha, 2008), explaining why it had not been identified in vitro 
previously. Secondly, reports in the last few years have identified a very good candidate for 
the processive helicase in the form of the CMG complex, which not only contains the MCM 
proteins, but also Cdc45 and GINS (Moyer et al., 2006, Pacek et al., 2006). I will return to 
this point when reviewing our current knowledge of the GINS protein complex (section 
1.6).  
From a functional point of view, it is not surprising that helicase activity of the eukaryotic 
MCM complex has been difficult to reproduce in vitro, given how central the regulation of 
MCM is to ensuring that DNA replication occurs once and only once during the cell cycle 
(section 1.4). The main difference between the prokaryotic and eukaryotic helicase and its 
regulation is that whilst the bacterial (and possibly also the archaeal) helicase is loaded in its 
active form, eukaryotic MCM helicase is loaded in its inactive form and is only activated in 
situ at the origins of replication (Remus & Diffley, 2009). Loading and activation of the 
eukaryotic MCM helicase in vivo involves many factors, as depicted in Figure 1.2, and the 
exact molecular mechanism of the activation is not clear. A combination of recent reports 
on pre-RC formation (Remus et al., 2009, Evrin et al., 2009) and the biochemistry of the 
CMG complex (Ilves et al., 2010) is beginning to allow us to speculate on the exact mode of 
activation and helicase action, as discussed in more details at the end of the next section 
(1.6).   
All in all, there is compelling and ever growing evidence to suggest that Mcm2-7 is the 
replicative helicase in eukaryotic organisms. Nevertheless, it should be noted that this 
hypothesis is not supported by high-resolution confocal microscopy data in higher 
eukaryotes. In a wide range of metazoan cells, including frog, hamster, mouse and human 
cells, MCMs are not concentrated at the sites of DNA replication and MCM proteins do not 
appear to colocalise with the core fork proteins such as RPA and PCNA (Figure 1.5) 
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(Madine et al., 1995a, Madine et al., 1995b, Krude et al., 1996, Dimitrova et al., 1999). It 
should be noted that according to the MCM licensing model (Figure 1.3), MCMs do 
preferentially mark unreplicated DNA. However, given their functional role at the forks 
(Figure 1.2), a subpopulation of MCM molecules would be expected to localise with DNA 
replication. This inability to detect MCM protein at the replication forks (as well as their 
vast excess compared to number of origins of replication) has been termed the ‘MCM 
paradox’ (Hyrien et al., 2003). Its resolution is considered important for the complete 
understanding of the function of the Mcm2-7 protein complex in the process of DNA 
replication (Laskey & Madine, 2003, Blow & Dutta, 2005, Hyrien et al., 2003). I will 
review the MCM paradox in more detail in the introduction to Chapter 4. 
 
Figure 1.5 MCM protein is not concentrated at sites of DNA replication (reproduced from Madine et 
al., 1995b). Nucleus of a single Xenopus cultured cell immunostained for newly replicated DNA using biotin-
dUTP (red) and Mcm3 (green). Immunostaining using RPA and biotin-dUTP produces a substantially higher 
degree of colocalisation than the image presented here (data not shown; Madine et al., 1995b).  
1.6 GINS protein complex 
GINS is one of the most recently identified DNA replication factors (Labib & Gambus, 
2007, MacNeill, 2010). It was independently characterised by three groups in 2003 
XlMcm3
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(Kanemaki et al., 2003, Takayama et al., 2003, Kubota et al., 2003). Since then, its role at 
the very heart of the replication process has been well corroborated in the literature, and 
GINS is emerging both as an important player in the pre-IC formation and the progression 
of the replisomes.  
The GINS heterotetramer is comprised of four evolutionarily conserved components (see 
Table 1-ii): Sld5 (synthetic lethality with dpb11-1), Psf1, Psf2, and Psf3 (partner of Sld 
five), which also give the complex its name (go-ichi-ni-san, meaning 5-1-2-3 in Japanese; 
Takayama et al., 2003).  As the acronyms imply, the first subunit to be discovered was Sld5, 
namely in the budding yeast screen aimed at identifying interacting partners of Dpb11 by 
screening for mutations that are lethal when combined with a permissive mutation dpb11-1. 
Interestingly, in addition to SLD5 this screen also identified novel genes SLD2, SLD3 and 
re-isolated SLD1 and SLD4, which turned out to be identical to DPB3 (the third largest 
subunit of Polε) and CDC45, respectively (Kamimura et al., 1998). The remaining three 
budding yeast subunits of the GINS complex were subsequently identified by a combination 
of Sld5 multicopy suppression screens and co-immunoprecipitation experiments (Takayama 
et al., 2003). During the same time, Sld5, Psf2 and Psf1 were also independently isolated in 
a screen for strains defective in cell cycle progression using a collection of heat-inducible 
degron-tagged budding yeast proteins of unknown function (Kanemaki et al., 2003). 
Protein name Alternative name Calculated molecular weight 
Sld5 GINS4 25,916 Da 
Psf3 GINS3 24,404 Da 
Psf2 GINS2 21,297 Da 
Psf1 GINS1 22,857 Da 
Table 1-ii Human GINS subunits. Source: NCBI database (accessed online). 
GINS subunits lack known motifs but are distantly related to each other, suggesting that the 
four subunits are a result of two duplication events, first ancestral GINS into Sld5/Psf1- and 
Psf2/Psf3-like proteins, and then each of these two proteins into Sld5&Psf1 and Psf2&Psf3, 
respectively (Makarova et al., 2005). GINS functional homologues have been identified in 
archaea (Table 1-i), and help to support the evolutionary model proposed by Koonin and 
colleagues (Makarova et al., 2005). Archaeal GINS homologues were first defined in silico 
through iterative BLAST searching (Makarova et al., 2005) and independently by yeast two-
hybrid screening of Sulfolubus solfataricus library for interacting partners of MCM 
(Marinsek et al., 2006). Both of these methods identified a GINS homologue with greater 
similarity to Sld5 and Psf1 than to Psf2 and Psf3, termed Gins15. Subsequent purification of 
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the Gins15-containing complex from proliferating Sulfolubus solfataricus using affinity 
chromatography identified another more divergent GINS homologue with greater similarity 
to Psf3 and Psf2 than to Sld5 and Psf1, termed Gins23 (Marinsek et al., 2006). Gins15 
homologues can be identified in all archaeal species whose genome information is available, 
whereas the much more divergent Gins23 homologues can only be reliably identified in a 
limited subset, which excludes most of the euryarchaeal species. Two of the species that 
contain Gins15 and Gins23 have been proposed to be of the more ancient archaeal lineages, 
suggesting that Gins15 and Gins23 could have both existed in the early archaea, and then 
Gins23 was subsequently lost from the majority of the euryarchaeal lineage or – more likely 
– diverged in its primary protein structure beyond the point of in silico BLAST-based 
recognition (MacNeill, 2010). This latter hypothesis would agree with the presence of all 
four GINS homologues (and not just Sld5 and Psf1) in all the eukaryotes studied to date. 
Gins15 and Gins23 appear to form a tetramer of two homodimers in all archaeal species 
where GINS was biochemically studied to date (Marinsek et al., 2006, Yoshimochi et al., 
2008). It remains to be determined what the quaternary structure of the Gins15 complex is 
in archaeal species that apparently lack Gins23. This is an interesting question as it could 
shed further light onto whether a very divergent form of Gins23 is present in euryarchaeal 
species or has indeed been lost during evolution from this lineage (MacNeill, 2010).  
Early reports showed that eukaryotic GINS is essential for replication initiation in budding 
yeast and Xenopus egg extracts (Kanemaki et al., 2003, Takayama et al., 2003, Kubota et 
al., 2003), and is also important for normal progression of the replisome in the former 
species (Kanemaki et al., 2003). Loading of GINS to the origins in yeast is mediated by the 
phosphorylated Sld2, complexed with Dpb11 and Polε, which together form the complex 
termed the pre-loading complex (pre-LC; Figure 1.2) (Muramatsu et al., 2010). Cut5, the 
Xenopus laevis functional homologue of Dpb11 has also been shown to be required for 
GINS and Cdc45 loading (Kubota et al., 2003). These molecular events might differ slightly 
in mammalian cells, since a recent report suggests that depletion of TopBP1, which is a 
mammalian homologue of Dpb11, does not affect the formation of the complex between 
GINS, Cdc45 and MCM (Im et al., 2009).  
After the origins have fired, GINS moves with the fork as a part of the replisome 
progression complex (Calzada et al., 2005, Gambus et al., 2006, Gambus et al., 2009). A 
multitude of interactions between the GINS complex and other members of the replisome 
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progression complex have been independently reported by various research groups and 
using various model organisms. For example, GINS appears to be important for the 
association of Cdc45 with the replisome in both yeast (Gambus et al., 2006, Pai et al., 2009) 
and human cells (Barkley et al., 2009). Recombinant human GINS also interacts and 
stimulates the activity of Polα-primase (De Falco et al., 2007). S.solfataricus GINS 
copurifies with a non-catalytic RecJ homologue (family of ssDNA exonuclease), and 
interacts with archaeal MCM and primase (Marinsek et al., 2006). This suggests that GINS 
could play a role as a coordinator of leading and lagging strand DNA synthesis (Marinsek et 
al., 2006). This role does not have to be mutually exclusive with the role of GINS as a 
helicase cofactor, which has become the focus of the biochemical studies in the past few 
years. Interestingly, human Mcm3/P1 protein was initially isolated as a part of the same 
complex with Polα (Thommes et al., 1992). 
Early studies on GINS reported an interaction with MCM and Cdc45 (Kubota et al., 2003). 
Cdc45 was originally identified as cdc45-1 cold-sensitive cell division cycle mutant in 
budding yeast (Moir et al., 1982). MCM genes were found to genetically interact with 
cdc45-1 either as suppressor (Moir et al., 1982) or synthetic lethality mutants (Zou et al., 
1997, Hardy, 1997). Similarly to GINS (Kanemaki et al., 2003) and MCM (Labib et al., 
2000) proteins, Cdc45 also has an essential role in the elongation of DNA replication 
(Tercero et al., 2000). Cdc45 chromatin association also corresponds well with origin 
activation (Masuda et al., 2003, Broderick & Nasheuer, 2009) and the progression of the 
replisome (Aparicio et al., 1997). This evidence underlined the similarities between Cdc45 
and GINS and pointed at a possibility that the molecular function of MCM, GINS and 
Cdc45 could be intimately related.  
Just before the role of the GINS complex in DNA replication became well defined, Cdc45 
was found to stimulate MCM helicase activity in Xenopus egg extracts (Masuda et al., 2003, 
Pacek & Walter, 2004). Botchan and colleagues (Moyer et al., 2006) built on this evidence 
to propose that the complex of GINS, MCM and Cdc45 proteins (CMG) is the processive 
helicase in eukaryotic cells. In the first report (Moyer et al., 2006), CMG protein complex 
that displayed processive helicase activity was purified from Drosophila embryo extracts by 
Cdc45 immunoaffinity. Similar slightly more circumstantial evidence for the function of 
GINS and Cdc45 as helicase cofactors in absence of DNA polymerase association was also 
reported in Xenopus egg extracts (Pacek et al., 2006).  
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This possible role of the CMG complex was very recently and elegantly confirmed by 
recombinant expression and biochemical characterisation of the Drosophila CMG complex, 
which shows that the presence of Cdc45 and GINS robustly stimulates the MCM helicase, 
as measured by the increased rate of ATP hydrolysis, increased helicase activity on plasmid 
substrates and increased ATP-dependent DNA affinity (Ilves et al., 2010). The core of these 
associations is conserved in archaea, where the GINS homologue from Pyrococcus furiosus 
appears to have a similar helicase-stimulating function (Yoshimochi et al., 2008). A Cdc45 
homologue in archaea has so far not been identified (Barry & Bell, 2006). One can only 
speculate as to whether this is because it is absent or because its sequence is too divergent to 
allow reliable identification. This makes it impossible to validate whether CMG also exists 
in archaea; although the absence of Cdc45-like proteins associating with archaeal GINS 
homologues when purified from cell extracts (Marinsek et al., 2006) might be a good 
indication that Cdc45 is not present and that the GINS-MCM interaction is evolutionarily 
the key component in the CMG complex. In agreement with this speculation, the association 
between recombinant Drosophila MCM and GINS is slightly stronger than the association 
of the two subcomplexes with Cdc45 (Ilves et al., 2010). 
One of my aims during this thesis was to purify recombinant GINS and perform structural 
analysis, as explained in section 3.1. However, this work was abandoned after the crystal 
structure of human GINS subunits had been solved independently by three other groups 
(Choi et al., 2007, Chang et al., 2007, Kamada et al., 2007). All structures are in good 
agreement with each other (MacNeill, 2010) and indicate a presence of a central pore 
channel. The presence of a central channel agrees with EM studies of recombinant Xenopus 
(Kubota et al., 2003) and human GINS (Boskovic et al., 2007), although the diameter of the 
central channel is significantly smaller in the crystal structures and is probably too small to 
accommodate single or double-stranded DNA (MacNeill, 2010). The analysis of structural 
data shows that four subunits have a related structural organisation, with two domains; a 
predominantly α-helical A-domain and predominantly β-stranded B-domain. Crystal 
structures also suggest that the C-terminal B-domain of Psf1 might be unordered and could 
therefore form an important interface for protein-protein interactions with the other DNA 
replication proteins.   
Rapidly growing knowledge about the GINS complex, as summarised here, is gradually 
allowing us to speculate as to the exact action of GINS at the replication forks and more 
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generally about the mechanism of MCM activation and its helicase mechanism. 
Saccharomyces cerevisiae pre-RC formation has recently been studied at the EM level using 
purified ORC, Cdc6, Cdt1 and MCM proteins loaded onto circular ARS-containing DNA, 
revealing interesting differences between free and loaded MCM (Remus et al., 2009). In 
solution, MCM forms a stable heteroheptameric complex with Cdt1, which mediates its 
loading (Remus et al., 2009), possibly using Mcm6 as the interacting partner (Wei et al., 
2010). Loading also requires ATP, ORC and Cdc6, as expected. Perhaps unexpectedly, 
loaded MCM encircles dsDNA and exclusively appears in a dodecameric form, with a head-
to-head arrangement (Remus et al., 2009) – an observation that has been independently 
confirmed by Speck and colleagues using a slightly different recombinant pre-RC system, 
also from budding yeast (Evrin et al., 2009). Parallels can also be drawn with structural 
studies on the archaeal MCM homologues, which appear as dodecamers with N-termini in 
the centre in certain species but single hexamers in others (Barry & Bell, 2006) – perhaps 
these differences are just due to structural snap-shots of different stages of the loading 
process. It remains to be determined how eukaryotic MCM loading factors induce this 
change of quaternary structure.  
Perhaps more importantly for this discussion, it also remains to be seen how this loaded but 
presumably still inactive MCM gets converted to an activated helicase with Cdc45 and 
GINS in tow. Various models for the helicase activity of MCM have been put forth 
(Takahashi et al., 2005), including steric exclusion (tracking along ssDNA separates the 
strands by steric exclusion), rotary pump model (fixed helicase spools dsDNA through its 
centre and thus unwinds it), T-antigen model (two physically connected helicases encircle 
dsDNA and pump it towards the helicase interface) and the ploughshare model (similar to 
the steric exclusion model, except that helicase encircles and tracks along dsDNA; strand 
separation happens because of the molecular ‘ploughshare’ that forms part of the helicase 
and inserts between the two DNA strands).  
At first glance, observations by Diffley and colleagues would favour models involving the 
helicase encircling dsDNA (i.e. not the steric exclusion model), with a particular preference 
for the T-antigen model, which corresponds most closely to the observed structure of loaded 
MCM (Remus et al., 2009). However, it should be noted that quantitative analysis of Mcm4 
in the budding yeast RPC indicates that there is only one MCM hexamer per replication fork 
(Gambus et al., 2006). Biochemical studies done with purified CMG from Drosophila 
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extracts and recombinant Drosophila CMG support the observations made by Labib and 
colleagues, since they never detect a double CMG in solution or on forked substrates 
(Moyer et al., 2006, Ilves et al., 2010). Furthermore, a fork is able to progress independently 
of its stalled sister fork (Doksani et al., 2009, Remus & Diffley, 2009). It is therefore more 
likely that MCM acts via a rotary pump or a ploughshare mechanism, if it encircles dsDNA. 
This would predict that MCM double hexamer separation occurs during origin firing, 
possibly brought about by the binding of Cdc45 and GINS and/or the phosphorylation by 
DDK, which indeed appears to mainly target the N-termini of Mcm2, Mcm4 and Mcm6 
(Sheu & Stillman, 2006, Remus et al., 2009).  
Nevertheless, assuming that sufficiently robust parallels can be drawn between fruit fly and 
yeast CMG (and assuming that the biochemical activity of the CMG complex is not 
drastically different when MCMs are first loaded onto DNA via the pre-RC intermediate 
before they are activated), it is important to note that recombinant CMG has no affinity for 
dsDNA (Ilves et al., 2010). This would therefore suggest that CMG actually acts via a steric 
exclusion model and that further isomerisation events have to take place between MCM 
loading (around the dsDNA) and activation (onto ssDNA, probably the leading strand since 
CMG is a 3’ to 5’ helicase; Ilves et al., 2010). In support of this, CMG displays an ATP-
dependent stimulation of MCM binding to DNA forked substrate and has a greatly 
increased helicase activity on circular ssDNA (Ilves et al., 2010), which suggests that 
addition of GINS and Cdc45 could mediate MCM ring re-opening, possibly by breaking the 
MCM ring at the Mcm2/5 gate (Bochman & Schwacha, 2007, Bochman & Schwacha, 
2008). This would further agree with the seemingly asymmetric affinity of the GINS for the 
MCM complex, with GINS binding most strongly to Mcm4 in both fruit fly (Ilves et al., 
2010) and human homologues by yeast two-hybrid (N Marinsek & SD Bell, unpublished 
data), which is at the opposite side of the ring to the Mcm2/5 gate (Ilves et al., 2010).  
Although this steric exclusion mode of action is perhaps one of the most complicated ways 
in which the helicase could be activated (Takahashi et al., 2005), it is perhaps still the best 
way to explain the need for a plethora of additional factors that have to assemble at the fork 
to activate the pre-RC. This model also satisfies the two slightly competing ‘requirements’ 
of the MCM licensing reaction. The first requirement is to allow loading of multiple MCM 
complexes per origin, all of which can act as potential bidirectional origins of replication in 
the case of replicative stress (Ge et al., 2007). Consistent with that, loaded pre-RC MCM 
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double hexamers slide along the DNA in a direction- and ATP-independent manner, but in a 
form that can lead to a possible origin activation, i.e. head-to-head (Remus et al., 2009, 
Evrin et al., 2009). Recombinant Drosophila CMG does not slide off from ssDNA anymore, 
suggesting tighter binding to DNA (Ilves et al., 2010). The second requirement is then to 
only activate a subset of loaded MCM helicase when further loading cannot occur anymore 
to ensure genomic stability. Perhaps the most secure way to achieve that is to require a 
‘secondary loading reaction’ in situ, during which the activated MCM goes from encircling 
a dsDNA to encircling a ssDNA?    
To conclude the summary of the GINS complex, apart from its key role in DNA replication, 
other roles for the GINS complex are emerging. Psf2 has been reported as a factor in 
chromosome segregation in M phase (Huang et al., 2005) and PSF1 is required for early 
embryogenesis in mice (Ueno et al., 2005). In Xenopus embryos, in situ hybridisation and 
unequal levels of expression of the subunits suggest that GINS proteins might play a role in 
development (Walter & Henry, 2004), as further suggested by the impairment of eye 
development upon PSF2 knock-down by morpholino oligos (Walter et al., 2008). GINS 
mRNA levels also appear to be upregulated in certain types of hepatic cancers (Obama et 
al., 2005). Nevertheless, this could simply be a consequence of increased rates of DNA 
synthesis, increased DNA content or fortuitous transcription via an upregulated oncogenic 
transcription factor in the malignant cells, as discussed at the end of Chapter 5. 
1.7 DNA replication proteins as cancer markers 
Cancer is characterised by the abnormal proliferation of cells in places where proliferation 
would not be expected. Cancer cells proliferate and therefore express the same cell cycle 
proteins as normal cycling cells. This makes proteins that are specifically expressed in 
proliferating cells (or a subset of the cell cycle phases) an obvious choice for cancer markers 
(Tachibana et al., 2005), and indeed a very powerful one, since their expression marks every 
type of cancer, independent of the tissue type and the exact underlying process of 
oncogenesis. A range of proliferation markers including Cdc45 (Pollok et al., 2007), Cdc6 
(Williams et al., 1998), geminin (Gonzalez et al., 2004), CAF-1 (Polo et al., 2004) and 
PCNA (Chan et al., 1983) have been characterised as proliferation markers. The best 
characterised to date are the MCM proteins (especially Mcm2 and Mcm5; Willams et al., 
1998, Freeman et al., 1999), which offer significant advantages owing to consistently 
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superior labelling index to the traditional ‘proliferation’ markers such as Ki67 (Wharton et 
al., 2001, Schrader et al., 2005, Szelachowska et al., 2006, Freeman et al., 1999). I will 
explore this point in more detail in the introduction to Chapter 5. 
1.8 Thesis aims 
At the start of my PhD project, the majority of the work on GINS summarised above had 
not been published. What was known from the initial published data confirmed an essential 
role for the GINS complex in the initiation and elongation phases of DNA replication 
(Kubota et al., 2003, Takayama et al., 2003, Kanemaki et al., 2003). In addition to 
published data, our unpublished observations confirmed that GINS and MCM homologues 
interact in archaea. This work was performed during my MSc project and concluded in my 
first year of PhD, resulting in a publication that is attached to this thesis in the Appendix 
(Marinsek et al., 2006). With this limited knowledge in mind, the underlying aims of my 
thesis were to: 
(1) Further elucidate the molecular function of GINS using the hyperthermophilic 
crenarchaeon Sulfolobus solfataricus P2. Here I would build on our early 
experiments suggesting a direct (at the time unpublished) GINS-MCM interaction in 
archaea using a biochemical approach, since genetic manipulations are very difficult 
to perform in this organism;  
(2) Explore the potential of antibodies to human GINS proteins as markers of pre-
malignancies and cancer. This approach had been shown to be successful for the 
MCM proteins (Freeman et al., 1999), but there were circumstances where 
antibodies to the MCMs have been of limited value only, so a comparison with 
novel markers would be particularly useful; 
(3) Use the antibody reagents produced for the studies of GINS proteins as cancer 
markers to further investigate the function of human GINS. These studies would 
include cellular, subcellular and molecular aspects of the GINS subunits, both 
quantitatively and qualitatively. They would also make comparisons to other 
components of the CMG complex, especially the MCMs; 
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(4) Attempt biochemical and structural studies of the human GINS complex. The initial 
expression of recombinant GINS was to generate antibodies in view of aim (2). 
However, given the promising yield of these recombinant proteins, I felt these could 
also be used in further studies. 
As mentioned in point (1), I initially hoped to be able to use the Sulfolobus solfataricus P2 
as the model system for my functional studies. However, the continuing absence of a 
biochemically assayable Sulfolobus GINS made this approach decreasingly tractable during 
my first year. After the publication on the initial characterisation of archaeal GINS 
(Marinsek et al., 2006), the decision was reached to make good use of the good quality 
antibody reagents produced in view of the second aim and therefore focus on the molecular 
characterisation of human GINS (aim 3). Aim 4 was extensively pursued during my first 
year, but was later side-tracked in light of comparable reports on this topic in the literature 
(Choi et al., 2007, Chang et al., 2007, Kamada et al., 2007, Boskovic et al., 2007, De Falco 
et al., 2007). 
Chapter 3 presents the generation and validation of antibody reagents and the purification of 
recombinant GINS proteins (aim 4). The initial, finite, rabbit sera had produced good 
antibodies to Sld5, Psf3, Psf1 and to some extent Psf2. However, for the longer-term use 
and for potential clinical applications, I embarked upon a strategy to produce mouse 
monoclonal antibodies to all four GINS subunits. These reagents were used in subsequent 
chapters. Chapter 4 describes the studies of the subnuclear localisation of GINS proteins by 
high-resolution confocal microscopy (aim 3). Here, I also show data on the quantification of 
the GINS subunits within cells, their presence throughout the cell cycle and their 
disappearance on entry into quiescence at the start of Chapter 5. The bulk of Chapter 5 then 
describes the evaluation of antibodies to GINS proteins, in particular Sld5, as a marker for 
cancer detection (aim 2). GINS antibodies are compared to the benchmark antibodies, that is 
those for the MCMs, particularly Mcm2. Comparisons are made on tissue samples stained 
for immunohistochemistry as well as cellular material isolated from the faeces and urine of 
cancer patients. Through a series of in vitro assays, the stability of GINS is evaluated 
against the MCMs to assess whether GINS have the potential of being a better marker in 
degradative extracellular material, namely faeces and urine. Chapter 6 concludes the work 
presented in this thesis. The article detailing my work on Sulfolobus GINS is included in the 
Appendix. 
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Chapter 2 Materials and Methods 
2.1 Constructs and cloning 
Constructs pGBK-Psf1, pET33-Psf2, pET30-Psf3 and pGAD-Sld5 were cloned during my 
undergraduate project and contain the full-length coding sequences of human GINS proteins 
(excluding the stop codons) amplified by PCR from SEG-1 cell line cDNA (gift from P 
Lao-Sirieix). Constructs pGBK-Psf1 and pGAD-Sld5 are based on the pGBKT7 (Clontech) 
yeast two-hybrid vector. They were used to subclone Psf1 and Sld5 as NdeI-XhoI fragments 
into pET30a expression vector (Novagen) to create pET30-Psf1 and pET30-Sld5 expression 
constructs. All four constructs (pET30-Psf1, pET33-Psf2, pET30-Psf3 and pET30-Sld5) 
expressed the relevant GINS subunit with a C-terminal hexahistidine tag. 
For the co-expression studies, I first engineered a TEV recognition sequence between the 
end of Sld5-coding sequence and the hexahistidine tag in pET30-Sld5 using the XhoI 
restriction enzyme site and a linker with XhoI-compatible overhangs (primers used for the 
linker were 5’-tcgaaaacctgtacttccagggagctg and 5’-tcgacagctccctggaagtacaggttt). Efficiency 
of the reaction was increased by restriction enzyme digestion with XhoI after ligation (note 
that incorporation of the linker destroyed the XhoI recognition sequence). The desired open 
reading frame of the resulting construct pET30-Sld5-TEV was amplified by PCR. PCR was 
also used to amplify the GINS coding sequences from pET30-Psf1, pET33-Psf2 and pET30-
Psf3 (stop codons were incorporated into reverse primer sequences). Primer details are 
available upon request.  
Amplified psf3 was inserted as a NotI-AflIII fragment into NotI-NcoI sites of pCOLA-Duet 
(Novagen). This was followed by an insertion of NdeI-psf1-AvrII to create pCOLA-Psf3-
Psf1. Amplified sld5-his was inserted as an NdeI-AvrII fragment into pCDF-Duet 
(Novagen) vector. This was followed by a ligation of NcoI-psf2-NotI to create pCDF-Psf2-
Sld5His.  
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All constructs were verified by DNA sequencing. Conservative mutation V97I (believed to 
be due to allelic variation in SEG-1 cells) was found in the psf1 open reading frame. Sld5-
containing open reading frame in pCDF-Psf2-Sld5His was followed by codons for 
LENLYFQGAVE.H6.stop. 
2.2 Commonly used solutions 
LB – 1.05%w/v SDS, 62.5mM Tris-HCl (pH6.8), 10%v/v glycerol, 0.35M β-
mercaptoethanol, 0.0125%w/v bromophenol blue 
PBS – 137mM NaCl, 2.7mM KCl, 8mM Na2HPO4, 2mM KH2PO4, pH7.4 
TBS – 10mM Tris-HCl pH8.0, 150mM NaCl 
2.3 Recombinant protein expressions 
Expression of recombinant proteins, harvesting and lysis of cells were done as described 
previously (Marsh et al., 2005), except that 0.5L cultures were used for co-expression 
studies. Differences in downstream applications of the lysates are detailed in the following 
paragraphs. 
For the purification of insoluble proteins, the clarified (35,000xg, 20min, 4°C) lysate was 
discarded and the pellet resuspended in 20mL TBS-U (TBS, 8M urea, 14mM β-
mercaptoethanol). Centrifugation was repeated and the supernatant applied onto 1.5mL Ni-
NTA agarose column (QIAGEN). The column was washed with 15mL TBS-U and then 
with 5mL TBS-U, 10mM imidazole. The bound material was eluted in TBS-U, 250mM 
imidazole and the positive fractions pooled for downstream applications. 
For production of rabbit anti-Sld5 and anti-Psf2 antisera, pooled Ni-column eluate was 
incubated at 4°C overnight after the buffer composition was adjusted to 17.5mM Tris-HCl 
pH8.0, 260mM NaCl, 2M urea, 14mM β-mercaptoethanol. The following day, samples 
were spun (16,100xg, 20min, 4°C) and the supernatants sent for immunisation of two 
rabbits. For immunisation with Psf1, pooled positive elution fractions were instead dialysed 
into TBS, 4M urea, 20mM β-mercaptoethanol and then spun (16,100xg, 20min, 4°C). Psf3 
antigen for rabbit immunisation was purified during my undergraduate project. 
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For production of antigens for immunisation of mice, pooled Ni-column eluates were 
diluted in equal volume of TBS and then dialysed via TBS, 2M urea into TBS pH7.4. 
For refolding experiments, pooled Ni-column eluates of each subunit were combined in 
approximately equimolar ratios and equilibrated by dialysis (2h minimum) into TBS, 20mM 
β-mercaptoethanol with either 4M, 2M and finally 0M deionised urea. After the last step, 
dialysis was repeated in fresh TBS, 20mM β-mercaptoethanol overnight. The next morning, 
dialysed sample was spun (16,100xg, 20min, 4°C) and the supernatant analysed using Hi-
load 26/60 Superdex-200 gel filtration column (GE Healthcare) equilibrated with the final 
dialysis buffer. Peak 10mL elution fractions were applied to a 1mL MonoQ HR5/5 column 
(GE Healthcare), washed (5mL) and eluted with a linear gradient to TBS, 850mM NaCl, 
20mM β-mercaptoethanol. 
Superdex-200 was calibrated in silico using http://www.embl-
hamburg.de/services/protein/protocols/purification/hiload26_200.html  (accessed 10 July 
2006). 
For the purification of GINS by co-expression with the removal of the His-tag from Sld5 
protein, the clarified (35,000xg, 20min, 4°C) lysate was applied onto 1.5mL Ni-NTA 
agarose column (QIAGEN). The column was washed with 15mL 2xTBS, 11mM β-
mercaptoethanol and then with 5mL 2xTBS, 11mM β-mercaptoethanol, 15mM imidazole. 
The bound material was eluted in 2xTBS, 11mM β-mercaptoethanol, 500mM imidazole, 
and the buffer exchanged for TBS, 14mM β-mercaptoethanol, 1mM DTT using a 5mL 
HiTrap Desalting column (GE Healthcare). Protein (approximately 0.375mg of Sld5) was 
digested with 9.4U AcTEV protease (Invitrogen) at 4°C and the reaction spun (16,100xg, 
20min, 4°C) before applying it onto 0.75mL Ni-NTA agarose column (QIAGEN). Flow-
through, washed with 2mL TBS, 14mM β-mercaptoethanol, was loaded onto Hi-load 26/60 
Superdex-200 gel filtration column (GE Healthcare). Eluting fractions (5mL) starting at 
105mL after injection were analysed by immunoblotting. 
For the simplified co-expression approach without the removal of the His-tag from Sld5 
protein, the clarified lysates of 2L induced bacterial culture was divided between 2 3mL Ni-
NTA agarose columns (QIAGEN). The columns were washed with 15mL (per column) 
2xTBS, 10mM β-mercaptoethanol, EDTA-free complete protease inhibitor cocktail (Roche) 
and then with 14mL 2xTBS, 10mM β-mercaptoethanol, 1mM imidazole; 5mL 2xTBS, 
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10mM β-mercaptoethanol, 10mM imidazole. The bound material was eluted in 7mL 
2xTBS, 10mM β-mercaptoethanol, 250mM imidazole. Eluate was loaded onto Hi-load 
26/60 Superdex-200 gel filtration column (GE Healthcare) equilibrated with 1xTBS, 20mM 
β-mercaptoethanol. Selected fractions were next loaded onto MonoQ GL10/100 (GE 
Healthcare), washed (3 column volumes) and eluted with a linear gradient to TBS, 850mM 
NaCl, 20mM β-mercaptoethanol over 20 column volumes. 
2.3.1 Expression analysis (bacterial whole cell lysates) 
E.coli cultures were harvested by centrifugation (10,000xg, 3min). Pellets were resuspended 
in 100µl 10mM Tris-HCl (pH8.0), 1mM EDTA-NaOH (pH8.0) per OD600 0.25. Equal 
volume of 2xLB was added. Cells were lysed by vortexing (1min). Twenty microlitre 
samples were analysed by SDS-PAGE followed by Coomassie staining.  
2.3.2 SDS-PAGE and Coomassie staining 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed on 
hand-cast gels using Mini-PROTEAN electrophoresis system (Bio-Rad). Stacking buffer 
contained 125mM Tris-HCl (pH6.8), 0.1% SDS and 3.75%(w/v) acrylamide and resolving 
buffer contained 375mM Tris-HCl (pH8.8), 0.1% SDS, and 12%(w/v) acrylamide unless 
stated otherwise. Samples were loaded in 1x Laemmli loading buffer (1xLB). Gels were run 
at constant voltage in Laemmli running buffer (3g Tris base, 14.4g glycine, 0.1% SDS).  
For Coomassie staining, a warm Coomassie stain (25%v/v isopropanol, 10%v/v acetic acid, 
0.25%w/v Coomassie brilliant blue R-250) was applied for approximately 5min with 
rocking. This was followed by several changes of destain (10%v/v acetic acid, 20%v/v 
methanol) with rocking overnight the following 24h. 
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2.4 Tissue culture 
2.4.1 Cell lines 
The human cell lines (adherent HeLa, WI38, EJ28, RT112, U2OS, SKOV3) were grown as 
monolayers in Dulbecco’s Modified Eagle Medium (DMEM+GlutaMAX-I, Gibco), 
supplemented with 10%(v/v) faetal calf serum (FCS) and 1%(v/v) penicillin and 
streptomycin (Sigma, catalogue number P0781). Antibiotics were generally omitted when 
cells were grown for experimental treatments, except for growth on coverslips and the WI38 
contact-inhibition experiments. After nucleofection, HeLa cells were grown in 
McCoy’s5A+GlutaMAX-I (Gibco) supplemented with 10%(v/v) FCS. Cultures were 
passaged by trypsinisation (1xTrypsin-EDTA, Sigma, catalogue number T4174) when they 
reached approximately 80-90% confluency. For WI38 cell line, care was taken to keep the 
exposure to trypsin solution to the minimum (approximately 1min). Cultures were grown in 
a humidified 37ºC incubator maintained at 10% CO2.  
2.4.2 Cell synchronisation 
To achieve a G0 (quiescence) phase arrest, WI38 cells were grown to confluence and then 
maintained with an exchange of full medium every 2-3 days. Care was taken to pour the 
medium off very gently so as to not lift off any cells, which would create gaps in the 
monolayer and cause further cell division. Day 0 of G0 phase was called when there was 
significant absence of round mitotic cells and cell-free areas visible.  
2.4.3 siRNA depletion 
To optimise the siRNA depletion of GINS subunits, I used the QIAGEN predesigned 
siRNAs (Table 2-i) at a concentration of 10µM or 20µM, as specified in the figure legends. 
Nucleofection was achieved using Cell Line Nucleofector Kit-R (Lonza) following 
manufacturer’s recommendations for transfection of HeLa cells (programme I-13), except 
that 15µL or 20µL siRNA was used per nucleofected sample (or 7.5µL/10µL each siRNA 
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where a pair was co-transfected), as specified in the figure legends. Transfected cells were 
plated into a 6-well plate; the medium was changed after 24h.   
siRNA Target DNA sequence  QIAGEN Product code 
siPsf1.1 CGCTGTAGGACTAGAACGAAA SI03195164 
siPsf1.2 TTGGGTGTTGCATCCGAGAAA SI03245676 
siPsf1.3 CAGGTCTACCATGTCAGCATT SI04176130 
siPsf1.4 CAGGTGGACGAAGTGATTTGA SI04258121 
siPsf2.1 CTGACCGGTGCTTATCCTCTA SI04439757 
siPsf2.2 AAGCCTTAGGTAAATAAGTCA SI00113288 
siPsf2.3 CTGGCGATTAACCTGAAACAA SI02653056 
siPsf2.4 CTCCTGTTAAATCATGCTTCA SI02653581 
siPsf3.1 CAACCTCGTTCAGAATTACAA SI04148991 
siPsf3.2 TTGATCATATTTGACGGTAAT SI04247446 
siPsf3.3 CAGGGTTCCAAGCTTGAACTA SI04319245 
siPsf3.4 ATGATTGGCTTTGTACATGAA SI00394471 
siPsf3.5 TAGAAGATCCCTGACCATTTA SI00394478 
siSld5.1 TACGTGTTTCTGAGAGTGAGA SI03226069 
siSld5.2 CTCACAGCACTTGATCCGATA SI04243323 
siSld5.3 CATGGCGAACACAGAGTCCTA SI04248377 
siSld5.4 TGGAGCTGTCCAGCTAATTTA SI04287535 
siControl Not given (proprietary) SI03650318 
Table 2-i List of siRNA sequences used in this study. 
For the lipid-based transfection of Psf3 siRNA into U2OS cells, M Gonzalez used 
Oligofectamine transfection reagent (Invitrogen) according to manufacturer’s 
recommendations. Oligonucleotides were used at a final concentration of 90nM. 
To analyse the degree of knock-down, cells (including any unattached cells floating in the 
medium) were harvested by trypsinisation. Cell counts were performed with the Vi-CELL 
device (Beckman Coulter). Harvested cells were washed and resuspended in 1xLB with the 
Complete EDTA-free protease inhibitor cocktail tablet (Roche) added. 
2.4.4 Cycloheximide treatment 
HeLa cells were seeded at 25,000 cells/well of a 6-well plate (surface area 9.6cm2/well) 24h 
before treatment. Cells were treated with 20µg/mL fresh cycloheximide solution, which has 
previously been shown to reduce new protein synthesis to less than 8% of normal levels 
(Okuno et al., 2001). Cells were harvested for expression analysis at the indicated times 
after the start of the treatment with accurate counting (over 200 cells counted for each time-
point).  
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2.4.5 EdU/BrdU labelling 
Cells were typically pulse-labelled with 20µM EdU (length of time is specified in the figure 
legends). In the initial EdU labelling experiment, cells were labelled, and washed in PBS at 
room temperature before placing them on ice, where run-on DNA synthesis is unlikely to 
occur (Mills et al., 2000). Cells were then permeabilised and fixed, as described below 
(2.4.7) and stored in absolute ethanol.  
For the optimised EdU labelling experiment, cells were pulsed for 10min only and kept in 
EdU-supplemented medium until transferring them to chilled PBS on ice. Cells were then 
permeabilised before fixation and fixed, as described below (2.4.7), and processed 
immediately for EdU detection and indirect immunofluorescence. 
To visualise incorporated EdU, fixed coverslips were processed for Click-iT assay EdU 
detection (Invitrogen) according to manufacturer’s recommendations.  
For BrdU labelling, cells were typically pulsed with 50µM BrdU for 20min. In order to 
visualise the incorporated BrdU by immunofluorescence, the standard immunofluorescence 
protocol was modified to include an acid denaturation step between permeabilisation after 
fixation (or storage in absolute ethanol, if coverslips were not processed straight away) and 
blocking of non-specific binding. DNA denaturation was achieved by 30min incubation in a 
1:1 mix of 4N HCl and PBS, 0.4% Tween-20, followed by a 5min wash in PBS, 0.4% 
Tween-20. To detect incorporated BrdU, anti-BrdU antibodies were used, as detailed in the 
section 2.5.1. 
2.4.6 Sample harvest for expression analysis (tissue culture cells) 
For cell culture whole-cell lysates, cells were first trypsinised under normal growth 
conditions. The reaction was stopped by addition of fresh medium or PBS containing FCS. 
Cells were counted using a haemocytometer, washed in PBS and resuspended to 
0.5x107cells/mL in 1xLB. 
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2.4.7 Sample processing for microscopy 
Cells (either grown on coverslips or harvested by trypsinisation and processed in 
suspension) were washed twice in PBS and fixed in fresh 4%(w/v) paraformaldehyde 
(Fisher Scientific) for 4-5min at room temperature. If cells in suspension were used, the 
fixed cells were at this point spun onto poly-L-lysine (Sigma, catalogue number P0879) 
coated coverslips (2000rpm, 5min, RT; Sorvall Legend RT Plus centrifuge). Finally, cells 
were permeabilised with TBS, 0.2% Triton-X100, 0.04% SDS for 5min. Coverslips were 
routinely stored in absolute ethanol at -20ºC until use in downstream applications.  
For experiments involving cells that were permeabilised before fixation, cells on coverslips 
were first washed in PBS on ice and then the soluble cellular components were removed by 
incubation for 5 min on ice in PBS, 0.1% Triton-X100, EDTA-free complete protease 
inhibitor cocktail tablet (Roche). Permeabilised cells were then briefly washed in PBS and 
fixed and processed, as described above (including permeabilisation step after fixation). As 
a control, I always included a coverslip that was processed in the same way, but without the 
addition of Triton-X100 detergent to the PBS. 
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2.5 Immunological techniques 
2.5.1 Antibodies used 
Antibody 
name 
Type Reference Application and dilution 
BrdU Rat monoclonal against BrdU Abcam ab6326 IF 1:200 
RPA Mouse monoclonal RPA32/RPA21 Abcam ab2175 IF 1:200 
Actin Rabbit polyclonal against all actin 
isoforms (α, β, γ) 
Sigma A2066 WB 1:800 
Mcm2 Mouse monoclonal (Mukherjee et al., 2001, 
Davies et al., 2002) 
Urine IP 9.5µL (2µg)  
IHC 1:40 
Mcm2 or 
BM28 
Mouse monoclonal against human 
Mcm2 peptide 
BD Transduction 
Laboratories 610700 
IF 1:40 (AD Mills) - 1:200 
(most experiments)  
WB 1:1,000 
Mcm2a Affinity purified goat polyclonal 
against Mcm2 peptide 
Santa Cruz sc-9839 WB 1:700 
Mcm3 Affinity purified goat polyclonal 
against Mcm3 peptide 
Santa Cruz sc-9850 WB 1:700 
Mcm6 Mouse monoclonal against Mcm6 
peptide 
BD Transduction 
Laboratories 611622  
WB: 1:800 
Mcm5 Mouse monoclonal culture 
supernatnat 
Ref IF 1:10 
ProExC Mouse monoclonal antibody 
cocktail, containing antibodies 
against Mcm2 and TOP2A  
BD Tripath 005-11000-40 IF 1:2 
PSA Goat affinity purified polyclonal Santa Cruz sc-7638 IF 1:50 
PCNA Mouse monoclonal, clone PC10 Sigma P8825 IF: 1:100 (AD Mills) – 
1:400 (my experiments) 
 GINS antibodies:   
rSld5, 
rPsf3, 
rPsf2, rPsf1 
Rabbit polyclonal against GINS 
subunits 
This thesis, Figure 3.6A WB 1:1,000 
rSld5, rPsf3 Purified rabbit polyclonal This thesis, Figure 3.7A IF 1:100-1:400 
IP: 1.5-2µL 
WB: 1:1,000 
rSld5B Purified rabbit polyclonal This thesis, data not shown Urine IP: 9.5µL (2µg) 
rPsf2, rPsf1 Purified rabbit polyclonal This thesis, Figure 3.7A IF 1:200 
WB: 1:1,000 
mSld5A, 
mSld5B 
mPsf2A 
Purified mouse monoclonal IgG1 
subclass 
This thesis, Figure 3.11, Figure 3.10 WB 1:100 IF 1:50 
 
a Where its use is specified in the figure legend; otherwise any Mcm2 antibody on WB was BM28 antibody. 
 
Table 2-ii List of primary antibodies used in this study. 
Secondary antibodies used in this study were (a) for western blotting, the following 
horseradish peroxidase-conjugated antibodies used at 1/10,000 dilution: Immunopure goat 
anti-rabbit IgG (Thermo Fisher Scientific), mouse monoclonal anti-sheep/goat IgG (Sigma 
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A9452) and goat anti-mouse IgG (Fab specific) from Sigma (catalogue number A2304; 
recognises all mouse IgG subclasses, which was important for monoclonal antibody 
testing); (b) for immunofluorescence, a selection of Alexa Fluor-labelled antibodies 
(Invitrogen Molecular Probes) against mouse (catalogue numbers A31622, A31570, 
A11001, A10036), rabbit (A11010, A21441, A11008, A31628) and goat (A21447) IgG, all 
used at 1:500 dilution. For use in high-resolution confocal microscopy, anti-rabbit antibody 
was usually highly cross-absorbed (catalogue number A31628 for Alexa-488-conjugated 
antibody). Care was taken to ensure that none of the secondary antibodies were raised in a 
species of any of the other primary antibodies in the mix. 
2.5.2 Antibody production and purification 
Rabbit immunisation and treatment of the animals, including the final serum withdrawal, 
was done by CovalAb UK Ltd. Rabbit antisera were purified by affinity chromatography for 
the original protein. Purified recombinant hexahistidine-tagged Psf3 and Sld5 in 2M urea 
were first passed over PD10 desalting column (GE Healthcare), to exchange urea for SDS, 
before cross-linking them to the SulfoLink column (Pierce). Affinity purification of the anti-
Psf3 and anti-Sld5 antisera was done according to the manufacturer’s recommendations. 
Positive (as determined by Ponceau S) fractions eluted from the column were tested by 
immunoblotting in parallel with the crude antisera for comparison. 
Mouse immunisation and generation of stable hybridomas was done by Babraham 
Bioscience Technologies (BBT) under the umbrella of Cambridge Research Biochemicals 
(CRB). Screening of post-immunisation and pre-immunisation bleeds, and all of the culture 
supernatants was performed in parallel by BBT (ELISA screening) and by me (strip 
immunoblotting and immunofluorescence). Supernatants from stable cultures obtained from 
BBT were tested for IgG isotype using IsoStrip Mouse Monoclonal Antibody Isotyping Kit 
(Roche). Given their isotype, selected mouse monoclonal antibodies were purified and 
concentrated using Protein G Sepharose (GE Healthcare), using 0.1M glycine pH2.9 to elute 
the antibody. 
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2.5.3 Immunoblotting 
Samples, usually resolved on 12%(w/v) acrylamide gel by SDS-PAGE unless stated 
otherwise, were blotted onto a nitrocellulose membrane using the wet (tank) transfer system 
(Bio-Rad Mini Trans-Blot cell) under constant current. Membranes were blocked in 
5%(w/v) marvel, TBST (overnight, 4°C). Primary antisera were detected using commercial 
horseradish peroxidase-coupled secondary antibodies. Antibody incubations were normally 
done in 5%(w/v) marvel, TBST. The blots were developed using ECL Western blotting 
detection system (GE Healthcare) and exposed onto Medical Super RX X-ray film (Fuji). 
X-ray films were converted into digital images by flatbed scanning. For stripping the 
membrane of bound antibodies, I used Restore Western Blot Stripping Buffer (Pierce, 
product number 21059). 
2.5.3.1 Strip immunoblotting 
For strip immunoblotting, sample was loaded into 1 large well and then processed for 
normal immunoblotting as above. The blot was then cut into strips and incubated in 8-well 
tanks in a humidifying chamber to prevent liquid loss. Washing was shorter than with 
normal immunoblotting; usually only 20min with 3 changes of the wash buffer. Alignment 
stripe was drawn with a pencil and a ruler before cutting so that individual strips could be 
accurately re-aligned afterwards. 
2.5.3.2 Quantitative immunoblotting 
To ensure that none of the lanes were grossly overloaded, which could lead to incomplete 
transfer and inaccuracies in quantification (Aldridge et al., 2008), all the samples were 
loaded at equal cell counts per unit volume. Edge wells were not used. Pre-flashed films 
with sub-maximally exposed band intensities were chosen for analysis to ensure linearity of 
signal for accurate quantification (Laskey & Mills, 1975). Analysis was done on TIFF 
images using the Analyze Gels submenu in ImageJ (Rasband, 2008), ensuring that all bands 
from the same gel strip were quantified in one operation, otherwise results would not be 
comparable. Where applicable, the 95% confidence limits for the mean were calculated by 
multiplying the standard error of the mean (SEM) by 1.96, where SEM is standard deviation 
divided by the square root of the sample size (number of measurements).  
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To derive the number of molecules of each GINS subunit per HeLa cell, I assumed that the 
recombinant GINS protein standard contained equimolar amounts of each subunit, so the 
mass of total GINS protein (1ng) was divided according to the mass ratios of the four 
subunits (so mass of Sld5 was 27% of 1ng and Psf1 only 24% of 1ng). Protein 
quantification of recombinant GINS and Mcm6 was done with Bradford Coomassie Plus 
Assay (Pierce) following manufacturer’s recommendations. BSA was used as the protein 
standard. 
2.5.4 Immunoprecipitation 
For immunopreciptations with rabbit GINS antibodies (section 3.3.3), protein extracts, 
prepared as published before (Krude et al., 1997), were a kind gift from AD Mills. After 
adjusting their volume and, if applicable, the salt concentration to 150mM NaCl with LSB 
(20mM HEPES-KOH pH7.8, 5mM potassium acetate, 0.5mM MgCl2, 0.5mM DTT), 
extracts were tumbled end over end with the specified antisera at 4°C. After 1.5h, 50µl 
protein A beads equilibrated in LSB were added, and the incubation was repeated for the 
specified length of time. Supernatants were removed and the insoluble fractions subjected to 
1mL TBST washes on ice over a period of 30min. The bound fraction was resuspended in 
50µl 1xLB, boiled, resolved by SDS-PAGE and immunoblotted. 
For immunoprecipitations using urine samples (section 5.5.2.2), urine samples, obtained 
with permission from the Local Research Ethics Committee guidelines (N Coleman & 
colleagues), were first spun (2,500rpm, 10min, RT; Sorvall Legend RT Plus centrifuge) to 
remove any cellular material. Complete protease inhibitor cocktail tablets (Roche) were 
added and the samples were stored at -80ºC. Upon thawing, urine pH was adjusted to pH8.0 
with 1M Tris-HCl pH8.0. Healthy donor’s urine was then spiked with 50µL soluble Triton-
X100 lysate of EJ28 cells and all samples were spun to remove any insoluble material 
(4,000rpm, 10min, 4ºC; Sorvall Legend RT Plus centrifuge). Immunoprecipitations were 
performed on 12mL supernatant from this spin using purified rSld5B and Mcm2 antibodies 
(see Table 2-ii) at 4ºC with rotation. After 1h, 50µl protein A beads equilibrated in TBS 
were added, and the incubation was repeated for another hour. Supernatants were removed 
and the insoluble fractions subjected to 10mL, and two 1mL washes with TBS washes on 
ice over a period of 20min. The specifically bound fraction was resuspended in 35µl 1xLB, 
boiled, resolved by SDS-PAGE (35% of eluate) and immunoblotted. 
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2.5.5 Immunofluorescence 
For indirect immunofluorescence, fixed samples (see section 2.4.7) were occasionally 
treated with ImageIT signal enhancer (Invitrogen) for 30min at room temperature, where 
stated. The coverslips were then always blocked for non-specific antibody binding with 
3%(w/v) BSA (Sigma, A2153) in TBS for 30min at room temperature. Coverslips were 
overlain with typically 50µL of the final antibody mix in a humidifying chamber and 
incubated protected from light at 37ºC for 1h unless stated otherwise. After both primary 
and secondary antibody incubations, coverslips were washed three times in TBS, 0.2% 
Triton-X100, 0.04% SDS over a course of 15min. To visualise DNA, Hoechst 33342 
(Invitrogen) at 10µg/mL was usually added to the secondary antibody mix. After the final 
wash and before mounting, each coverslip was dipped briefly in water, excess water was 
blotted off and the coverslip was mounted over Vectashield anti-bleaching agent (catalogue 
number H-1000, Vector Laboratories) or if Hoechst was not used, then Vectashield with 
DAPI (catalogue number H-1200, Vector Laboratories) was used. Mounted coverslips were 
sealed with clear varnish and imaged promptly as detailed below (2.6). After imaging, slides 
were stored protected from light at -20ºC. 
For the direct labelling, AD Mills directly labelled purified rSld5 antibody by covalently 
attaching the Alexa-488 fluorophore to the antibody through amine-reactive groups using 
the Invitrogen Microscale Antibody Labelling Kit according to manufacturer’s 
recommendations. Staining of cells was as described above, observing the following 
sequence of incubations (all at 1h, 37ºC): first the cells were immunostained with unlabelled 
rPsf3 antibody, followed by detection of the bound antibody with anti-rabbit IgG labelled 
with Alexa-546 fluorophore. After extensive washing, the cells were incubated with the 
Alexa-488 labelled rSld5 antibody.  
2.5.6 Immunohistochemistry 
Archival blocks of paraffin embedded, formalin-fixed human tissue, obtained from surgical 
resection specimens, were retrieved in accordance with the Local Research Ethics 
Committee guidelines (permission obtained by N Coleman & colleagues). 
The experimental procedure described here was performed by P Stacey and L Morris as 
described previously (Freeman et al., 1999). Briefly, serial paraffin sections (5µm) were cut 
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onto aminopropyltriethoxysilane (APES) coated slides and dewaxed. Antigen retrieval was 
achieved by pressure-cooking or microwave treatment in a programmable microwave 
(MicroMED T/T Mega) in 0.08M citrate buffer (pH6.0) for varying lengths of time, 
depending on the tissue.  
Sections were usually stained with the Dako Autostainer System (DAKO) using a standard 
Autostainer protocol. The slides were then lightly counterstained with Papanicolaou (Pap) 
stain. Coverslips were applied with DEPEX mounting medium (Gurr, BDH). Negative 
controls were performed by omitting the primary antibody.  
2.6 Microscopy image collection and processing 
2.6.1 Confocal microscopy 
Immunofluorescent samples were imaged using BioRad 1024 confocal laser scanning 
microscope.  
Field views were taken with the 40X lens. Special care was taken to take pictures of 
representative field views in the middle of the coverslip, where the staining was expected to 
be most uniform.  
High-resolution images were taken with the highest magnification lens (60X) with high 
zoom values (usually between 8X and 10X) and at an image resolution of 1024x1024 pixel 
(8-bit/pixel). To maximise the resolution and the dynamic range of the image, 
aperture/detector pinhole was reduced to 1 airy unit for the longest wavelength channel, and 
the same optical section (0.8µm) for all others and gain was set as high as possible for each 
channel individually, whilst ensuring that no extensive sections of the image are over-
exposed (level value 255), just occasional pixels. Images for individual channels were 
recorded sequentially (using Lambda strobing) and Kalman averaging, usually of 5 images, 
was used. For quantitative imaging, sample bleaching was kept to the minimum and all 
samples in the experimental set were collected under the same conditions.  
Images were collected in the PIC format (minimum automatic image rendering) and 
converted to TIFF by ImageJ. Adobe Photoshop CS3 10.0 was used to process the image. 
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For all processing steps, care was taken that the steps were identical for test and control 
images. 
For most high-resolution images, the following steps were followed for every channel 
before compiling them into an RGB format: 
(1) Image levels adjusted for every channel (aim being to narrow the levels so as to 
exclude extreme values not represented on the image); 
(2) Gaussian blur applied at the appropriate radius; 
(3) Image level readjusted if needed for every channel; 
(4) Sharpen mask applied. 
2.6.2 Alignment checks 
Images of alignment and intensity beads (FocalCheck Fluorescence microscope test slide 
number 1, Invitrogen, Cat. No. F36909) were taken with the same lens and with the same 
zoom as the experimental images. Images of the alignment beads were processed in the 
same way as the experimental images before assessing the degree of misalisgnment. Image 
translation in the x & y direction was done using ImageJ software. 
2.6.3 Pixel intensity profiling and image thresholding 
Image analysis was done on unprocessed misalignment-corrected images. I used line width 
of 6 pixels (typically 0.17µm, depending on the zoom) on 1024x1024 resolution images to 
plot the pixel intensity profiles for individual channels in ImageJ (Rasband, 2008). 
For binary images, the unprocessed image of every channel was thresholded down to the 
level where white pixels started appearing outside the nucleus in Photoshop. This was 
monitored by previewing the image as the threshold level was adjusted. Care was taken to 
ensure that the same level of threshold (on a per channel basis) was selected for images 
from the same coverslip.  
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2.6.4 ScanR imaging 
Quantitative analysis of total fluorescence of immunostained cells was performed by AD 
Mills using the ScanR Analysis software (Olympus Soft Imaging Solutions). Images were 
collected with a 20X objective. The exposure of the different channels was adjusted to 
maximise the dynamic range. DNA stain was used as the mask to score the total nuclear 
fluorescence. 
2.7 Additional methods relating to the study of GINS proteins 
as cancer markers 
2.7.1 Trypsin stability experiment 
For the trypsin stability testing experiment, HeLa whole-cell extracts (kind gift from CG 
Scarpini) were first desalted through microspin G25 column (GE Healthcare). Trypsin was 
added at 1:500 and the reaction was allowed to proceed at room temperature. Aliquots were 
removed from the reaction tube at the times specified in the figure legend, and the 
proteolysis was stopped by addition of an equal volume of 2xLB, followed by immediate 
freezing.  
2.7.2 Urine spiking experiments 
Urine samples from healthy volunteers were obtained according to the guidelines of the 
MRC Regulatory Support Centre. Urine samples were first spun (2,500rpm, 10min, RT; 
Sorvall Legend RT Plus centrifuge) to remove any cellular material and then either stored at 
-80ºC or used immediately. 
For incubation of detergent-lysed cells in urine, EJ28 and RT112 cells were lysed in 0.5% 
Triton-X100 and added to the urine supernatants at a concentration such that 5x105 cells was 
collected per time point (0.95mL urine). Cell lysates-spiked urine was incubated in the 
refrigerator (approx. 4ºC) and at 37ºC and time points were harvested at times specified in 
the figure. Harvested samples were kept at -80ºC until the end of the experiment, when they 
were batch-processed for TCA precipitation. 
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TCA precipitation of 950µL urine supernatant was performed by adding 10µL 2%(w/v) 
sodium deoxycholate (20min, 4ºC), followed by 100µL 100%(w/v) TCA. After 1h and 
15min on ice, samples were spun (16,000xg, 15min, 4ºC) and the pellet was washed in 1mL 
acetone, 0.05M HCl followed by 1mL acetone. Pellets were dried and resuspended in 50µL 
1xLB and the pH was adjusted using 1M Tris pH8.5 where necessary. Ten microlitre 
samples were loaded on SDS-PAGE for immunoblotting analysis. 
For incubation of whole cells in urine, harvested intact EJ28 cells (2x106 per time point) 
were added to 6.5mL processed urine aliquots in small tissue culture flasks with a filter cap 
to ensure good ventilation of the samples. Flasks were incubated in the refrigerator (approx. 
4ºC) and at 37ºC. At each time point, a flask was removed from the incubator and a 20µL 
sample of the urine was visualised under the light microscope for the number and general 
morphology of the cells. Urine was then spun (2,000rpm, 5min, RT; Sorvall Legend RT 
Plus centrifuge). Supernatant was processed for TCA precipitation, as detailed in the 
previous paragraph, whereas the cell pellet was resuspended in 400µL 1xLB. Ten microlitre 
samples were loaded on SDS-PAGE for immunoblotting analysis. 
2.7.3 Colonocyte analysis 
The isolation of colonocytes from stools of cancer patients was performed by E Ikelle. Both 
the plasma/thrombin-clot (Figure 5.3) and the liquid (smear) technique (Figure 5.7) of 
colonocyte isolation were used, as previously published (White et al., 2009). Permission to 
carry out this study and consent from the patients was obtained in accordance with the Local 
Research Ethics Committee guidelines (N Coleman & colleagues). 
2.7.4 Pilot study of Sld5 detection in clinical urine samples 
The permission for the study was obtained from the Local Research Ethics Committee 
guidelines (DE Neal & colleagues). Urine samples were obtained from men attending the 
prostate and bladder cancer clinics at the Addenbrooke’s Hospital, Cambridge with 
symptoms suggestive of prostate or bladder cancers, but before any treatment was started. 
Patient recruitment and sample collection was done by J Burge and colleagues at the clinic. 
Complete protease inhibitors tablet (Roche; 1 tablet per 50mL or less of urine) was added to 
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the urine samples immediately after collection; and care was taken to keep the samples on 
ice and process them as fast as possible, typically within 1h of the clinic closing time.   
To process the samples, urine was spun (2,500rpm, 10min, RT; Sorvall Legend RT Plus 
centrifuge) and the supernatant was immediately frozen down in 10-25mL aliquots at -80ºC. 
The pellet was washed in 50mL PBS and fixed in 1mL 4% paraformaldehyde in PBS (5min, 
RT). One millilitre of TBS was added to stop the fixation and then the fixed cells, cell 
fragments and other debris in the pellet were spun onto poly-L-lysine (Sigma, catalogue 
number P0879) coated coverslips (2000rpm, 5min, RT; Sorvall Legend RT Plus centrifuge). 
Cells were briefly washed in TBS and stored in absolute ethanol at -20ºC until batch 
processing for immunofluorescence (which begun by rehydrating and permeabilising the 
cells for 5min in TBS, 0.2% Triton-X100, 0.04% SDS), as described in section 2.5.5. A few 
samples were processed by AD Mills in my absence to ensure that maximum number of 
samples could be recruited for the study. 
Stained samples were analysed by confocal microscopy by myself and AD Mills. We were 
unaware of the clinical diagnosis and each other’s findings when analysing the slides. 
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Chapter 3 Production of recombinant GINS and 
GINS antibodies 
Introduction 
This chapter describes two key sets of reagents generated during my project: recombinant 
human GINS protein and antibodies against human GINS subunits. At the time when I 
started my project, nothing was known about the structure and biochemical function of the 
GINS protein. There were also no antibodies available against human GINS.  Expression of 
recombinant human GINS was explored with the aim of attempting structural and 
biochemical studies; as well as being able to produce the antigens for production of GINS 
antibodies and the reagents for their characterisation. Production of GINS antibodies was 
explored with the aim of obtaining high-quality reagents for immunofluorescence studies of 
GINS localisation and function in the human nucleus, and to test the applicability of GINS 
proteins as proliferation markers. I generated both rabbit polyclonal and mouse monoclonal 
antibodies, with the latter set aimed at providing perpetual reagents for large-scale studies 
and commercial application of GINS proteins in cancer detection.  
 
Results 
3.1 Recombinant GINS expression and purification strategies 
Human GINS subunits were initially cloned and expressed individually in E.coli for the 
purposes of antibody production (see section 3.2). In agreement with the published data 
(Takayama et al., 2003), hexahistidine-tagged GINS subunits were largely insoluble when 
expressed in E.coli (Figure 3.1A and data not shown). Following affinity purification in the 
presence of 8M urea, Psf2, Psf3 and Sld5 remained soluble upon dilution to 2M urea 
(Figure 3.1B), whereas Psf1 was only soluble in 4 M urea, and then became irreversibly 
insoluble at lower urea concentrations, even after multiple-step dialysis (Figure 3.1C). 
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Figure 3.1 Recombinant hexahistidine-tagged GINS subunits are insoluble in E.coli. (A) Acrylamide 
gel stained with Coomassie. Induced E.coli culture transformed with construct pET-Sld5 was harvested after 
4.5h at 37°C (see lane 1 for SDS-cell lysate), cracked, clarified by centrifugation (Supernatant lane) and the 
pellet resuspended in 75% volume of 8M urea-containing buffer (Pellet lane). (B) Antigens used for rabbit 
immunisation. Insoluble (8M urea) fractions of the induced E.coli lysates transformed with the expression 
constructs pET-Psf2, pET-Psf3 and pET-Sld5 respectively were purified over separate Ni-columns and diluted 
into a 2M urea-containing buffer before analysing the samples by SDS-PAGE and Coomassie staining. (C) 
Hexahistidine-tagged Psf1 was purified in the same way as in (B), except that the affinity purified protein was 
subjected to dialysis. Samples after dialysis into 4M and 2M urea were spun and the supernatants analysed by 
SDS-PAGE and Coomassie staining. 
In the light of high yields of the recombinant protein needed for antibody production, I 
investigated the possibility of studying the human GINS complex biochemically. To achieve 
this, I attempted three different purification strategies in turn (Figure 3.2), which are 
described below. 
 
Figure 3.2 Flow-chart summary of the three purification methods presented in Figure 3.3 (refolding), 
Figure 3.4 (co-expression) and Figure 3.5 (simplified co-expression). 
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3.1.1 Refolding strategy 
My co-immunoprecipitation studies (shown and discussed later; Figure 3.19) and data 
published by others (Gambus et al., 2006, Moyer et al., 2006) suggest that GINS subunits 
form a tight complex in vivo. I therefore mixed affinity-purified subunits in 8M urea in 
approximately equimolar ratios before performing a multiple-step dialysis with decreasing 
urea concentration (see Figure 3.2 for a flow-chart of the entire purification procedure). This 
treatment yielded a soluble fraction containing all four subunits (Figure 3.3A, 1×TBS lane). 
Note that most individual GINS subunits (Sld5, Psf3, Psf2) were all insoluble in solutions of 
less than 2M urea (data not shown), whereas Psf1 on its own was only soluble down to 4M 
urea (Figure 3.1C). 
The soluble fraction was investigated by gel filtration. The most prominent peak (Figure 
3.3B, 185mL peak) eluted at roughly the volume expected of a heterotetramer and contained 
the four subunits with a convincing 1:1:1:1 stoichiometry (Figure 3.3A, fraction 18). I 
consistently observed a portion of the soluble fraction eluting with the void column volume 
(Figure 3.3B, fraction 11). I take this to represent the high MW aggregates, which inevitably 
form during refolding, perhaps due to non-stoichiometric ratios of the subunits before 
dialysis (note that similar high MW aggregates were observed during refolding of individual 
subunits on their own; data not shown) and possibly because in vivo folding is edited by 
chaperones.  
Despite the sub-analytical resolution of the preparative gel filtration column used in this 
experiment, it should nevertheless be noted that the peak protein fraction eluted from the 
column later than expected (185mL (85kDa) as detected on the A280 trace in Figure 3.3B 
versus predicted 180mL (101kDa) for a His-tagged heterotetramer). In light of experiments 
with the untagged recombinant complex (see below), this slight retardation could be a result 
of the charged His-tags that were present in all subunits. Alternatively, the peak fraction 
might contain a mix of species (e.g. heterotrimers), but the symmetric peak centred on the 
fraction 18 on the A280 trace (Figure 3.3B) suggests that it was produced by a single 
species. Nevertheless, the presence of other peaks on the A280 trace indicates that other 
subcomplexes might exist in the refolded sample. Fractions other than 18 displayed 
considerable variation in subunit composition from experiment to experiment (three 
independent large-scale purifications were performed). This may reflect the slight 
differences in the ratios of certain subunits in the intial 8M urea mix (data not shown). 
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Different subunits, especially Psf2 and Sld5 seem to be eluting ahead of fraction 18 (panel 
C), perhaps hinting at a formation of subcomplexes of potential in vivo relevance. It should 
be noted that the tighter association of Sld5 and Psf2 is consistent with the behaviour of the 
purified native complex in budding yeast (Gambus et al., 2006).   
Combined peak fractions from the gel filtration (fractions 18 and 19 in Figure 3.3A) were 
loaded on the MonoQ column. The four subunits were found to co-elute (Figure 3.3C, 
fraction 9) in one near-symmetric peak (Figure 3.3D), indicative of a homogeneous 
population. Psf3 had a slight tendency to dissociate from the complex at 300mM NaCl 
(Figure 3.3C, fractions 6 and 7), hinting at its weaker association compared to other 
subunits.  
The reproducible outcome of the multiple-step dialysis and further purification, and the 
increased solubility of Psf1 in the presence of other GINS subunits all indicate that this 
approach constitutes a viable method for obtaining recombinant GINS protein for 
biochemical studies.  
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Figure 3.3 Combined recombinant GINS subunits can be successfully refolded and purified for 
biochemical studies. (A) Purified recombinant hexahistidine-tagged GINS subunits were combined in 
approximately equimolar ratios (“8M urea”) and refolded by multiple-step dialysis from 8, through 4, 2 to 0 M 
urea. Supernatant (“1×TBS”) after dialysis (7mL) was loaded onto Superdex-200 gel filtration column and 
20µl portions of the eluting 10-mL fractions  analysed by SDS-PAGE followed by Coomassie staining. Pellet 
after dialysis (“Pellet”, 4× concentration of the supernatant) was included for comparison. (B) A280 trace of 
the chromatography run in (A). (C) Fractions 18 and 19 from the gel filtration column in (A) were combined 
(“Load”), loaded onto 1mL MonoQ column and the bound protein eluted by increasing salt concentration. 
Indicated portions of the eluting fractions (0.5mL) as well as the unbound material (FT1 and FT2) were 
analysed by SDS-PAGE followed by Coomassie staining. (D) A280 and conductivity (diagonal line) traces of 
the MonoQ column run from (C). 
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3.1.2 Co-expression strategy 
The reconstitution experiments of the entire GINS complex (Figure 3.3), whilst successful, 
nevertheless used His-tagged subunits, which might interfere with refolding and/or 
biochemical properties of the complex. Therefore, I next attempted an improved expression 
and purification strategy to circumvent the potential problem that four His-tagged subunits 
may pose by coexpressing the heterotetramer in a single E.coli strain. To this end, I cloned 
human GINS subunits into pCDF-Duet and pCOLA-Duet vectors, engineering a TEV-
cleavable hexahistidine tag to the C-terminus of Sld5 and leaving the rest of the subunits 
untagged. 
Analysis revealed that the majority of Sld5 was insoluble (Figure 3.4B, lane 1), but this 
might be due to non-stoichiometric expression levels of the different subunits upon 
induction (Figure 3.4A). Indeed, when the soluble whole-cell extract from 0.5L of induced 
E.coli culture was purified over a Ni-column, I was able to recover approximately 1.5mg 
GINS from the eluate. This represents at least an 8-fold increase in yield per unit volume of 
bacterial culture compared to soluble (ie not refolded solubilised) yields obtained upon 
independent expression of subunits (data not shown).  
In order to improve the purity of the recombinant proteins and cleave off the hexahistidine 
tag, which might be affecting the properties of the complex, I performed TEV digestion of 
the desalted eluate from Figure 3.4B (lanes 5–7). Optimisation under a range of 
temperatures (4, 30, 37°C) and duration of digestion (between 1h and 8 days) failed to 
define a condition where complete digestion could be observed (Figure 3.4C and data not 
shown). Furthermore, the GINS complex containing the Sld5 species with the hexahistidine 
tag cleaved off was partially unstable (Figure 3.4C, compare lanes 1 and 2). Moreover, 
when the TEV-treated reaction was passed over a Ni-column, tagged Sld5 failed to bind the 
matrix, although His-tagged TEV did (Figure 3.4C, lane 3). The apparent inability to bind 
was not dependent on presence of TEV or DTT in the reaction, and was consistently 
observed both in desalted and dialysed protein samples (data not shown). A proposed 
explanation is given below. This problem could be overcome by digesting with TEV on the 
column in batch mode, although it is not clear how much the presence of a His-tag on TEV 
would affect the efficiency of this reaction, perhaps also requiring a longer linker. 
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To further characterise the digested protein sample, eluate from the Ni-column (Figure 
3.4C, lane 3) was loaded onto a gel filtration column and the eluting fractions analysed by 
immunoblotting (Figure 3.4D). Hexahistidine-tagged Sld5 primarily eluted with the void 
column volume (fraction 2), suggesting that its inability to bind the Ni-column could be 
because of aggregation forming very high MW clusters, possibly coordinated by the His-
tags. Promisingly, all four GINS subunits followed roughly the same elution profile and 
peaked at the elution volume corresponding to approximately 109kDa (fraction 15), whereas 
monomers were barely detectable (data not shown). This is consistent with subunits forming 
a heterotetramer (96.5kDa) with a slight increase in Stokes radius due to the ring geometry 
of the complex (Chang et al., 2007, Choi et al., 2007). 
Co-expression within a single E.coli strain of all four GINS subunits (His-tagged Sld5 and 
untagged Psf1–3) produced higher yields of soluble GINS complex. Although complete 
cleavage of the His-tag from Sld5 was not achieved, it is likely that this complex would 
behave more like a native complex than that reconstituted from the refolding strategy 
because of the four His-tagged subunits (Section 3.1.1).  
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Figure 3.4 Co-expression of GINS subunits increases their solubility in E.coli. (A) Induction profile of 
exponentially growing E.coli culture carrying pCOLA-Psf3-Psf1 and pCDF-Psf2-Sld5His expression vectors. 
SDS-lysates of the culture were made at the indicated time points and analysed by SDS-PAGE and Coomassie 
staining.  (B) Affinity purification of soluble GINS complex from the induced E.coli culture from (A) 
(resolved by SDS-PAGE, stained by Coomassie). Cracked whole-cell extract was spun (Load) and passed over 
a Ni-column. Flow-through (FT) and pellet (3-times as concentrated) were saved for comparison. After 
washing and mild elution with 15mM imidazole (NE), bound material was eluted with 500mM imidazole (E1–
E4). Note that only Sld5 was hexahistidine-tagged. (C) Positive elution fractions from (B) were desalted to 
remove imidazole and then digested with TEV at 4ºC for 2.5 days. Resulting sample (+TEV) was spun to 
remove insoluble material. Supernatant (Soluble TEV) was loaded onto Ni-column and the flow-through (Ni-
NTA FT) collected for down-stream applications. The identity of bands labelled in the close-up picture was 
confirmed by immunoblotting (see panel D) and MALDI-TOF. (D) Unbound Ni-column fraction from C (lane 
3) was loaded onto Hi-load 26/60 Superdex-200 gel filtration column. Eluting 5mL fractions (fraction 1 
corresponds to 105mL) were analysed by immunoblotting using rabbit antisera. 
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3.1.3 Crystallisation attempts 
The end product of refolding strategy purification (Figure 3.3C, 0.5mL of approximately 
15mg/mL protein in lane 9) reproducibly formed small crystals in crystallisation attempts by 
L Pellegrini. Unfortunately, there was a kinetic barrier to the growth of the crystals under a 
range of conditions, which could not be overcome (L Pellegrini, personal communication).  
In the hope of purifying a better quality co-expressed complex for further crystallisation 
attempts, I later expressed the complex without any hexahistidine tags (data not shown). 
The optimisation of this expression strategy was interrupted by prolonged illness and 
intermission. By the time I resumed my experimental work, four independent groups had 
reported the crystal (Kamada et al., 2007, Choi et al., 2007, Chang et al., 2007) and single-
particle electron microscopy (Boskovic et al., 2007) structure of the human GINS complex, 
negating my need for further attempts.  
3.1.4 Simplified co-expression strategy 
I later revisited the purification of the complex to provide the reagent for ELISA screening 
of GINS antibody-expressing hybridomas (section 3.2.2). The simplified co-expression 
strategy was also used in an attempt to reconstitute the entire CMG complex in 
collaboration with R Parker and JP Chong, who had purified soluble human MCM by co-
expression of hexahistidine-tagged subunits in E.coli (personal communication).  
Given the presence of multiple hexahistidine tags in the recombinant MCM, I decided to 
leave the Sld5 protein tagged in the first instance and therefore substantially simplify the 
purification strategy (see flow-chart in Figure 3.2). I co-expressed the four subunits in a 
single E.coli strain as before (section 3.1.2), except that the Ni-NTA column eluate was next 
resolved by gel filtration (Figure 3.5A) and finally concentrated using the MonoQ column 
(Figure 3.5B). This resulted in a reasonably purified and concentrated complex as seen in 
this Coomassie-stained gel (Figure 3.5B). Fraction 15 (Figure 3.5B) contained 750µg GINS 
tetramer at a concentration of 250µg/mL from 2L of induced bacterial culture.  
The stoichiometry of the final eluting fraction was not as good as for the final eluate 
recovered after the refolding strategy (compare Figure 3.5B, fraction 15 with Figure 3.3C, 
fraction 10), which also agrees with a slightly asymmetric A280 peak surrounding fraction 
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15 (Figure 3.5B). The main difference between the two MonoQ purifications was that the 
one presented in Figure 3.5B has a higher binding capacity and used a shallower salt 
gradient with the aim of better resolving the contaminating bands from the GINS tetramer. 
This further suggests that Psf3 is the most weakly associated subunit of the human complex, 
as noted above (3.1.1) and in the literature for yeast and frog GINS complex (Takayama et 
al., 2003, Kubota et al., 2003). Stoichiometry of the final eluate in Figure 3.5B could have 
also been affected by the non-stoichiometric expression levels of the different subunits in 
bacteria (Figure 3.4A). This could have been tackled by tagging the poorest-expressing or 
most insoluble subunit (Psf1) rather than Sld5. 
 
Figure 3.5 Co-expression of GINS subunits without removal of His-tag on Sld5.  (A) GINS tetramer 
was expressed and purified as before (untagged Psf1-3 and His-tagge Sld5; Figure 3.4A and B). Eluate from 
the Ni-NTA column (‘Load’) was loaded onto Hi-load 26/60 Superdex-200 gel filtration column. Eluting 
fractions (5mL) were analysed by SDS-PAGE and Coomassie staining.  (B) Four fractions (185-200mL) from 
the gel filtration column in A were combined (‘Load’), loaded onto 7.85mL MonoQ column and the bound 
protein eluted by increasing salt concentration. Eluting fractions (3mL) were analysed by SDS-PAGE 
followed by Coomassie staining.  
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Purified tetramer (e.g. fraction 15 in Figure 3.5B) was sent to R Parker for biochemical 
characterisation. He confirmed that my protein preparation does not have any helicase 
activity, but has so far not been able to test whether the protein is biochemically active in 
the MCM assays due to unrelated technical difficulties (R Parker, personal communication).  
In summary, co-expression without cleavage of the His-tag from Sld5 substantially stream-
lined the purification process and produced good yields of pure GINS complex. For future 
use in biochemical studies, the concentration and stoichiometry of this protein preparation 
could be improved further to match those originally achieved using the refolding strategy. 
This could possibly be achieved by using alternative His-tagged subunits, as mentioned 
above, and/or scaling up the volume of the induced E.coli culture. 
3.2 Antibody generation 
Good antibodies against GINS proteins were essential to address the aims of this research 
project (1.8). When I started, there were no good commercial antibodies or published 
reagents available against human GINS (a GenWay Psf2 antibody was tested, but only 
produced a faint Psf2 signal with various cross-reacting bands by western blotting; data not 
shown). I therefore generated my own. Rabbit polyclonal antibodies were characterised at 
the start of my degree, except for the rabbit Psf3 antibody, which was generated at the end 
of my 6 months MSc project (Figure 3.6A, panel ‘Crude rPsf3 antisera’). Rabbit polyclonal 
antibodies were the key reagents for studies presented in chapters 4 and 5. Mouse 
monoclonal antibodies were generated in my final year, so they were only available for a 
couple of months before the end of experimental work. They nevertheless proved most 
valuable in verifying the high-resolution confocal microscopy findings obtained with rabbit 
antibodies (Figure 4.12) and in giving the work on GINS proteins as cancer markers a 
secure future (Chapter 5).      
3.2.1 Rabbit polyclonal antibodies 
Immunisation of rabbits for the production of rabbit polyclonal antibodies against the four 
GINS subunits was done by CovalAb, whereas I performed all the other steps, including 
antigen purification, testing of bleeds and modifications to the immunisation protocol.  
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Two and four rabbit polyclonal antisera were raised per Sld5/Psf3 and Psf2/Psf1 subunits, 
respectively, using full-length recombinant proteins shown in Figure 3.1B and Figure 3.1C 
(lane 2) as immunogens. As summarised in Table 3-i, all antisera recognised a band 
corresponding to the respective subunit by immunoblotting in both human and mouse 
extracts, although the signal was very weak for Psf1.i, Psf1.ii, Psf2.i, Psf2.ii, and Psf3.i. 
Signal strength was improved upon prolonged immunisation of the next 4 rabbits injected 
with Psf1 and Psf2 antigens (rabbits Psf1/2.iii and Psf1/2.iv in Table 3-i). All antisera 
displayed some degree of binding to higher molecular weight bands in cell extracts (Figure 
3.6A), These bands were generally much weaker than the immunogen band and varied 
between rabbits injected with the same antigen (data not shown). They were therefore 
considered to be non-specific.  
Injected 
antigen 
Rabbit 
ID 
Relative intensity 
of WB staining  
(1:1,000) 
Outcome of affinity purification  
(WB evaluation; Figure 3.6 and data not shown) ID of the best performing 
fraction 
Sld5.i ++++ Efficient removal of background staining rSld5B Sld5 
Sld5.ii +++++ Efficient removal of higher molecular weight cross-
reacting band 
rSld5 
Psf3.i +(+) Not attempted N/A Psf3 
Psf3.ii +++ Efficient removal of higher molecular weight cross-
reacting band 
rPsf3 
Psf2.i + None 
Psf2.ii + 
Not successful (low pH, high pH, high salt elution 
attempted) None 
Psf2.iii ++ Efficient removal of background staining and 
increased intensity, but one high-molecular weight 
cross-reacting band remaining 
rPsf2 
Psf2 
Psf2.iv ++ Efficient removal of background staining and 
increased intensity, but one high-molecular weight 
band cross-reacting remaining1 and substantially 
stronger than the Psf2 band 
None 
Psf1.i (+) N/A 
Psf1.ii (+) 
Not attempted 
N/A 
Psf1.iii +(+) Efficient removal of background staining and 
increased intensity, but several weak cross-reacting 
bands remaining 
rPsf1B 
Psf1 
Psf1.iv +(+) Efficient removal of background staining and 
increased intensity, but one high-molecular weight 
cross-reacting band remaining 
rPsf1 
 
1 Higher-molecular weight cross-reacting band was of different mobility to the one identified with Psf2.iii antisera. 
 
Table 3-i Summary of rabbit antisera testing and purification. Western blotting (‘WB’) was performed 
using both HeLa and mouse NIH3T3 whole-cell extracts. 
Unpurified antisera were useful for immunoblotting (with the addition of the appropriate 
controls), but needed to be purified in order for the antisera to be reliable for other 
applications. I therefore used affinity chromatography to purify 9 out of the 12 antisera, as 
summarised in Table 3-i. Fractions recovered from the affinity columns were tested by 
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immunoblotting. Only the best eluting fraction for each subunit is presented in Figure 3.6, 
although it should be noted that I also purified alternative antibodies (from another pair of 
rabbits) recognising Sld5 and Psf1 (termed rSld5B and rPsf1B; see Table 3-i).  
Psf3 and Sld5 purifications resulted in antibody fractions with improved specificity for the 
respective antigens. Western blots probed with these enriched fractions recognised Psf3 and 
Sld5 (Figure 3.6B).  No significant non-specific binding could be detected in HeLa or 
mouse extracts (lanes 2, 3, 6, 7 – note absence of higher molecular weight bands), even after 
prolonged exposure (data not shown). Neither antisera reacted cleanly with the frog egg 
extract. However, they still recognised bands corresponding to the expected size for XlPsf3 
and XlSld5 (Figure 3.6B, lanes 4 and 8).   
Psf1 and Psf2 purifications did not remove antibody species that cross-reacted with higher 
molecular weight bands, but did improve the background staining (grey staining across the 
whole membrane in Figure 3.6A is substantially reduced in panel B). Unfortunately, the 
rPsf2 cross-reacting band appears to be present in the nucleus (Figure 3.6C), which might 
make this antibody unsuitable for immunostaining of intact cells. Nevertheless, it should be 
noted that non-specific binding, which the purified antisera exhibit on denatured protein 
extracts separated by SDS-PAGE might not necessarily exist in the three-dimensional 
environment of the cell, where proteins assume their proper folded and interacting state. 
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Figure 3.6 Evaluation of affinity-purified rPsf3, rSld5, 
rPsf1 and rPsf2 antibodies. Extracts were a gift from AD Mills.  
(A) Western blots were performed on recombinant protein 
from Figure 3.1B and  extracts from asynchronous HeLa and 
mouse NIH3T3 cells (approximately 2.5µg protein/lane). 
Membranes were probed with the specified rabbit antisera. 
Pre-immune sera did not recognise any of the bands in this 
figure (data not shown). Panel ‘crude rPsf3 antisera’ was 
generated during my MSc project, but is included here because 
it enables evaluation of the rPsf3 antibody purification.  (B) 
Similar experiment to that in panel A, this time with the 
addition of Xenopus laevis egg extract in the left two 
membranes (‘Xl’; approximately 3µg protein/lane). The 
membranes were probed with the specified purified antibodies.  
(C) Western blotting of nuclear soluble and chromatin-bound 
fractions from SKOV3 cells using purified rPsf2 antibody.  
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Given the clean signal of the purified GINS antibodies by immunoblotting (Figure 3.6), I 
tested their staining pattern by immunofluorescence. For these assays I used the same vial of 
purified antibodies that was simultaneously used to probe SDS whole-cell lysates of HeLa 
cells by western blotting. This was to reconfirm the purity of purified antibodies. The initial 
tests for rabbit antisera (Figure 3.6) were all performed on dounce-homogenised and spun 
extracts. With this processing a loss of protein due to insolubility and/or degradation during 
homogenisation could contribute to an artefactually cleaner signal on the western blot. SDS 
whole-cell lysates are a more rigorous test of the purity of the antibodies.  
All antisera produced a predominantly nuclear stain with punctate foci (Figure 3.7B). This 
staining was absent from nuclei probed with pre-immune rabbit sera (data not shown). 
Exclusion of the antibodies from condensed chromatin was observed in mitosis, combined 
with a slight increase in the cytoplasmic staining (Figure 3.7B, cells marked ‘M’ and data 
not shown for Sld5), as would be expected for proteins with constant protein levels during 
the cell cycle that are released from the chromatin during mitosis but not degraded (Aparicio 
et al., 2009). 
Anti-rPsf3 produced the cleanest staining pattern by immunoblotting (a single band of 
expected MW, Figure 3.7C) and immunofluorescence (almost no cytoplasmic staining and a 
strong nuclear stain, Figure 3.7B). Staining with rSld5 showed a stronger cytoplasmic 
component than rPsf3 (Figure 3.7B) and more cross-reacting bands on the strip blot (Figure 
3.7C). Antibodies rPsf1 and rPsf2 showed the highest degree of cytoplasmic staining and 
the lowest signal-to-noise ratio on the western blot. In all cases, the cytoplasmic signal was 
virtually undetectable at higher dilutions of the antibody, whilst the nuclear punctate pattern 
remained prominent.  
The Sld5 band on the strip blot was stronger than the bands from other GINS subunits 
(Figure 3.7C); this could either be because of the higher titre or affinity of the rSld5 
antibody for denatured Sld5, or because of higher concentration of Sld5 protein in the cell 
(Figure 4.1). Nevertheless, it is interesting to note that the stronger signal on the western 
blot does not obviously correlate with a stronger immunofluorescent Sld5 signal in the 
nucleus (Figure 3.7B). 
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Figure 3.7 Titration of purified rabbit GINS antisera for use in high-resolution immunofluorescence 
microscopy.  (A) Serial dilution test for immunofluorescence (merged DNA and antibody stain images). HeLa 
asynchronously cycling cells were grown on coverslips, fixed, permeabilised and immunostained using the 
purified rabbit antisera at the specified dilutions. All images for a specific antibody were taken with the same 
settings.  (B) (NEXT PAGE) Images from panel A, showing the rabbit antibody channel only. DNA stain 
showed colocalisation with the strong antibody stain (see panel A), except on condensed chromatin (cells 
marked ‘M’).  (C) (NEXT PAGE) Strip immunoblotting of the same antisera (0.1%v/v dilution of each). 
Expected migration of the GINS subunits is marked; note that MW of Psf1 is greater than that of Psf2 but their 
migration on SDS-PAGE appears to be reversed (for example, see Figure 3.4C), as also reported by others 
(Aparicio et al., 2009). 
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All in all, I successfully generated rabbit polyclonal antibodies against all four GINS 
subunits, including 6 purified antibodies (rSld5, rSld5B, rPsf3, rPsf2, rPsf1, rPsf1B), of 
which rSld5 and rPsf3 appeared most specific and strongest by immunoblotting and 
immunofluorescence. They were therefore evaluated in other applications 
(immunohistochemistry and immunoprecipitation), as described below (section 3.3). Crude 
antisera were used throughout my thesis for immunoblotting analysis, whereas the best 4 
purified antibodies (rSld5, rPsf3, rPsf2 and rPsf1) were used for immunofluorescence 
studies. 
3.2.2 Mouse monoclonal antibodies 
Rabbit antibodies were instrumental in enabling me to carry out the key early experiments 
to characterise GINS as a proliferation marker (Chapter 5). Given promising results from 
those experiments and the filing of the patent, I started exploring commercialisation 
strategies for GINS proteins as markers for cancer. I considered it essential to obtain a long-
term solution for the unlimited supply of good-quality (i.e. immunofluorescence- and 
hopefully immunoprecipitation-quality) GINS antibodies. With the help of RA Laskey, AD 
Mills and N Mathon I successfully applied to the Development Grant Fund at MRC 
Technology, which enabled me to finance the work presented in this section.  
My first priority for monoclonal antibody production was to generate good Sld5 monoclonal 
antibodies (Sld5 protein being the focus of Chapter 5), but I also considered it relevant to 
generate antibodies against other subunits, if possible, since the immune response can be 
variable and other subunits, especially Psf1 (which produced the weakest rabbit antibody; 
see Figure 3.6), are also protected by the patent (Bell, 2006).  
Project design was decided in consultation with Babraham Bioscience Technologies (BBT). 
We initially considered injection with the purified soluble tetramer to save some mice. 
However, it was thought that the four subunits might vary in their immunogenic properties, 
judging from their response in rabbits (see above: ‘Intensity of WB staining’ in Table 3-i). 
Combined with superior purity of individually expressed subunits and the need to use the 
soluble tetramer for ELISA screening of positive clones, we decided to express and purify 
the four GINS immunogens independently (Figure 3.8A).  
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After purification over the Ni-column, I dialysed purified subunits into TBS (Figure 3.8B, 
TBS lanes), whereupon Psf1–3 solutions all turned cloudy, whereas Sld5 remained soluble 
(data not shown). Unspun samples were sent to BBT for injection into five Balb/c mice per 
GINS subunit. I also supplied BBT with the soluble recombinant GINS tetramer purified 
according to the simplified co-expression strategy explained above (section 3.1.4). 
 
 
 
 
 
 
Figure 3.8 GINS subunits purified for mouse immunisation. Acrylamide gels stained with Coomassie.   
(A) E.coli cultures were transformed with the indicated constructs and bulked up for protein expression. SDS-
cell lysates were collected before (‘0h’) and at the end of induction (‘+4h’).  (B) After 4h at 37°C, the cultures 
were cracked. The pellets were resuspended in 8M urea-containing buffer and purified over separate Ni-NTA 
columns. Eluates were diluted into 4M urea-containing buffer (‘Urea’ lanes; data not shown for Psf3 and Sld5) 
and dialysed into TBS (‘TBS’ lanes). Identity of marked bands was confirmed by immunoblotting with rabbit 
antisera.  (C) Comparison of recombinant dialysed Psf3 from panel B (‘Old’) with fresh recombinant Psf3 
expressed, purified and dialysed for the second immunisation of mice with Psf3. Equal volumes of both preps 
were loaded. 
Summary of the monoclonal antibody production stages and outcomes is presented in Table 
3-ii. In Stage I, BBT immunised the mice 4 times over a course of 9 weeks. Test bleeds 
were taken after the third immunisation and tested together with pre-immune bleeds in three 
ways (ELISA, western blotting and immunofluorescence), as summarised in Table 3-ii. 
BBT performed and evaluated ELISAs using the purified GINS tetramer that I had supplied 
to them (e.g. Figure 3.5B, fraction 15), whilst I, independently, tested the pre-immune and 
immunised bleeds by strip immunoblotting of HeLa whole-cell lysates (see Figure 3.9A for 
an example) and immunofluorescence of HeLa cells (see Figure 3.9B for an example). 
The best responder from each group (shaded mice in Table 3-ii), selected jointly by BBT 
and myself, was taken through to Stage II for spleenic injection, extraction, cell fusion and 
the first round of cloning. The best clones from each group, where applicable, were again 
selected jointly by BBT and myself based on the same criteria (ELISA, immunoblotting and 
immunofluorescence in decreasing order of importance). Selected clones were subcloned by 
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BBT to obtain stable cultures. BBT sent me the final culture supernatant of the stable 
clones, which I tested by strip immunoblotting (Figure 3.10). After isotyping and affinity 
purification, I also tested the antibodies by immunofluorescence (Figure 3.11). What 
follows is a brief summary of the project outcomes for each of the GINS immunogens. 
  Stage I testing 
Injected 
antigen 
Mouse 
ID 
ELISA rank 
(recombinant GINS) 
WB rank 
(HeLa whole-cell lysates) 
IF rank 
(HeLa) 
Stage II 
summary 
Stage III 
summary 
175.A1 5 4 4 
175.A2 4 5 1 
175.A3 2 1 3 
175.A4 1 2 2 
Sld5 
175.A5 3 3 5 
5 clones 
selected 
for 
subcloning 
(Stage III) 
5 positive 
hybridomas  
192.1 2-3 2 3 
192.2 1 3 2 
192.3 5 4 4-5 
192.4 2-3 1 1 
Psf3 
192.5 4 5 4-5 
No 
positive 
ELISA 
clones 
N/A 
175.D1 Mouse died 
175.D2 1 1 1-3 
175.D3 2 0 (undetectable) 1-3 
175.D4 3 0 (undetectable) 1-3 
Psf2 
175.D5 4 0 (undetectable) 4 
3 clones 
selected 
for 
subcloning 
(Stage III) 
2 positive 
hybridomas 
175.C1 3 2 3 
175.C2 4 3 4-5 
175.C3 5 4 1 
175.C4 1 1 2 
Psf1 
175.C5 2 0 (undetectable) 4-5 
Only 
weakly 
positive 
ELISA 
clones 
N/A 
Table 3-ii Summary of mouse monoclonal GINS antibody production; see text for details. WB = strip 
immunoblotting; IF = immunofluorescence. All pre-immune bleeds tested negative for ELISA, WB and IF 
under Stage I testing (data not shown). 
Sld5 antigen appeared very immunogenic: mice had the largest spleens and substantially 
higher titres compared to other subunits by ELISA (E Astoul, personal communication). 
Correspondingly, we were able to isolate 5 promising clones in Stage II, which BBT  
successfully subcloned into stable hybridoma cell lines. Of these, four displayed a single 
band by immunoblotting (Figure 3.10). I therefore purified these culture supernatants by 
affinity purification to test the concentrated antibodies for immunofluorescence. Purified 
antibodies mSld5A and mSld5B both produced a strong predominantly nuclear focal pattern 
(Figure 3.11) that closely resembles the staining pattern produced by the rSld5 antibody 
(Figure 3.7). Similarly to rSld5, mSld5A and mSld5B also showed exclusion from 
condensed chromatin in mitosis (data not shown). 
The first batch of Psf3 protein (Figure 3.8B) did not produce a satisfactory immune 
response in the mice (data not shown), so a more concentrated and purified antigen (Figure 
3.8C) was injected into 5 new mice. Post-immune bleeds from these mice produced 
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promising results by immunofluorescence, especially bleed 192.4 (Figure 3.9B), which also 
generated a clean, albeit weak, signal by strip immunoblotting (Figure 3.9A). Mouse 192.4 
was therefore chosen for Stage II, but unfortunately did not produce any stable productive 
hybridomas (P Lynch, personal communication). Given time constraints, the decision was 
made to stop this project at that point and save the final bleed of mouse 192.4 for mouse 
polyclonal Psf3 antibodies, which I plan to characterise in due course. At the same time, 
BBT decided to boost mice 192.1 and 192.2 (the other two good ELISA responders) with 
Psf3 in TitreMax adjuvant and freeze down the spleenic cells so that the project could be 
revisited in the future. 
Psf2 immunisation only elicited one satisfactory mouse immune response (175.D2), which 
was sacrificed for Stage II and ultimately produced 3 stable hybridomas at the end of Stage 
III. Two of these clones produced antibodies that detected a Psf2-size band by 
immunoblotting, whereas the supernatant from clone 6G3.H1 tested negative (Figure 3.10), 
even when the culture supernatant was used undiluted (data not shown). This is most 
probably due to a very low concentration of Psf2-specific antibodies in the culture 
supernatant (ELISA score was less than third that of the other final culture supernatants; P 
Lynch, personal communication). The two positive clones were concentrated by affinity 
chromatography. Purified mPsf2B antibody still strongly reacted with a higher molecular-
weight band (data not shown) and was therefore not tested for immunofluorescence. 
Purified mPsf2A produced a strong predominantly nuclear focal pattern (Figure 3.11) that 
closely resembles the staining pattern produced by the rPsf2 antibody (Figure 3.7). Notably, 
cytoplasmic staining by mPsf2A was stronger than that of mSld5A and mSld5B, relative to 
the strength of the nuclear stain (compare the relevant panels in Figure 3.11) and its 
exclusion from condensed chromatin, although visible, was less striking (data not shown).  
Psf1 fusions responded poorly in Stage II with only 2 weakly positive clones identified by 
ELISA (P Lynch, personal communication). When the initial mouse bleed was tested on 
HeLa whole-cell lysates with siRNA-reduced Psf1 protein levels, I did not observe the 
reduction in the signal that was detectable by rPsf1 antibodies (data not shown). It was 
therefore decided to stop the Psf1 project in the interest of prioritising characterisation of 
clones against other GINS subunits.  
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Figure 3.9 Validation of mouse 
bleeds drawn pre- and post-
immunisation with Psf3 recombinant 
protein.  (A) Strip immunoblotting 
using HeLa whole-cell lysates. Strips 
were probed with the specified 
antibodies/sera at 1:500 dilution and 
aligned before exposure to x-ray film.  
(B) Indirect immunofluorescence 
microscopy of HeLa cells grown on 
coverslips. Mouse bleeds were used at 
1:50 dilution. Only the mouse 
antibody channel images are shown; 
DNA stain images were also collected 
and showed colocalisation with the 
strong antibody stain (data not 
shown), except on condensed 
chromatin (cells marked ‘M’). 
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In summary, the project fulfilled its main aim by isolating stable Sld5-producing 
hybridomas (Table 3-ii; 5 clones in all). Four of these antibodies produce a single band on a 
western blot (Figure 3.10) and two of them (mSld5A and mSld5B) hold promise as 
immunofluorescence-grade antibodies (Figure 3.11). The project was also partially 
successful at complementing the repertoire of rabbit polyclonal antibodies against other 
GINS subunits with a pair of substantially stronger Psf2 monoclonal antibodies (Figure 
3.10: compare rPsf2 and mPsf2A/B signal), one of which appears suitable for 
immunofluorescence studies (mPsf2A; Figure 3.11), and a potential mouse polyclonal anti-
Psf3 antibody with a good immunofluorescence staining pattern (Mouse ID 192.4, Figure 
3.9B), which has yet to be fully characterised. A selection of the monoclonal antibodies may 
prove useful for commercialisation, part of the requirement from MRC Technology, donors 
of the Development Grant Fund.   
 
Figure 3.10 Strip immunoblotting of final (Stage III) culture supernatants of mSld5 and mPsf2 mouse 
hybridoma cell lines. HeLa whole-cell lysates were resolved by SDS-PAGE and processed for strip 
immunoblotting. Culture supernatants were used at 1:5 dilution.  
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Figure 3.11 Titration of mSld5 and mPsf2 purified antibodies for 
immunofluorescence microscopy. Hybridoma culture supernatants from 
Figure 3.10 were purified using protein G affinity chromatography. Eluting 
fractions were tested for the strength of the signal by strip immunoblotting 
(data not shown). Based on the signal strength, a set of dilutions was chosen 
to test by indirect immunofluorescence microscopy of HeLa cells grown on 
coverslips. Only the mouse antibody channel images are shown; DNA stain 
images were also collected and showed colocalisation with the strong 
antibody stain (data not shown). Images for mSld5A, mSld5B and mSld5C 
were collected under the same conditions. Laser intensity and gain were 
increased to collect the mSld5D images.    Scale bar: 10µm. 
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3.3 Antibody validation 
Having generated a large set of antibodies against GINS subunits, it was important to 
carefully validate them for use in colocalisation studies (Chapter 4), cancer screening 
(Chapter 5) and for potential commercialisation (of mouse monoclonal antibodies).  
Section 3.3 focuses on the validation of the best antibodies identified in section 3.2 (rPsf1, 
rPsf2, rPsf3, rSld5, mSld5A, mSld5B and mPsf2A) since they are the ones used in further 
experiments described in this thesis. I first describe validation of the antibodies by siRNA 
depletion, which was complicated by the difficulties in achieving a good degree of knock-
down of GINS subunits. I then present further evaluation of the antibodies for use in 
immunohistochemistry and immunoprecipitation.  
3.3.1 Validation by siRNA depletion 
Clean immunoblotting signals of the expected size, nuclear staining pattern by 
immunofluorescence and good agreement between mouse and rabbit antibodies in both 
applications already provided some assurance that they are specific. It was nevertheless 
essential to show that the western blotting and immunofluorescence signals disappear if a 
GINS subunit is depleted whilst the rest of the proteome is kept as constant as possible.  
Depletion of mRNA by siRNA is probably the most powerful gene silencing tool currently 
available for mammalian tissue cell culture, owing to the efficiency and specificity of 
knock-down (Nature, 2003) and was considered best suited for this purpose. Antigen 
blocking as a means of validating the immunofluorescence staining was also considered, but 
was decided against since antigen blocking cannot distinguish between binding to GINS 
epitopes or to other similar epitopes in the fixed nucleus (Harlow & Lane, 1999). Given that 
all antibodies were affinity purified (rabbit by antigen affinity; mouse by protein G affinity 
column), any remaining cross-reactivity is more likely due to shared epitopes rather than the 
presence of spurious antibodies from the serum/culture supernatant, which should have been 
removed during affinity purification.   
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3.3.1.1 Half-life of GINS proteins in HeLa 
Rate of protein turnover is an important parameter for siRNA depletion experiments; 
proteins with long half-lives might require higher concentrations of siRNA or longer time-
courses to achieve an efficient reduction. To determine the half-life of GINS proteins, I 
treated HeLa cells with cycloheximide, a potent inhibitor of the 60S ribosomal subunit 
(Schneider-Poetsch et al., 2010) and hence any further translation  
Samples from two independent experiments were harvested at intervals after the start of 
cycloheximide treatment and analysed by immunoblotting using two western blotting 
membranes per experiment in parallel. The immunoblotted membranes were exposed on a 
pre-flashed x-ray film multiple times (see Figure 3.12A and Figure 3.12B for sample 
exposures). Both membranes and multiple non-saturated exposures were quantified and 
visualised on a scatter plot (Figure 3.12C). To estimate the half-life of GINS proteins and 
Mcm2 as a control, I added a linear trendline. Other types of regression curves were 
considered (data not shown), but did not fit the data as well as the linear trend. 
According to Figure 3.12C, Sld5 had the shortest estimated half-life of 21.5h; Psf3 half-life 
was estimated at 34.5h and Mcm2 half-life was 42h. These are substantially longer than the 
published data. Mendez and colleagues state the half-life of Psf1-3 subunits to be in the 
order of 8h (Aparicio et al., 2009). Approximately 60% of Mcm3 is turned over in 24h 
(Musahl et al., 1998). It is also unclear what the reason for this difference is; possibly a 
combination of (a) discarding floating cells at each time-point, which should arguably be 
included in the analysis, and (b) pre-flashing the films before exposure, which ensures that 
weak bands are not under-represented (published data might have not used this technique).  
Given these concerns, my half-life values may be over-estimated. Nevertheless, I can 
conclude all four GINS subunits, like Mcm2, have relative long half-lives, ranging from 
21.5h for Sld5 to 35h under my experimental conditions. These long half-lives are likely to 
impinge on the efficiency of siRNA knock-down.  
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Figure 3.12 GINS half-life upon inhibition of protein synthesis by cycloheximide. HeLa cells were 
treated with 20µg/mL cycloheximide (‘CHX’) and harvested as whole-cell lysates at the indicated times. 
Samples were resuspended at 0.5x107cells/mL with accurate cell counting. Harvested cells excluded any cells 
floating cells in the medium (which were clearly visible 2h after the start of treatment and beyond). Samples 
from the first (A) and the second (B) experiment were analysed by quantitative immunoblotting; the same 
membrane was probed with the antibodies indicated on the left in sequence without stripping the membrane 
between incubations.  (C) Scatter plot of experiments from panels A and B. For each time-point, multiple 
exposures from 2 membranes were used to calculate the average intensity, which was then plotted on this 
scatter graph. Two points were discarded as outliers (value greater than 1.1 at 4h after the start of the 
experiment). 
3.3.1.2 Optimising siRNA depletion of GINS subunits 
I first compared 4 pre-designed siRNA molecules per GINS subunit (see Table 2-i for the 
complete list) to determine the most efficient oligonucleotide sequence for knock-down. 
Nucleofection was chosen as the transfection method, given its superior efficiency and 
lower cytotoxicity compared to other non-viral delivery strategies in a range of different cell 
lines (Bradburne et al., 2009). HeLa cells were transfected with target siRNAs or non-
silencing siRNA with no homology to any known mammalian gene (Qiagen, 2009), 
harvested at regular intervals 1, 2 and 3 or 4 days after treatment and processed for 
quantitative immunoblotting. GINS signal was normalised to the actin loading control in 
order to account for any differences in loading or loss of cells during washing.  
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Example results for Sld5 and Psf1 are presented in Figure 3.13. Knock-down was visible for 
all siRNAs tested, although the degree of knock-down varied between siRNA species, with 
siPsf1.2 and siSld5.2 being the most efficient (Figure 3.13C). Generally speaking, the 
knock-down levels were comparable at 2 and 3 days after nucleofection (Figure 3.13C) and 
were almost invariably better than 1 day after transfection (Figure 3.13, panels A and B: 
decreasing trend in signal intensity from day 1 to day 2 for all siRNA species except 
siPsf1.1). I did not harvest day 4 samples for this experiment, but the results of Psf3 siRNA 
time-course below (Figure 3.14B) indicate that day 4 signals would not show a further 
reduction.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Comparison of efficiency of different Sld5 (A) and Psf1 (B) siRNAs. HeLa cells were 
nucleofected with the indicated siRNAs (20µL each at a concentration of 20µM for Sld5, 10µM for Psf1) and 
harvested 1, 2 and 3 days after nucleofection. ‘siControl’ was a highly validated non-silencing siRNA. 
Quantitative immunoblotting was performed on 5x104 cells per lane using the antibodies indicated on the left 
of each panel.  (C) Analysis of panels A and B. Sld5/Psf1 signal was normalised to the total actin before 
comparing it to the Sld5/Psf1 signal in siControl. Day 2 siControl from the same membrane was used for all 
days. Error bars indicate the 95% confidence limits for the mean.  
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Whilst the first set of tests identified an efficient siRNA species for Psf1 knock-down 
(siPsf1.2; Figure 3.13B), it was hoped that Sld5 (Figure 3.13A), Psf2 and especially Psf3 
knock-downs (data not shown) could be improved further. I therefore selected the best 
siRNA species, as summarised in Table 3-iii, and next tested whether combinations of 
siRNAs could result in a better degree of knock-down for Psf2, Psf3 and Sld5 proteins. 
Conclusions are summarised in Table 3-iii. Example results are presented in Figure 3.14 and 
Figure 3.15. 
The combinations of siRNAs produced better degrees of knock-down than single siRNAs 
for Psf3 (compare siPsf3.1+4 and siPsf3.1 curves in Figure 3.14B) and Sld5 (data not 
shown). The kinetics of knock-down appeared to be similar for all subunits, with the 
minimum expression observed 2-3 days after nucleofection (Figure 3.13C, Figure 3.14B and 
further data not shown). For Sld5, siRNA combination siSld5.1+2 reduced the signal by 
80% (data not shown). For Psf3, the reduction in signal appeared not to exceed 50% 
(siPsf3.1+4, Figure 3.14B). On the other hand, the combination of siRNAs did not improve 
the degree of knock-down for Psf2 protein. As demonstrated in Figure 3.15, siPsf2.4 had the 
same if not better effect on its own than in combination with other siRNA species. 
Nevertheless, it should be noted that the efficacy was only compared for one time-point. 
Given that use of multiple siRNAs increases the possibility of off-target effects, it was 
decided to preferentially use siPsf2.4 on its own.  
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Figure 3.14 Time course of Psf3 knock-down and comparison of Psf3 knock-down using a single and a 
combination of Psf3 siRNAs.  (A) HeLa cells were nucleofected with the indicated siRNAs (15µL total 
volume at a concentration of 10µM) and harvested at the indicated days after transfection. ‘siControl’ was a 
highly validated non-silencing siRNA. Quantitative immunoblotting was performed on 1x104 cells per lane 
(except in lane siPsf3.1+4 2d, which was underloaded due to accidental loss of cells during processing) using 
the antibodies indicated on the left of each panel.  (B) Quantitative analysis of panel A. Psf3 signal was 
normalised to the total actin signal before comparing it to the Psf3 signal in siControl. Day 2 siControl was 
used for all days.  
 
 
 
 
 
 
Figure 3.15 Comparison of knock-down efficiency of Psf2 siRNA species in combination.  (A) HeLa 
cells were nucleofected with the indicated siRNAs (20µL at a concentration of 10µM) and harvested 33h after 
transfection. ‘siControl’ was a highly validated non-silencing siRNA. Quantitative immunoblotting was 
performed on 5x104 cells per lane using the antibodies indicated on the left.  (B) Analysis of panel A. Psf2 
signal was normalised to the total actin signal before comparing it to the Psf2 signal in siControl. Error bars 
indicate the 95% confidence limits for the mean.   
As summarised in Table 3-iii, nucleofection using siRNA species on their own or in 
combination resulted in an effective reduction of protein levels for all subunits except Psf3, 
where the maximum reduction observed was only 50% (Figure 3.14B). This fits with my 
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observation that Psf3 is the GINS subunit with the longest half-life in HeLa cells (Figure 
3.12C).  
Mendez and colleagues reported more than 70% knock-down of Psf3 protein in HeLa cells 
using two rounds of lipid-based transfection (Aparicio et al., 2009). This prompted me to 
test if lipid-based transfection could result in a better degree of knock-down for Psf3. M 
Gonzalez transfected a batch of U2OS cells, which I harvested 2 days after transfection and 
analysed the degree of knock-down by western blotting. Even with a single round of lipid-
based transfection, this resulted in a knock-down efficiency comparable to that previously 
published by Mendez and colleagues (Aparicio et al., 2009). This represents a substantial 
improvement compared to transfection by nucleofection, which I speculate is probably due 
to the higher concentration of siRNA delivered per cell by liposomes, although other 
reasons such as differences between cell lines cannot be excluded. Lipid-based transfection 
was also tested on siRNAs against other GINS subunits, as summarised in Table 3-iii, but 
the efficiency of knock-down was comparable to that observed when using nucleofection 
(data not shown).  
 
Figure 3.16 Knock-down of Psf3 protein is more efficient when using lipid-based siRNA transfection. M 
Gonzalez transfected U2OS cells with the siRNA species indicated on the top. I harvested the samples 46.5h 
after transfection for total protein analysis by immunoblotting. Rough quantification of the reduction in Psf3 
signal (which was first normalised to the actin loading control) is given (films were not pre-flashed). 
All in all, I optimised conditions for efficient siRNA-mediated reduction in protein levels 
for all GINS subunits, as summarised in Table 3-iii. Psf3 knock-down was technically the 
most challenging, which might be due to the longer half-life of this subunit (Figure 3.12). 
Importantly, the optimisation of GINS protein depletions by siRNA at the same time 
confirmed the specificity of rabbit antibodies for immunoblotting. The validation of mouse 
antibodies for western blotting and both sets of antibodies for immunofluorescence are 
presented next. 
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Effectiveness of single siRNA species GINS 
subunit Nucleofection (HeLa) Lipid-based (U2OS) 
The most effective siRNA 
combination (HeLa) 
Sld5 si5.2* > si5.1 ≥ (si5.3 = si5.4) 
* 75%, 3d [Figure 3.13A] (si5.2 = si5.4) > si5.3 (si5.1 not tested) si5.1+2  80%, 2d 
Psf3 siPsf3.1 > (siPf3.2 = siPsf3.4) (si3.5 = si3.4) ≥ si3.1 >> si3.2 
(si3.3 not tested) 
Approx. 70%, 2d [Figure 3.16] 
si3.1+4  
50%, 2d [Figure 3.14] 
Psf2 si2.4 > (si2.1 = si2.2 = si2.3) si2.4 > si2.3 > (si2.2 = si2.1) 
 si2.4  
85%, 33h [Figure 3.15]  No advantage over single siRNA species [Figure 3.15] 
Psf1 si1.2* > (si1.3 = si1.4) >> si1.1  
* 90%, 3d [Figure 3.13B] si1.2 = si1.4 > si1.1 (si1.3 not tested) Not tested 
Table 3-iii Summary of siRNA species testing and reference to data presented in this thesis. Where no 
reference is given, data is not shown. Notes in grey refer to the maximum reduction in western blotting signal 
and the time after nucleofection that the reduction was observed. 
3.3.1.3 Antibody validation by siRNA depletion 
Aim of this section was to validate the specificity of key rabbit and mouse antibodies for 
immunoblotting and immunofluorescence studies. This was a time-critical experiment to 
allow me to proceed with studies in the other chapters of my thesis, which is why the data 
was collected before the siRNA knock-down conditions were fully optimised, as can be 
seen by comparing Table 3-iii with Table 3-iv.  
Knock-down was performed on HeLa cells using combinations of siRNA species against 
different GINS subunits. Highly validated non-silencing control siRNA was used as a 
control. The same nucleofection reaction was evaluated by quantitative immunoblotting 
(WB) and immunofluorescence (IF) in parallel. AD Mills also evaluated the Psf3 coverslip 
by ScanR analysis. Table 3-iv summarises the results, which are presented in Figure 3.17. 
siRNA Rabbit 
antibody 
Remaining IF 
signal  
Remaining 
WB signal 
Mouse 
antibody 
Remaining 
IF signal 
Remaining 
WB signal 
siSld5.1+2 rSld5 ↓↓ 0.34 mSld5A ↓↓ 0.17 
siSld5.1+2 rSld5 ↓↓ 0.34 mSld5B ↓↓ 0.19 
siPsf3.1+4 rPsf3 =  
(0.78 by ScanR) 
0.53 mSld5A = 0.90 
siPsf2.2+3 rPsf2 - 0.25 mPsf2A ↓ 0.18 
siPsf1.1+4 rPsf1 ↓↓ 0.44 mSld5B ↓ 0.78 (rSld5) 
Table 3-iv Summary of siRNA validation of the key GINS antibodies. WB signal upon knock-down: 
measured by quantitative immunoblotting using the same mouse or rabbit antibody except for Sld5 on 
Psf1/Psf3 knock-downs. Remaining IF signal was qualitatively scored independently by AD Mills and myself 
as clearly reduced (↓↓), marginally reduced (↓) or no clear difference (=); scores by both observers were in 
agreement. 
WB reduction was observed for all the rabbit antibodies tested, as already noted above 
(3.3.1.2). In addition, I was able to confirm the specificity of mouse antibodies for 
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immunoblotting: reduction in WB signal when probing with mSld5A or mSld5B was 
comparable to rSld5 (Figure 3.17-I-B and Figure 3.17-II-B). Comparable reduction was also 
observed for mPsf2A and rPsf2 (Figure 3.17-IV-B). I was also able to observe a 
concomitant reduction in mSld5 WB signal when I knocked-down Psf1 (Figure 3.17-V-B) 
protein, as reported by others (Aparicio et al., 2009). This further validates Psf1, Psf3 and 
Sld5 antibodies as those recognising subunits of the same (GINS) complex. 
When reduction was observed by WB, the reduction was generally seen by IF as well. This 
agreement was particularly tight for antibodies rSld5 (Figure 3.17-I-A and Figure 3.17-II-
A), mSld5A (Figure 3.17-I-A), mSld5B (Figure 3.17-II-A) and rPsf1 (Figure 3.17-V-A), 
which also detected a substantial reduction in the WB signal (see Table 3-iv). Reduction by 
IF was limited to the nuclear staining; cytoplasmic staining did not change, confirming that 
it is nonspecific (for example, see rSld5 staining in Figure 3.17-I-A).  
When the reduction in WB signal was only 50% or less, the IF signal only showed a 
marginal decrease (mSld5B; Figure 3.17-V-A) or no apparent decrease at all (rPsf3; Figure 
3.17-III-A).  Interestingly, IF signals produced by mPsf2A and rPsf2 did not follow this 
pattern: reduction by WB for these antibodies was 75%, whereas the decrease in IF was 
barely detectable (Figure 3.17-IV). Furthermore, the reduction was uneven: as can be seen 
from Figure 3.17-IV-A, the green signal (rPsf2) was not reduced as much as the red 
(mPsf2A). By immunoblotting rPsf2 displayed more cross-reactivity than mPsf2A (compare 
strip blots in Figure 3.7C and Figure 3.10). A stronger persisting nuclear signal by IF 
following knock-down indicates the persistence of the contaminating cross-reactivity with 
the rabbit antibody, which agrees with the results of the initial validation (Figure 3.6C). 
Given these concerns and the presence of a stronger cytoplasmic staining for these 
antibodies (Figure 3.7B and Figure 3.11), rPsf2 and mPsf2A were not used for high-
resolution immunofluorescence and immunohistochemical studies in subsequent 
experiments. 
As already noted above, I did not observe an obvious reduction in the rPsf3 staining by IF, 
although the WB reduction was 47%. I used the highest tested dilution of the rPsf3 antibody 
(1:400; Figure 3.7A) to stain the coverslip in this experiment (Figure 3.17-III-A) in order to 
minimise the potential cross-reactive signal, as recommended by the literature (Harlow & 
Lane, 1999). However, it is possible that the reduction in the IF signal would be more 
obvious at a higher antibody concentration. AD Mills therefore analysed the coverslip from 
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Figure 3.17-III-A using ScanR to detect any subtle differences in signal intensity between 
the control and knock-down coverslips. I analysed the data, as presented in Table 3-v, and 
confirmed a small (22%) but reproducible reduction in the total nuclear rPsf3 signal.  
Coverslip Nuclei analysed Total FITC (rPsf3) 
signal  
Error Nuclei-adjusted 
average 
Non-silencing siRNA 1374 1.33x106 1.45x104 1.33x106 
Psf3 siRNA #1 1578 1.06x106 1.05x104 1.05x106 
Psf3 siRNA #2 983 1.03x106 1.12x104  
No rPsf3 control #1 1301 2.19x104 9.5x102 2.49x104 
No rPsf3 control #2 330 3.68x104 6.4x103  
Table 3-v Reduction in rPsf3 IF staining upon Psf3 siRNA treatment is detectable by ScanR. I stained 
the coverslips, as detailed in Figure 3.17 legend. AD Mills quantified the total FITC fluorescence by ScanR 
with DNA stain as the mask and I analysed the data. Table presents data for two knock-down coverslips, one 
control coverslip and two coverslips stained with the same primary and secondary antibodies except for rPsf3 
to estimate the background fluorescence (‘No rPsf3 control’). The reduction in signal was calculated as 22% 
by subtracting the background fluorescence from the control and Psf3 siRNA average values and then taking 
the ratio of the two. 
To summarise, this experiment confirmed the specificity of all key GINS antibodies (rPsf1, 
rPsf2, rPsf3, rSld5, mSld5A, mSld5B and mPsf2A) for western blotting. The experiment 
also confirmed the siRNA-sensitivity of the nuclear staining produced by antibodies rPsf1, 
rSld5, mSld5A, mSld5B and rPsf3 in IF. A slight reduction in the nuclear staining was also 
observed for mPsf2A, but there was a large discrepancy between the reduction seen by WB 
and IF, which is why both mPsf2A and rPsf2 were not used in most subsequent 
immunofluorescence and immunohistochemical studies. Discrepancy between WB and IF 
signal was also noted for the rPsf3 antibody, but did not lead to the exclusion of this 
antibody because rPsf3 produced a clean and strong signal by IF and WB (Figure 3.7). 
Importantly, due to the partial nature of the knock-downs used in this experiment, I was 
unable to confirm that all of the IF signal is specific. This is an important consideration for 
high-resolution immunofluorescence studies and is therefore revisited in the next chapter.   
   
Figure 3.17 (FOLLOWING 5 PAGES) Validation of key GINS antibodies for immunofluorescence (A) 
and immunoblotting (B).   This figure consists of 5 pages, page (I) validates antibodies rSld5 and mSld5A, (II) 
validates mSld5B, (III) validates rPsf3, (IV) validates rPsf2 and mPsf2A and (V) validates rPsf1.   HeLa cells 
were nucleofected with the indicated siRNAs and seeded onto coverslips. Coverslips were fixed, 
permeabilised and processed for indirect immunofluorescence of the indicated antibodies using ImageIT and 
BSA as blocking reagents before antibody incubation. Special care was taken to image the focal plane, which 
showed the most intense signal for the channel representing the protein downregulated by siRNA.  (B) HeLa 
cells grown in the same well as the coverslips processed for immunofluorescence were harvested for whole 
cell protein lysates and analysed by quantitative immunoblotting.     
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3.3.2 Immunohistochemical validation 
In collaboration with CG Scarpini and N Coleman, I also further validated the antibodies 
using paraffin-embedded human tissue sections. CG Scarpini stained a range of human 
tissue types using my rSld5 and rPsf3 purified antibodies, which is presented in more detail 
in section 5.2 in the final chapter. As discussed in 5.2, both rSld5 and to a large extent rPsf3 
staining is specific for the nuclei of proliferating cells, and closely mirrors the staining of 
Mcm2, which is a highly validated proliferation marker (Freeman et al., 1999). Data 
presented in Figure 3.18 (my staining with technical assistance from P Stacey) illustrates 
that mSld5A and mSld5B staining is similarly restricted to the nuclei of proliferating cells: 
i. Basal epithelial layer of the normal cervix (see arrows in Figure 3.18A) and 
morphologically distinct pre-malignant areas in dysplastic cervix (Figure 3.18A, 
right picture); 
ii. Larger nuclei of the bladder transitional cell carcinoma but not the smaller 
differentiated nuclei that are not in cycle (Figure 3.18B); 
iii. Nuclei of the glandular tissue of the colon adenocarcinoma, but not nuclei of the 
surrounding differentiated colon tissue (Figure 3.18B, right half).  
This staining pattern suggests that Sld5 holds promise as a specific proliferation marker, 
which will be discussed in detail in the final results chapter (Chapter 5). For the purposes of 
this chapter, I conclude that although the weak mSld5B staining could be improved by using 
a lower dilution of that antibody, both antibodies clearly work for immunohistochemistry, 
producing a clean and specific nuclear stain. This further validates mSld5A and mSld5B for 
use in immunostaining applications.    
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Figure 3.18 Mouse monoclonal antibodies against Sld5 in immunohistochemistry. Brown peroxidase 
staining indicates the presence of bound antibody and was entirely absent from parallel slides stained with the 
secondary and tertiary antibody only (data not shown). P Stacey stained paraffin-embedded tissue sections 
using the specified antibodies. I analysed the staining quality with advice from CG Scarpini about the key 
morphological/pathological features of the examined tissues.    
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3.3.3 Validation of rSld5 and rPsf3 by immunoprecipitaion 
Immunoprecipitation studies of the human cell extracts were performed to further evaluate 
the purified rSld5 and rPsf3 antibodies and study the protein complexes that associate with 
GINS in vivo in human cells. 
Initially, the immunoprecipitation was performed on HeLa nuclear extracts using purified 
rPsf3 antibody. Antibody was able to efficiently immunodeplete Psf3 (Figure 3.19A, lane 5) 
and to a large extent the other GINS subunits from the extract (a hint of Sld5 could still be 
detected in the flow-through, lane 3). An association with Mcm2 or Mcm3 could not be 
detected (Figure 3.19A, lane 5), although I have been previously able to detect a weak two-
hybrid interaction between Mcm2 and all the GINS subunits (N Marinsek and SD Bell, 
unpublished data). 
Subsequently, SKOV3 cells were first fractionated into nuclear soluble and chromatin-
bound fractions. The fractions were immunoprecipitated with the purified rSld5 antibody. I 
observed detectable background staining at the level of Sld5 and Psf3 proteins (Figure 
3.19B, PI lanes), which is most probably due to cross-reactivity of the rabbit antibody eluted 
from the immunoprecipitation column with the rabbit secondary antibody (see discussion in 
section 5.4). Despite this technical difficulty, I was able to specifically detect all the GINS 
subunits in the eluting fractions (lanes 2, 5, 8 and not lanes 3, 6, 9, as expected), but again 
no convincing association with the Mcm2 or Mcm3. This result confirms a DNA-
independent association of the GINS complex, initially reported in the budding yeast 
(Gambus et al., 2006). 
Given the proposed role of the CMG complex as a processive helicase, I speculated that the 
interaction between GINS and MCM might only be detectable in synchronised replicating 
nuclei. Indeed, soon after these results, Mendez and colleagues reported the co-
immunoprecipitation of Psf1 and Psf2 with Mcm3 from extracted S-phase chromatin 
(Aparicio et al., 2009). I therefore did not pursue this line of experimentation any further. 
This set of experiments is nevertheless included here because it confirms that the purified 
rSld5 and rPsf3 antibodies are able to isolate not just the respective antigens, but the whole 
GINS complex from human cell extracts. This further validates rPsf1, rPsf2, rPsf3 and rSld5 
antibodies as those recognising subunits of the same (GINS) complex. 
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Figure 3.19 Purified rPsf3 and rSld5 rabbit antibodies isolate the GINS complex from human nuclear 
extracts.  (A) HeLa nuclear extracts (gift from AD Mills) were immunoprecipitated using 1.5µl purified rPsf3 
(α) or pre-immune (PI) antisera (1.5h incubation, 5 washes). Starting material (Load, 5%), unbound (5%) and 
bound fractions (approximately 40%) were analysed by western blotting using the specified antibodies. Starred 
band (*) in Psf3 lane 5 is believed to be due to recombinant hexahistidine-tagged Psf3 that has leached off the 
affinity column during antisera purification.  (B) SKOV3 nuclear extracts were first fractionated into nuclear 
soluble and chromatin fractions by AD Mills. The chromatin fraction was solubilised by addition of either 
DNaseI (‘DNaseI chromatin’) or 400mM salt (‘KAc chromatin’). I performed the coimmunoprecipitations 
with 2µl purified rSld5 (α) or pre-immune (PI) antisera (3.5h incubation, 4 washes). Starting material (Load, 
1%) and the bound fractions (α, PI; approximately 40%) were analysed by western blotting using the specified 
antibodies. 
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Discussion 
This chapter described the production and validation of key GINS antibody and protein 
reagents developed during the course of my project.  
Production of soluble recombinant GINS tetramer was a major and promising focus in my 
first year, so it is unfortunate that the project had to be prematurely terminated due to 
illness. Nevertheless, I still benefited from the reagents, which were later used for 
immunisation of mice (Figure 3.8), ELISA screening of hybridomas cell lines and 
estimation of GINS protein amounts in HeLa cells (Figure 4.1). It is also hoped that the 
recombinant GINS work will soon bear more fruit through the recently established 
collaboration with R Parker and JP Chong. R Parker is currently setting up further 
biochemical studies using the improved MCM protein purification method (personal 
communication). We are also hoping to perform EM studies of the entire CMG complex in 
the near future.  
I successfully generated a good set of GINS antibodies. This positive outcome might in part 
be thanks to the availability of highly concentrated and purified immunogens (Figure 3.1, 
Figure 3.8). Table 3-vi summarises the validation process of the antibodies described in this 
chapter. Antibodies in bold are considered as validated for use in the applications shaded in 
green. The range of validated antibodies covers all four GINS subunits for immunoblotting, 
and all but Psf2 for immunofluorescence. Importantly, the validation of the IF signal in this 
chapter is limited to confirming that the signal is sensitive to siRNA depletion of the 
corresponding protein, but not necessarily that all of the nuclear signal is due to binding to 
that specific protein. Immunofluorescence validation is therefore revisited in the next 
chapter, when antibodies rPsf1, rPsf3, rSld5, mSld5A and mSld5B are used for high-
resolution confocal microscopy studies of the GINS complex.   
Some antibodies were not evaluated for all applications, owing to the poorer quality of the 
WB signal (e.g. mPsf2B) or time constraints (e.g. mSld5A and mSld5B have yet to be 
evaluated by immunoprecipitation because they have only been available for a short time). 
Further validation of applications shaded in yellow, combined with epitope mapping, would 
significantly improve the applicability and the commercialisation potential of high-quality 
mouse antibodies (mPsf2A, rSld5A, rSld5B) and therefore deserves attention in the future. 
Depending on the results of epitope mapping and these further validations, the range of 
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mouse monoclonal antibodies against Sld5 could even be combined into an antibody 
cocktail (Harlow & Lane, 1999).  
Antibody Relative 
WB signal 
WB: siRNA 
sensitivity? 
Nuclear  
IF signal 
IF: siRNA 
sensitivity? 
IHC IP 
rPsf1 +, x  +, X    
rPsf1B (+) NT NT    
rPsf2 +,  x  +, X    
mPsf2A ++  +, X ?   
mPsf2B ++, X NT NT    
rPsf3 +++  +++ ? +++, X  (GINS) 
mPsf3 (polyclonal) 
Mouse ID 192.4 
(+) NT ++ NT   
rSld5 ++++  ++  ++  (GINS) 
rSld5B +++ NT NT    (GINS) 
mSld5A ++++  ++  + NT 
mSld5B +++  +  (+) NT 
mSld5C ++ NT (+), X NT   
mSld5D + NT Different 
staining pattern 
NT   
Mouse hybridoma 
Sld5.7E12.B11 
+, X NT NT    
Table 3-vi Summary of antibody reagents generated in Chapter 3 & their validation. ‘+’ denotes the 
strength of signal of the correct MW (WB) or in the nucleus (IF). Cross-reacting bands (WB) or cytoplasmic 
staining (IF) is denoted with ‘X’ or ‘x’ depending on the strength of the signal. ‘NT’ – not tested.   
This chapter also describes knock-down of GINS proteins by RNAi for the purposes of 
antibody validation. These experiments had to be extensively optimised because siRNA 
transfection conditions routinely used in our laboratory did not produce satisfactory degree 
of knock-down for any of the GINS subunits (data not shown). I ultimately achieved 
efficient knock-down of subunits either by increasing the siRNA concentration (Psf1, Psf2), 
using a combination of siRNA species (Sld5) or employing a more potent but less uniform 
lipid-based siRNA delivery method (Psf3). Despite these improvements, the knock-down 
was never complete and longer time-course experiments showed a restoration of normal 
protein levels after 4 or more days (Figure 3.14B and data not shown).  
Incomplete knock-down could be a result of non-uniform transfection, which would 
produce a subpopulation of cells proliferating at a normal rate (published data shows that 
reduction in GINS protein levels results in attenuated proliferation rates; Aparicio et al., 
2009). However, given high transfection efficiency of nucleofection (Figure 3.17A: as 
evidenced by the degree of reduction in the signal being equal in all nuclei), it is unlikely 
that this is the main explanation. Instead, I speculate that incomplete knock-down could at 
least in part be due to the long protein half-life (Figure 3.12).  This fits with the observation 
that Psf3, which is the most stable subunit in the cycloheximide experiments (Figure 3.12C), 
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was also the one that proved most difficult to knock-down by siRNA (Table 3-iii). 
Alternatively or additionally, GINS mRNA expression may be restricted to a specific phase 
of the cell cycle, which is known to be the case for MCM mRNAs (Tsuruga et al., 1997). 
This fits with the need to transfect cells with siRNAs twice in the space of 24h to achieve 
efficient knock-down (Aparicio et al., 2009). It would be useful to analyse GINS mRNA 
expression at different stages of the cell cycle. This knowledge might help to target the 
knock-down to a specific phase of the cell cycle by synchronisation of cells before 
transfection. Alternatively, given that knock-down of any GINS subunits causes a 
concomitant reduction in the level of other subunits (Figure 3.17; Aparicio et al., 2009), 
using siRNAs against multiple GINS subunit simultaneously might also increase the 
efficiency of knock-down.  
In passing, several lines of evidence in this chapter also suggest that some GINS protein 
might not exist as a part of the tetramer. For example, recombinant Psf3 readily dissociates 
from the recombinant GINS complex when the salt concentration is increased (Figure 3.3C). 
Furthermore, Psf3 has a longer half-life than the other GINS subunits (Figure 3.12). And 
finally, Psf3 immunodepletion does not completely immunodeplete Sld5 (Figure 3.19A). 
This is consistent with the published observation that yeast and frog Psf3 is the least stably 
associated subunit in the GINS complex (Takayama et al., 2003, Kubota et al., 2003) and 
might be important for understanding the biochemical function of the GINS complex and its 
subunits. I will return to this point in the next chapter, when I explore the nuclear 
colocalisation of GINS proteins between themselves and in relation to the MCM complex 
and other members of the core DNA replication machinery.  
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Chapter 4 Subnuclear localisation of GINS 
proteins 
Introduction 
MCM proteins are very abundant with 10-40 molecules of the complex per typical 
metazoan origin (Burkhart et al., 1995, Lei et al., 1996). The number of MCM proteins is 
clearly higher than what is needed to support DNA replication: near-maximal rate of DNA 
replication can be achieved in Xenopus laevis with only 1-2 MCM complexes loaded per 
replication origin (Edwards et al., 2002, Oehlmann et al., 2004). Furthermore, if the MCM 
levels are reduced by 90% in human cells, the viability and genomic stability of cells is 
seemingly not affected, at least not under normal conditions (Ge et al., 2007). Experimental 
evidence of this apparent excess of MCM proteins is replicated with observation made by 
confocal microscopy at high-resolution, where the majority of chromatin-bound MCM does 
not colocalise with the sites of active replication. The paradox was initially described in 
Xenopus laevis (Madine et al., 1995b) and then also in human nuclei by a number of 
different research groups (Krude et al., 1996, Dimitrova et al., 1999, Prasanth et al., 2004). 
It has also been reported that MCM protein does not colocalise with various other DNA 
replication proteins that it molecularly interacts with. For example, ORC complex should 
mediate the loading of the MCM complex through the interaction with Cdt1/Cdc6 and 
should therefore also define the position of loading; but it does not colocalise with MCM 
(Romanowski et al., 1996, Ritzi et al., 1998). 
Various explanations for this phenomenon, termed the ‘MCM paradox’, have been proposed 
in the literature. For example, it has been suggested that MCM could function at a distance 
as a fixed pump that forces DNA into replication forks (Laskey & Madine, 2003). Blow and 
colleagues have also proposed that the excess MCM might function under conditions of 
replicative stress (Ge et al., 2007). The hypotheses could be refined if it was known what 
nuclear sites or proteins MCM foci colocalise with, and I hoped that GINS might be able to 
shed some light on this. 
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GINS subunits displayed a similar focal pattern in the initial immunofluorescence staining 
experiments (Figure 3.7B, Figure 3.11) to that observed for MCM in high-resolution 
confocal microscopy. Furthermore, GINS and MCM interaction has been extensively 
documented in the literature, using a variety of different approaches. In fission yeast, the 
association during S phase (and perhaps in other stages of the cell cycle) was detected by 
bimolecular fluorescence complementation (Akman & MacNeill, 2009). 
Immunoprecipitation experiments confirm that this association also exists in S-phase human 
nuclei (Aparicio et al., 2009). Armed with an extensive set of validated GINS antibodies 
(Table 3-vi), I therefore compared the subnuclear localisation of the two protein complexes 
in HeLa cells, with the aim of revisiting the MCM paradox.  
 
Results 
4.1 GINS molecules outnumber replication forks 
To better understand the relationship between core DNA replication machinery and GINS, 
and between individual GINS subunits, I sought to estimate the number of molecules of 
each subunit per cell. The HeLa cell line was chosen as a reference because it was the main 
cell line used for high resolution immunofluorescence studies in this chapter and because 
cell numbers data for other core DNA replication machinery proteins is readily available for 
this cell line in the literature (see Table 4-i). As a protein standard, I used recombinant 
GINS tetramer that was produced by coexpression of the four subunits in a single E.coli 
strain, with Sld5 being hexahistidine-tagged. I quantitated the purified tetramer (Figure 
3.5B, fraction 15) and took into account the residual contaminating bands in the same 
fraction (estimated at 10%, data not shown). Defined amounts of recombinant GINS were 
then loaded alongside accurately counted fresh HeLa whole-cell lysates and analysed by 
quantitative immunoblotting (Figure 4.1A).  
Results of the calculation are presented in Table 4-i. My numbers are slightly lower than 
those published by Mendez and colleagues, who estimate that there are between 500,000 
and 1,100,000 GINS molecules/cell in tumour-derived cell lines (Aparicio et al., 2009). My 
experiment included Mcm6 as an internal control (Figure 4.1B): I measured the 
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concentration of GINS and Mcm6 proteins at the same time, and used the same HeLa 
whole-cell extract to estimate the number of Mcm6 molecules per cell. Given that the 
estimate is in good agreement with the published data for Mcm3 (Burkhart et al., 1995), this 
increases the confidence in my measurements.  
A typical mammalian nucleus is believed to contain roughly 30,000 replicons, which are 
activated at different times in the S phase (Aladjem et al., 2006a). The number of RPA and 
especially Cdc45 molecules appears to be similar to the number of replicons, whereas GINS 
molecules are significantly more abundant, being either equal to (Burkhart et al., 1995, 
Aparicio et al., 2009) or less so than the subunits of the MCM complex (my data, Table 4-i).  
Numbers for the individual GINS subunits appear to differ slightly between each other. For 
example, Sld5 is seemingly twice as abundant as Psf2 (Table 4-i). These differences may be 
within experimental error, which could be confirmed if I was able to use a more 
stoichiometric protein standard, such as the refolded tetramer from Figure 3.3C (lane 10). 
In summary, I estimated that there are between 1-3x105 molecules of each GINS subunit 
present per HeLa cell, which is more than is needed to populate all replicons. Furthermore, 
my data also suggests that Sld5 and Psf3 protein might be more abundant than the two other 
GINS subunits.  
 
 
 
 
 
 
Figure 4.1 Molecules of GINS subunits per cell are more numerous than replicons. Quantitative 
immunoblotting analysis of HeLa asynchronously cycling cells (50,000 cells per lane; two separate culture 
harvesting and counting events) and the indicated amounts of recombinant protein. Signal from the two HeLa 
lanes was quantified using the most similar-intensity recombinant protein signal (1ng) as a reference point. 
Measurements from both lanes and multiple exposures were averaged before calculating the number of 
molecules per cell (number on the right; see also Table 4-i). (A) Recombinant GINS complex was from Figure 
3.5B, fraction 15 (note that Sld5 subunit was hexahistidine-tagged). The same immunoblotting membrane was 
probed for all GINS subunits in sequence. (B) Recombinant Mcm6 protein was a kind gift from R Parker. 
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Protein Numbers of molecules per HeLa cell Reference 
RPA 104–105 (Wold, 1997) 
Cdc45 4.5x104 (Pollok et al., 2007) 
Sld5 (2.6 ± 0.1) x 105 (Figure 4.1A) 
Psf3 (2.3 ± 0.3) x 105 (Figure 4.1A) 
Psf2 (1.3 ± 0.1) x 105 (Figure 4.1A) 
Psf1 (1.5 ± 0.3) x 105 (Figure 4.1A) 
Mcm3 1x106 (Burkhart et al., 1995) 
Mcm6 2x106 (Figure 4.1B) 
Table 4-i Comparison of number of molecules per HeLa cell for selected DNA replication proteins.  
4.2 The ‘GINS paradox’ 
MCM and GINS proteins are both more numerous than replicons (Figure 4.1). What is the 
function of excess GINS? Can the investigation of GINS localisation in the nucleus shed 
light on the MCM paradox? Section 4.2 summarises the early experiments addressing this 
question, which were performed collaboratively with AD Mills. They are included because 
they are a result of our collaborative efforts and are critical for the proper understanding of 
the sequence of experiments in the rest of this chapter. The results described in the 
remainder of this chapter are entirely my own. 
4.2.1 Rabbit Sld5 and Psf3 antibodies colocalise 
Knock-down experiments described in the previous chapter confirmed that the intensity of 
nuclear staining correlates with GINS protein levels, as measured by western blotting 
(Figure 3.17). However, due to incomplete knock-downs, the siRNA experiments could not 
confirm that all of the nuclear signal in IF is specific. Confirming total specificity of the 
staining was an important requirement for high-resolution immunofluorescence studies of 
GINS proteins. Since Psf3 and Sld5 proteins are thought to exist as part of the same 
complex (Figure 3.19; Aparicio et al, 2009; MacNeill, 2010), it is expected that they would 
localise to the same areas of the nucleus. Antibodies recognising Psf3 and Sld5 epitopes and 
no other epitopes should therefore display a very good degree of colocalisation. We used 
this rationale to assess the specificity of staining of the rSld5 and rPsf3 antibodies. 
By directly labelling the rSld5 antibody and visualising rPsf3 antibody by indirect 
immunofluorescence, we detected a very good degree of colocalisation (Figure 4.2C), 
allowing for differences in intensities between directly labelled antibody (Figure 4.2A-i) and 
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the antibody detected through the use of a secondary antibody (panel A-ii). This 
colocalisation was specific to nuclei labelled with both antibodies and was not a result of 
bleed-through between the channels, since an empty green channel of nuclei stained with 
rPsf3 in the red channel did not show a signal (panel B-iv) when processed in the same way 
as the faint green channel of a double-labelled image (compare panels A-i and B-i for the 
extent of image processing and panels B-i and B-iv, which show lack of bleed-through from 
the red channel). This indicated that rPsf3 and rSld5 antibodies are very likely to be specific 
and useful for high-resolution immunofluorescence studies.  
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Figure 4.2 rSld5 and rPsf3 antibodies largely colocalise. Asynchronous U2OS cells were grown on 
coverslips, fixed and processed for immunofluorescence. There were three antibody incubations in the 
following sequence: rPsf3, anti-rabbit secondary antibody labelled with Alexa-546 fluorophore, and lastly 
either rSld5 directly labelled with Alexa-488 or no rSld5 antibody.  (A) Field view for comparison of signal 
intensity from the directly labelled channel (A-i) with the indirectly labelled one (A-ii).  (B) High-resolution 
images were processed in order to bring up the levels in the green channel (B-i and B-iv).  (C) Binary high-
resolution images, illustrating the extent of colocalisation (black colour). Images were initially processed as 
illustrated in panel B and subsequently thresholded using ImageJ software. B-iii and C-ii are based on the 
same raw image. 
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4.2.2 GINS antibodies do not colocalise with DNA replication or MCM 
proteins 
Having validated rPsf3 and rSld5 antibodies for high-resolution immunofluorescence 
studies, we next tested the degree of colocalisation between GINS and replicating DNA or 
MCM proteins.  
The localisation of GINS and MCM was compared in a number of cell lines (data not 
shown, apart from for SKOV3; Figure 4.3) using two different well-characterised MCM 
antibodies against Mcm2 (Todorov et al., 1994, Todorov et al., 1995) and Mcm5 (Freeman 
et al., 1999). To focus on the chromatin-bound protein fraction, which is arguably where 
GINS and MCM association might be more likely to take place, nuclei were permeabilised 
before fixation to remove any soluble nuclear protein (Gilbert & Fulton, 1985, Dimitrova & 
Gilbert, 2000). Surprisingly, the majority of chromatin-bound MCM and GINS foci did not 
colocalise despite the removal of soluble material, apart from a few partially and even fewer 
completely overlapping foci per optical slice (Figure 4.3A: note the yellow foci in the 
merged images). This pattern was independent of the fluorescent channel used to visualise 
the bound antibodies (note the secondary antibody swap between upper and lower panels of 
Figure 4.3A). If soluble material was not removed before fixation, the degree of 
colocalisation was improved by virtue of the much more abundant MCM stain occupying 
the majority of the optical slice (Figure 4.3B: observe global staining in the Mcm5 channel). 
However, the brightest foci of one stain still often coincided with local minima in the other 
(see arrows in Figure 4.3B). Pattern presented in Figure 4.3 for rPsf3 and Mcm5 was very 
similar to the colocalisation pattern between rSld5 and Mcm2 (data not shown).  
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Figure 4.3 Psf3 and Mcm5 antibodies do not colocalise. SKOV3 cells were grown on coverslips and 
processed for indirect immunofluorescence. Cells in panel (A) were permeabilised before fixation. Mcm5 and 
rPsf3 antibodies were visualised using secondary antibodies labelled with either Alexa-488 or Alexa-546 
fluorophores (note fluorophore swap between between top and bottom panels in A). Arrow in B denotes an 
area illustrating the discrepancy in the signal intensity (local maximum in rPsf3 channel and a local minimum 
in the Mcm5 channel).   
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We also observed differences in the behaviour of the two protein complexes during mitosis. 
Psf3 and Mcm5 signals were both absent from condensed mitotic chromatin (Figure 4.4, 
compare top and middle panels). Some telophase/G1 boundary nuclei contained a 
chromatin-localised Mcm5 signal, but no chromatin-localised Psf3 signal (Figure 4.4, 
bottom row), implying that GINS association with the nuclear structure occurs after MCM 
had already been loaded.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Psf3 localisation dynamics during mitosis. HeLa cells were grown on coverslips and 
processed for indirect immunofluorescence using rPsf3 and Mcm5 antibodies. Cells were not permeabilised 
before fixation. 
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Lastly, we also tested if GINS antibodies colocalise with sites of DNA replication as judged 
by BrdU labelling or other markers of DNA replication (RPA, PCNA). GINS complex has 
been shown to have an essential role in the elongation of DNA replication in frog and yeast 
(Kanemaki et al., 2003, Takayama et al., 2003, Kubota et al., 2003) and was hence expected 
that colocalisation will be clearly detectable.  
Figure 4.5 illustrates the result obtained using rPsf3 antibody together with BrdU or PCNA 
in permeabilised HeLa cells. As shown in the figure, rPsf3 antibody did not colocalise well 
with DNA replication. Even in the early S nuclei (such as the BrdU-labelled nucleus in 
Figure 4.5), where both stains showed a dense punctate nuclear staining, local maxima in 
one channel almost invariably corresponded to local minima in the other channel. The 
discrepancy was perhaps even more striking in the late S nucleus (PCNA versus rPsf3 in 
Figure 4.5): rPsf3 antibody showed a very similar staining pattern to PCNA, with large 
strong foci in the middle of the nucleus, and a faint but discernable stain on the nuclear face 
of the envelope. However, none of the brightest spots colocalised, and the colocalisation 
between medium-intensity signals was restricted to a few areas, where the two signals 
overlapped (see arrows in the merge PCNA/rPsf3 picture, Figure 4.5). Imporantly, data in 
Figure 4.5 was in agreement with similar experiments performed in a number of different 
cell lines (including U2OS, HEK293T, SKOV3 and HCT116), using both rPsf3 and rSld5 
antibodies (data not shown).  
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Figure 4.5 GINS rPsf3 antibody does not colocalise with sites of DNA replication and PCNA. HeLa 
cells were grown on coverslips, pulsed with BrdU (30min) and permeabilised before fixation where shown 
(see label on the left). Coverslips were processed for indirect immunofluorescence using rPsf3 and BrdU or 
PCNA antibodies, as stated on the images. Arrows denote a selection of foci that colocalise. 
All in all, these studies could not detect any significant colocalisation between GINS and 
MCM, or GINS and the sites of DNA replication. It appeared that instead of shedding light 
onto the MCM paradox, we managed to introduce yet another, termed the ‘GINS paradox’. 
To explain these observations, we hypothesised that there might be a subpopulation of 
GINS that does colocalise with the MCM proteins, which is small and might only become 
apparent if excess MCM is knocked-down to a non-lethal degree (Ge et al., 2007) or if the 
cells are synchronised in S phase. This would agree with the observations from Drosophila 
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where the CMG complex might only represent a minority of the total GINS and MCM in 
the nucleus (Moyer et al., 2006). Furthermore, MCM and GINS interaction by 
immunoprecipitation is only detectable in S-phase extracts (Aparicio et al., 2009). GINS 
non-colocalisation with the replication machinery could be similarly explained by 
considering that GINS molecules are in excess compared to the number of replication forks 
(Table 4-i). It is therefore possible that only small numbers are recruited to the active 
replication forks. Furthermore, given the sequential, non-concerted firing of replication 
forks in mammalian cells, excess GINS foci might represent the protein that is poised for 
replication later in the S phase. This might then shed light on what stage exactly the pre-RC 
to pre-IC conversion takes place and what controls that conversion, making the ‘GINS 
paradox’ an important phenomenon in its own right. 
4.3 The paradox of positive controls 
When I took over the whole of the work on high-resolution localisation studies of GINS in 
human cells, my aim was to confirm the observations recorded jointly with AD Mills and 
explore some avenues detailed in the final paragraph of the previous section (4.2.2). Before 
I could be certain of the biological significance of our results in 4.2, I also wanted to ensure 
that the experimental system behaves as expected according to the previously published 
literature; in other words that replication fork proteins (such as RPA and PCNA) do 
colocalise with themselves and with sites of DNA replication but not with MCM (Madine et 
al., 1995b, Dimitrova et al., 1999). Thirdly, I also wanted to validate further GINS 
antibodies (rPsf1, mSld5A and mSld5B) for use in high-resolution confocal microscopy in 
order that the colocalisation of individual GINS subunits could be explored in more detail. 
As discussed above, it seemed probable that the interactions between GINS, MCM and the 
replication machinery are complex and possibly dependent on the cell cycle stage. I 
therefore reasoned that I should focus on a particular phase of the cell cycle so that any 
colocalisation patterns might become easier to observe. My synchronisation experiments 
(data not shown) and data published by others (Aparicio et al., 2009) showed that GINS 
proteins are present at equal levels in all the stages of the cell cycle, whereas chromatin-
binding of the complex is largely restricted to S phase. I therefore decided to focus on high-
resolution imaging of cells in S phase in the first instance, with a potential to explore G1 
phase cells later, given that this is when MCM licensing occurs (DePamphilis et al., 2006). 
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To label cells that are undergoing DNA replication (and therefore in S phase of the cell 
cycle) in an asynchronous cell population grown on coverslips, I used 5-ethynyl-2’-
deoxyuridine (EdU). I replaced BrdU labelling with EdU labelling since it circumvents the 
need for acid/DNaseI treatment and frees up an antibody channel for multiplex 
immunofluorescence. The use of EdU labelling of active DNA replication should be less 
disruptive to the epitopes and produce a more reliable IF signal.  
To optimise the EdU labelling conditions, I first tested the concentration of EdU that 
produces strong foci and observed no substantial differences in labelling efficiency or 
observable toxic effects in the range of 5 to 50µM EdU (data not shown). No signal could 
be detected if cells were not labelled with EdU but processed in the same way (data not 
shown). I next set up a trial to assess the minimum EdU pulse length that could be used for 
high-resolution colocalisation studies (Figure 4.6). Pulse length of 5min produced detectable 
foci (Figure 4.6). Nevertheless, the signal was too weak for a satisfactory signal-to-noise 
ratio unless the laser intensity was increased to the level that resulted in rapid bleaching of 
the sample (data not show). Both 15min and 22min pulses produced excellent signal 
strength, stronger than a 10min pulse. Signal from a 22min pulse was stronger than a 15min 
pulse (data not shown). This is not immediately obvious in Figure 4.6 because both images 
are largely saturated. Nevertheless, a pulse of 10min might be more useful because it 
produces better-defined DNA replication foci than longer pulses (Figure 4.6), therefore 
increasing the resolution. I will return to this point in the next section. 
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Figure 4.6 Titration of EdU pulse length. Field views of asynchronous HeLa cells grown on coverslips 
and pulsed with 20µM EdU for the indicated times. Fixed coverslips were processed for EdU detection using 
Alexa Fluor-488 labelled azide. All images were collected under the same conditions. 
I next tested how a 20min EdU pulse colocalises with RPA as a positive control for the 
high-resolution confocal microscopy imaging. I was expecting to show that markers of 
DNA replication machinery (that AD Mills and I found not to colocalise with GINS 
antibodies; Figure 4.5) colocalise with nascent DNA. Nuclei were permeabilised before 
fixation, so it was expected that very little RPA would be present outside the sites of active 
DNA replication as marked by EdU (Dimitrova & Gilbert, 2000, Salic & Mitchison, 2008). 
However, as shown in Figure 4.7A, images contained a surprisingly small number of 
perfectly colocalised foci. Instead, foci were often adjacent to each other or located in areas 
where the other stain was completely absent (Figure 4.7A).  
At the same time, I was also testing mSld5A mouse monoclonal antibody for use in these 
studies (only rPsf3 and rSld5 had been used up to that point). Given that incomplete siRNA 
knock-downs described in section 3.3.1 above could not test that all of the 
immunofluorescence staining of these antibodies is due to binding to Sld5, I first validated 
the new antibodies with reference to the purified rabbit polyclonal antibodies validated 
above (Figure 4.2). Near-perfect colocalisation of rSld5 and mSld5A was predicted, and 
very good colocalisation of mSld5A and rPsf3 (akin to the results from the direct labelling 
experiment in Figure 4.2). Instead, I again observed a surprisingly small degree of 
colocalisation (Figure 4.7B).  
EdU / DNA
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Figure 4.7 Unexpectedly low degree of colocalisation of positive controls using high-resolution 
confocal microscopy. HeLa asynchronously cycling cells were grown on coverslips, permeabilised before 
fixation and processed for indirect immunofluorescence (A, B) and EdU detection (20min pulse) (A). Sld5A 
mouse monoclonal antibody in panel B was the unpurified hybridoma culture supernatant diluted 1:2.  
In the absence of the confusing results in Figure 4.7A, panel B could be interpreted as 
simply suggesting that mSld5A antibody is not suitable for high-resolution 
immunofluorescence studies (given that rSld5 and rPsf3 have been validated above; Figure 
4.2). However, this was difficult to reconcile with the observation that all three antibodies 
were broadly specific for their respective proteins and of seemingly comparable quality in 
the initial validation (Table 3-vi). Moreover, the high degree of non-overlap between the 
EdU and RPA labels (Figure 4.7A) using the same experimental set-up cast some doubt 
onto the validity of data in Figure 4.7B, of our initial data presented in this chapter (Figure 
4.2, Figure 4.3 and Figure 4.5) and potentially the MCM paradox as a whole. This led to a 
systematic review of the experimental evidence and the procedure that generated it. 
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4.4 Critical evaluation of confocal microscopy for high-
resolution colocalisation studies 
Any combination of the following factors could contribute to the unexpected levels of non-
colocalisation where colocalisation was expected (e.g. Figure 4.7): 
(a) Microscope misalignment between the channels in any combination of x, y or z axes; 
(b) Non-specific binding of antibodies: 
(i) Unpurified mSld5A from Stage II hybridoma production was used in Figure 4.7A 
because final clones were not yet available at that time; 
(ii) Commercial RPA antibody had not been optimised in our hands; 
(iii) The secondary antibodies and DNA stain used were from a communal stock.   
(c) EdU pulse was 20min long, which might have compromised the resolution, as discussed 
above (Figure 4.6). 
(d) Speed of processing from labelling to permeabilisation: it took approximately 7 minutes 
to place the coverslips on ice after the EdU label was removed (due to bulk processing of 24 
coverslips). This is a relatively short time considering that S phase takes 6-8 hours in HeLa 
cells, but the EdU pulse time minimisation experiment (Figure 4.6) attests to the fact that 
significant amounts of DNA are replicated even in 10 minutes; 
(e) Delay between fixation and imaging: after fixation, coverslips were stored in 100% 
ethanol at -20°C overnight before immunostaining. There was also another day’s delay 
between mounting the coverslips and imaging. Considering that pFA does not appear to fix 
DNA as well as the proteins (AD Mills, unpublished observation), this could have 
contributed to the artefactually low degree of colocalisation. 
I first addressed the potential issues listed in (b). Namely, I purified mouse mSld5A and 
mSld5B antibodies (data not shown; validation presented in Figure 3.11) and replaced all 
secondary antibody reagents with fresh stocks and optimised their dilution. I routinely tested 
if secondary antibodies produce any staining on their own. Images of cells stained with 
secondary antibodies only, taken (and processed) in the same way as the experimental 
images, never produced a detectable signal (data not shown). Lastly, I also optimised the 
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dilution of all primary antibodies used in this chapter (data not shown). From then on, I used 
the highest dilution that still produced a strong signal in order to minimise the potential 
cross-reactive signal, as recommended in the literature (Harlow & Lane, 1999).  
4.4.1 Evaluation of microscope alignment 
I next addressed the other global factor that could have contributed to confusing results in 
Figure 4.7, namely that of microscope (mis)alignment. I started by getting the microscope 
professionally serviced and thereafter testing the inter-channel alignment using alignment 
beads during each image collection experiment. After the servicing, a degree of horizontal 
(x/y plane) misalignment was still detectable with the 60X lens at higher zooms (panel A1, 
Figure 4.8). This misalignment was corrected by a 2 or 3 pixel shift in the x direction, which 
equates to a move of no more than 0.08 µm. This is on the limit of the theoretical horizontal 
resolution for a confocal microscope (Bolte & Cordelieres, 2006).  
When the alignment was corrected in the experimental images with the shorter EdU pulse 
and faster processing (data presented in detail in section 4.4.2.1), the improvement was only 
marginal (compare white arrow in Figure 4.8B), and did not improve the overall visual 
impression of the degree of colocalisation (panels B and C). All in all, the remaining 2 or 3 
pixel x/y plane misalignment had no significant effect on the general visual impression of 
the degree of colocalisation, although it was considered important to correct the images 
before evaluating individual nuclear spots or quantifying the image for the degree of 
colocalisation.  
When studying the corrected images in Figure 4.8, it was also noted that some of the smaller 
foci remained exclusively red or green (magenta arrows in panels B2 and C2), and that the 
colocalisation was generally better the larger the focus (compare smaller and larger foci in 
B2). This could be due to vertical (z-axis) misalignment. This I checked by moving the 
microfocus up & down whilst continuingly scanning the alignment beads and checking that 
signal from all channels disappears at the same time. I found that DAPI channel disappeared 
last, but that FITC and Texas Red channels appeared and disappeared at the same time, 
confirming that z-axis alignment is good for the purposes of colocalisation studies using the 
green and red channels (all studies in this chapter). In hindsight, using z-stacks to test the z-
misalignment might have been a more rigorous check.  
     
  115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Alignment testing of the channels on the serviced confocal microscope: comparison of 
original and aligned images from a typical experiment (EdU and RPA colocalisation, see Figure 4.10 below, 
which used a shorter 10min EdU pulse with faster processing). All images were taken with a 60X lens and 
9.5X zoom (at a 1024×1024 resolution), with variable red and green channel settings depending on the 
fluorophore intensity in each image. Images were processed in Photoshop before the degree of misalignment 
was determined by studying the images of the alignment beads (A1). Panels A2-C2 were corrected by moving 
the red channel 3 pixels to the left.  
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I also collected images on another recently serviced confocal microscope of a different 
make (Zeiss LSM510). Although the comparison was not based on exactly the same cells 
(only comparable cells from the same coverslip), it was concluded that a similar degree of 
non-colocalisation is present in all images (data not shown). It is therefore very unlikely that 
non-colocalisation is due to faulty equipment. 
In conclusion, the remaining x/y- and z-misalignment of the confocal microscope after 
servicing appears not to significantly (visually) affect the degree of colocalisation, although 
it is important that the alignment is continuously checked and corrected before closely 
investigating the images or quantifying the degree of colocalisation. There are remaining 
concerns that the study attempts (a) to assess colocalisation of spots the size of which are at 
the limit of resolution (typical diameter of foci in Figure 4.8 was 0.1-0.5µm) and/or (b) to 
assume that all peaks at high-resolution will represent specific binding, whereas some might 
inevitably be non-specific. The next step was therefore to check whether it is possible to 
produce images of satisfactory colocalisation for cellular constituents that are known to 
colocalise, as reported in the literature and predicted according to their functional 
association.  
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4.4.2 EdU and RPA or PCNA colocalise when image collection and 
processing are optimised 
4.4.2.1 Improved EdU, RPA and PCNA colocalisation 
Given concerns about the processing time in the initial EdU versus RPA colocalisation 
experiment (Figure 4.7), I set up a repeat experiment with an EdU pulse length of 10min, 
followed by immediate processing and image collection. PCNA and Mcm2 were also 
included as two widely used commercially available antibodies that would help calibrate the 
degree of colocalisation. Compared to RPA, it was expected that PCNA and Mcm2 will 
show a similar and lesser degree of colocalisation with EdU, respectively. 
Field views of the experiment are presented in Figure 4.9. Unpermeabilised cells did not 
show any substantial variation in the intensity of the PCNA, RPA or Mcm2 staining, 
suggesting constant total protein levels throughout the cell cycle. Patterns described next in 
this paragraph are therefore a result of differences in the structure-bound portion of the three 
proteins. Analysing nuclei that were permeabilised before fixation, all EdU-positive nuclei 
were also RPA or PCNA positive. The trend was similar for Mcm2, except that there was 
more discrepancy in intensity between Mcm2 and EdU (i.e. some nuclei which stained 
strongly for Mcm2 were low for EdU, and vice-versa). All EdU-negative nuclei had almost 
no RPA and PCNA staining. This was in contrast to Mcm2 staining, where a number of 
strongly-positive Mcm2 nuclei showed no EdU signal. This is as expected for G1 cells. Less 
than 20% of nuclei were negative for Mcm2 (all of which were also EdU-negative), which 
agrees with the anticipated level of cells in G2 and M phases of the cell cycle. The staining 
patterns described in this paragraph agree with the literature (Todorov et al., 1995). This 
validates the experimental procedures of EdU labelling and permeabilisation before 
fixation. 
     
  118 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9       
Field views of HeLa 
asynchronously cycling 
cells grown on 
coverslips and pulsed 
with 20µm EdU for 
10min before 
harvesting. Cells were 
either permeabilised 
before fixation, or just 
kept on ice (non-
permeabilised controls) 
and then processed 
immediately for EdU 
detection using Alexa 
Fluor 488 labelled 
azide, and for indirect 
immunofluorescence 
staining of RPA, PCNA 
or Mcm2.  
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I next studied the high-resolution images of representative nuclei showing nascent DNA 
(EdU) and RPA and PCNA antibodies visualised by indirect immunofluorescence (cells 
were premeabilised before fixation). I was initially not entirely satisfied with the degree of 
colocalisation when processing the images the conventional way (Figure 4.10A1 and B1), 
especially when compared to previously published data for sperm nuclei replicating in 
Xenopus egg extracts (Madine et al., 1995b) and PCNA/RPA double labelling in Chinese 
hamster ovary cells (Dimitrova et al., 1999). However, upon careful consideration of 
extreme enlargements (see the black-and-white insets in A1), I decided to critically analyse 
these images further. Densitometric line profiles across these nuclei are shown in Figure 
4.10A3 and B3. These traces showed that all peaks of EdU coincide with peaks of RPA 
(panel A3), although the relative intensities of the two peaks might be different (see starred 
green EdU peaks in panel A3). Similar densitometric traces comparing PCNA and nascent 
DNA (EdU) also showed broad colocalisation, albeit not as tightly as RPA and EdU (B3). 
In other words, DNA replication foci are always near-coincident1 with RPA and PCNA 
peaks, as expected. I attempted to illustrate that point on a global scale through the use of 
thresholded images (Figure 4.10, A2 and B2), which change the appearance of most green 
peaks from the original images to yellow peaks. Although dynamic image information is 
lost through the use of thresholding, this technique helps to validate the line profile 
conclusions by looking at the entire two-dimensional image, provided the threshold level is 
chosen with care.  
Data in Figure 4.10 suggests that RPA and especially PCNA foci also exist outside of areas 
of detectable DNA replication (see ‘?’ in line graphs in panels A3 and B3). This non-
colocalisation could not be reconciled by the use of line profiles or thresholding. The RPA 
and PCNA foci that lack EdU could therefore exist due to (in descending order of 
likelihood): 
(a) Sites of DNA replication below the limit of EdU detection (incorporation for less 
than 5min); 
(b) Similarly to (a), sites of assembled pre-replication complex just before DNA 
replication initiates;                                                         
1 Functional separation of the replicon elements might be discernable in high-resolution images (RPA 
represents unwound ssDNA; PCNA represents processive polymerase locations and EdU is newly synthesised 
DNA), contributing to overlapping but not coincident foci. 
     
  120 
(c) RPA and PCNA being involved in other cellular processes, such as DNA repair 
(Wold, 1997);  
(d) Non-specific binding of the commercial PCNA and RPA antibodies, which were not 
evaluated by means of siRNA knock-downs (technically challenging given the 
essential nature of these proteins for DNA replication).  
On the whole, the degree of colocalisation of EdU with RPA or EdU with PCNA (note the 
directionality) was substantially tighter than observed previously (Figure 4.7B), especially 
once high-resolution images were investigated by line plots and thresholding. The degree of 
colocalisation in Figure 4.10 is not as good as has previously been reported for RPA and 
biotin-dUTP (which marks nascent DNA) colocalisation in sperm nuclei replicating in 
Xenopus egg extracts. There are conceivable biological reasons for these differences (for 
example, asynchronous firing of origins in mammalian cells and their faster DNA synthesis 
rates and replication focus dynamics relative to Xenopus sperm nuclei, perhaps due to lower 
temperature range at which frog cells are grown). The degree of colocalisation was also not 
as food as has previously been reported for RPA and PCNA colocalisation in a mammalian 
Chinese hamster ovary cell line with similar replication rates (Dimitrova et al., 1999). 
However, the published images from the report by Gilbert and colleagues appear to have a 
flattened dynamic range of grey values, judging by the appearance of the images in the 
paper, making them look more like the thresholded images akin to the ones presented in 
Figure 4.10A2/B2. This could contribute to a seemingly better degree of colocalisation. 
Indeed, a very recent report by CM Green and colleagues shows images of EdU and 
RPA/PCNA colocalisation that show a very similar degree of colocalisation (by visual 
comparison) to the ones presented in Figure 4.10 (Cseresnyes et al., 2009). 
Given the careful validation of our equipment and the experimental procedure, I conclude 
that the degree of colocalisation could not be improved further within the realms of the 
experimental set-up. The results presented here are therefore likely to reflect the localisation 
of DNA replication processes in live mammalian cells at high-resolution.  
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Figure 4.10 RPA and PCNA colocalisation with sites of replication revisited. HeLa asynchronously 
cycling cells were grown on coverslips and pulsed with 20µM EdU for 10min before harvesting. Coverslips 
were permeabilised with 0.1% Triton-X100, fixed, permeabilised and processed for EdU detection and indirect 
immunofluorescence of RPA (A) or PCNA (B). All images were shifted as indicated by the alignment and 
intensity beads. Images in panels A1 and B1 were processed as usual (levels, Gaussian blur and sharpen). 
Panels A2 and B2 represent threshold copies of the same unprocessed images (threshold level was chosen such 
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that white pixels just started appearing outside of the nucleus). (A3) and (B3) Unprocessed images were used 
to plot intensity profiles of grey values for both the green and the red channels. Starred peaks (‘*’) denote 
strong EdU peaks that contain a weaker RPA/PCNA peak in the same location. Question-marked peaks (‘?’) 
denote strong RPA/PCNA peaks that do not obviously coincide with an EdU peak, not even when investigated 
with line profiles. 
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4.4.2.2 EdU and Mcm2 colocalisation revisited 
Given the near-perfect colocalisation of EdU with RPA or EdU with PCNA, I next 
compared the high-resolution staining pattern of Mcm2 and DNA replication foci. High-
resolution images from the experiment described in 4.4.2.1 were analysed for colocalisation 
of Mcm2 and EdU. The EdU staining pattern was used as a guide to classify the three 
images as early, mid- and late S phase in Figure 4.11A. As expected, I did not detect a good 
degree of colocalisation between Mcm2 and EdU on a global scale (Figure 4.11A) 
compared to the degree of colocalisation observed with RPA or PCNA and EdU (Figure 
4.10). This observation was confirmed by examining the line profiles (Figure 4.11B). 
Compared to line profiles from Figure 4.10A3/B3, Mcm2 and EdU were much less often 
coincident, particularly in the early S phase nucleus. Degree of coincidence apparently 
increased through to late S-phase (compare the number of Mcm2 peaks with coincident 
EdU peaks in Figure 4.11B).  
In summary, the corrections to the microscope alignment and optimisation of the image 
collection and processing significantly improved the quality of the final imaging data 
(compare images Figure 4.7A and Figure 4.10A). The improved experimental technique 
(EdU labelling, sample processing, image collection and processing) was validated at both 
relevant ends of the spectrum of degrees of colocalisation. Namely, I showed colocalisation 
of labels that are expected to localise (Figure 4.10A), as reported by others. In addition, I 
showed that proteins reported as not colocalising in the literature also display a low degree 
of colocalisation in my experimental set-up (Figure 4.11A). A colocalisation analysis 
showing complete exclusion was missing (e.g. RNA polymerase II versus EdU), but was not 
considered essential for the purposes of this study until after GINS antibodies had been re-
validated (section 4.5) and I was in a position to analyse the degree of colocalisation 
quantitatively.  
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Figure 4.11 Mcm2 colocalisation with sites of DNA replication revisited. HeLa asynchronously cycling 
cells were grown on coverslips and pulsed with 20µM EdU for 10min before harvesting. Coverslips were 
fixed, permeabilised and immediately processed for EdU detection and indirect immunofluorescence of 
Mcm2. All images were shifted as indicated by the alignment and intensity beads. Images in (A) were 
processed as usual (levels, Gaussian blur and sharpen). Line profiles of unprocessed images are plotted in (B). 
Directionality of the intensity profiles: left corresponds to the labelled side of the line. 
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4.5 The paradox of GINS antibodies 
Having validated the experimental set-up for high-resolution confocal microscopy using 
known co-localising components of DNA replication machinery (especially EdU marking 
nascent DNA and RPA), I next revisited the apparent paradoxical non-colocalisation of 
mSld5A and rSld5 antibodies (Figure 4.7B). To do this, I took high-resolution images of the 
representative nuclei from the siRNA experiment presented in Figure 3.17, excluding rPsf2 
and mPsf2 due to concerns about their specificity (especially rPsf2) in immunofluorescence, 
as discussed in section 3.3.1.3. Coverslips were stained with purified antibodies at optimised 
concentrations. Both control siRNA-transfected and knock-down coverslips were studied (at 
least 8 nuclei from each coverslip). Importantly, knock-down coverslips were not expected 
to show a complete disappearance of the signal, since the degree of reduction, as measured 
by quantitative immunoblotting was only between 47 and 66%, depending on the treatment 
(Table 3-iv).  
This experiment included a coverslip stained with mSld5A and rSld5, which was a repeat of 
the experiment presented in Figure 4.7B, except that (i) mSld5A in the new experiment was 
affinity purified from hybridoma culture supernatant, (ii) both antibodies were applied at the 
highest usable dilution, as optimised above (Figure 3.7A/B and Figure 3.11) and (iii) 
secondary antibodies were from a fresh stock. In addition, the microscope alignment had 
been optimised in the interim (Figure 4.8) and verified at the start of this experiment as a 
routine check (data not shown). A representative nucleus with wild-type levels of Sld5 
protein (‘Non-silencing siRNA’) is shown in Figure 4.12A. Although the signal strength 
was better than before (compare with Figure 4.7B) and each antibody signal viewed in 
isolation showed a similar focal nuclear pattern (Figure 4.12A: see grey images of the 
individual channels), the merged channel still displayed the same confusing non-
coincidence of foci (Figure 4.12A: only a few yellow foci in the merged image). By eye, 
there was an obvious difference in the degree of colocalisation between this image and 
images showing good colocalisation of RPA/PCNA and EdU (compare Figure 4.12A with 
Figure 4.10A1+B1). I nevertheless examined line profiles (Figure 4.12A), since this proved 
instrumental in confirming the colocalisation of EdU with RPA/PCNA (Figure 4.10A3+B3), 
as discussed above. I also processed the images using thresholding (Figure 4.12A), which 
previously improved the global appearance of colocalisation for EdU and RPA/PCNA by 
equilibrating the intensity of staining in the two channels (Figure 4.10A2+B2). Whilst both 
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of these types of analyses singled out a few foci that showed good colocalisation (a total of 
2 starred peaks in Figure 4.12A), they also confirmed that there is a substantial difference 
between the degree of colocalisation in HeLa cells stained with RPA/PCNA antibodies and 
EdU and HeLa cells labelled with rSld5 and mSld5A. The extent of colocalisation was even 
lower in coverslips stained with rSld5 and mSld5B (Figure 4.12B). All in all, this was most 
unexpected and very confusing, given that rSld5, mSld5A and mSld5B antibodies should 
have the same specificity, which had been validated as shown (Chapter 3), namely: 
(a) All three antibodies produce relatively clean siRNA-sensitive signals of the same 
molecular weight by immunoblotting (Figure 3.7C, Figure 3.10);  
(b) All produce similar siRNA-sensitive focal nuclear patterns (with very little 
cytoplasmic staining) by immunofluorescence (Figure 3.17-I-A and -II-A); 
(c) All three antibodies produce a specific nuclear staining by immunohistochemistry 
(Figure 3.18B, Figure 5.2); 
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Figure 4.12 (THIS AND NEXT PAGE) Colocalisation of GINS 
antibodies using high-resolution confocal microscopy (high-resolution 
images of the experiment presented in Figure 3.17). HeLa cells were 
nucleofected with the indicated siRNAs (see each panel) and seeded onto 
coverslips. Coverslips were fixed, permeabilised and processed for 
indirect immunofluorescence of the indicated antibodies using ImageIT 
and BSA as blocking reagents before antibody incubation. Images were taken under the same conditions for 
knock-down and control coverslips, but conditions were adjusted for each combination of antibodies to 
maximise the dynamic range. Images were processed as usual (levels, Gaussian blur and sharpen), except for 2 
thresholded images. Thresholding and line profiles were performed on unprocessed images. Starred (‘*’) peaks 
denote those that show perfect colocalisation. 
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I considered the following explanations to reconcile the unexpected result of double 
labelling with mSld5A, mSld5B and rSld5 antibodies investigated by high-resolution 
confocal microscopy:  
(1) Could it be that all three antibodies recognise different isoforms of Sld5 or different 
subcomplexes with a variation of epitopes exposed? Given that rSld5 is a polyclonal 
antibody, and all three antibodies were raised against an identical immunogen 
(purified in a very similar way), it is difficult to envisage that some component 
antibodies in the rSld5 would not recognise the mSld5B/A epitopes. This is 
therefore a very unlikely explanation. 
(2) Although special care was taken to use all antibodies at concentrations which 
produced sub-maximal staining intensities (especially for the rabbit antisera), I also 
considered whether antibodies recognising the same protein compete for epitopes or 
sterically hinder each other and are therefore not able to produce high degrees of 
colocalisation. I soon realised that the epitope competition could not explain the 
observed complete absence of one or the other antibody from green/red foci. Given 
their intensity, it is assumed that these peaks are not composed of just a single 
molecule of the protein, but rather a cluster, offering both antibodies a good number 
of opportunities to bind each focus. Steric hindrance can therefore not provide an 
explanation for the observed results. 
(3) Could it be that both mSld5A and mSld5B antibodies are not suitable for high-
resolution immunofluorescence studies, whereas rSld5 is? The latter antibody was 
previously validated by myself and AD Mills (Figure 4.3) and showed a very good 
degree of colocalisation with rPsf3, another component of the GINS complex. It is 
also the only anti-Sld5 antibody that has so far been successfully validated by 
immunoprecipitation (Figure 3.19B). This explanation is difficult to reconcile with 
the similar behaviour of the three antibodies in the initial siRNA validation 
experiments (compare rSld5 and mSld5 staining by IF/WB in Figure 3.17-I-A/B and 
-II-A/B). Nevertheless, this is an important point to keep in mind. 
(4) Is it possible that all antibodies bind Sld5 protein in cells fixed on coverslips, but 
that the antibodies also detectably interact with other unrelated proteins in the 
nucleus? This would be in better agreement with data presented in Figure 3.17-I-
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A/B and -II-A/B, but is still difficult to reconcile with the very clean signal given by 
these antibodies in other immunological applications, such as immunoblotting and 
immunohistochemistry. However, it is important to bear in mind that 
immunostaining of cells is inherently more prone to increased probability of cross-
reaction due to (a) a large number of epitopes displayed in many different states of 
denaturation and (b) localised high concentration of various epitopes, promoting the 
formation of low-affinity interactions (Harlow & Lane, 1999). It is therefore 
possible that despite a very specific signal by western blotting and 
immunohistochemistry, not all nuclear signal seen by immunofluorescence is due to 
binding of the antibodies to Sld5 protein, especially when investigated at high 
resolution and at a higher signal-to-noise ratio than with immunohistochemistry. 
So far, I have only discussed the results and possible explanations for cells labelled with the 
Sld5 antibody pairs. However, the same experiment also included high-resolution imaging 
of cells stained with antibodies against different GINS subunits (rPsf1&mSld5A and 
rPsf3&mSld5B). The low degree of colocalisation between these labels was comparable to 
the degree of colocalisation observed using pairs of Sld5 antibodies (compare panels A, C, 
E and F in Figure 4.12). This result could imply that a much smaller proportion of each 
nuclear GINS subunit than expected is actually present in the tetrameric complex. However, 
in my immunoprecipitation experiments (Figure 3.19A) and those published by Mendez and 
colleagues (Aparicio et al., 2009), the majority of all four subunits is co-depleted from the 
extract when using an antibody against just one GINS subunit. Nevertheless, a possibility 
that some GINS protein precipitates or is otherwise removed from the IP reaction during 
extract processing cannot be excluded, especially given the indications of poor solubility of 
individual recombinant subunits (Figure 3.1). This problem would not affect proteins that 
are fixed directly in live cells without disturbing the nucleoplasm before fixation. 
An alternative explanation for why rPsf1&mSld5A and rPsf3&mSld5B images do not show 
a good degree of colocalisation could again be that mSld5A and mSld5B antibodies are not 
suitable for high-resolution immunofluorescence studies, as discussed in point (3) above. 
Alternatively, given the unexpected and broadly similar lack of colocalisation between any 
of the antibodies tested in this section, it is also possible that antibodies show a detectable 
level of non-specific binding in IF, as discussed under point (4). Explanations (1) and (2) 
should not apply to antibodies recognising different proteins. 
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Returning briefly to point (4), I was hoping that the comparison of knock-down and control 
coverslips under high-resolution would give me some clues as to whether there is a 
particular part of the signal that is non-specific. Upon global examination of the images, 
nothing obvious stood out: it appeared that all nuclear signal is reduced uniformly in knock-
down images, without changing the staining pattern in any obvious way (compare panels A 
and B, C and D, F and G in Figure 4.12). The same conclusion was made when comparing 
thresholded images (Figure 4.12A/B and further data not shown). Finally, I also compared 
densitometric traces of the same channel between knock-down and control mSld5A/rSld5-
stained cells. The trace of the control and knock-down cells again appears to be very 
similar, allowing for differences in amplitude (compare panels A and B). This would again 
suggest that all of the signal is specific, or that the patterns of non-specific and specific 
staining are too complex to separate by visual comparison.  
All in all, the improved image collection and processing has turned out not to solve the 
‘GINS antibodies paradox’, i.e. the phenomenon of seemingly specific antibodies against 
the same protein subunit or subunits of the same (GINS) complex showing a very poor 
degree of colocalisation by high-resolution confocal microscopy. It has so far been 
impossible to reconcile which reason(s) contributed to the unexpected results described in 
this section, although the two most likely explanations so far are (a) that a subset of the 
antibodies is not suitable for high-resolution immunofluorescence staining, whilst the other 
ones, chiefly rPsf3 and rSld5 are suitable, or (b) that all antibodies show a certain degree of 
non-specific staining in high-resolution immunofluorescence staining that does not seem to 
affect the quality of GINS antibodies in other immunological applications.  
Addressing technical issues of imaging a molecularly crowded nucleus at high resolution is 
considered to be an important future direction. I am currently testing if permeabilisation 
before fixation or the fixation conditions themselves (such as pH, time of fixation, using 
different fixatives) affect the degree of colocalisation of the GINS antibodies. I also 
consider it important to confirm that rSld5 and rPsf3 validation presented in Figure 4.3 is 
reproducible using direct labelling of both antibodies. The initial direct labelling was done 
with one secondary antibody, which could have potentially transferred from the unlabelled 
rPsf3 antibody to the labelled rSld5 during the final 1h incubation at 37ºC (a quick 
paraformaldehyde fix after the secondary antibody incubation would have controlled for 
that). Given the weight that this validation carries for deciding the priority of further 
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troubleshooting experiments, this is the other essential outstanding experiment to perform 
before deciding the fate of future efforts to investigate high-resolution subnuclear 
localisation of GINS subunits with the antibodies described in this thesis. 
 
Discussion 
The initial aim of the work presented in this chapter was to explore the subnuclear 
localisation of the GINS proteins and evaluate their degree of colocalisation with the MCM 
complex, with which GINS has been shown to interact by immunoprecipitation, 
biochemical studies and bimolecular fluorescence complementation (Akman & MacNeill, 
2009, Aparicio et al., 2009, Ilves et al., 2010), and with the process of DNA replication 
itself, where GINS has shown to be essential (Aparicio et al., 2009) and localised to nascent 
DNA on extended chromatin fibres (Cohen et al., 2009). Initial colocalisation studies, 
performed in collaboration with AD Mills, could not detect any striking degree of 
colocalisation between the GINS antibodies and either MCM proteins (Figure 4.3) or the 
DNA replication machinery itself (Figure 4.5), although we did manage to confirm that 
rPsf3 and rSld5 antibodies colocalise (Figure 4.2). During my validation of additional GINS 
antibodies for use in high-resolution confocal microscopy, I found a surprising lack of 
colocalisation between two anti-Sld5 antibodies, which both showed siRNA-sensitivity of 
the immunofluorescence signal in the initial validation experiments (Figure 4.7B). This, 
together with an apparent lack of tight colocalisation between RPA and nascent DNA 
(Figure 4.7A) forced me to evaluate the experimental set-up before carrying out further 
work on the apparent non-colocalisation of GINS with MCM or DNA replication. I was 
successful in optimising the image collection and processing and showed that my improved 
data on colocalisation of EdU and RPA/PCNA (Figure 4.10) agrees with the published 
literature. Nevertheless, these improvements did not reconcile the paradoxical lack of 
colocalisation between mSld5A and rSld5 antibodies, which was reproduced even after 
careful scrutiny of the experimental system (Figure 4.12A). The reasons for this observation 
have not yet been fully elucidated. This has prevented me from returning to the original 
biological question until the paradox of GINS antibodies has been resolved. 
The paradoxical non-colocalisation between different GINS subunits has been a very 
intriguing observation. It was most surprising how antibodies that appear so clean by 
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immunoblotting and by immunofluorescence and have undergone very extensive validation 
in Chapter 3 can be so widely wrong when investigated by high-resolution confocal 
microscopy (Figure 4.12). Although I have not been able to confirm the reasons behind this 
experimentally, I hypothesise that this paradox is some sort of an artefact, although 
biologically-significant reasons cannot yet be excluded.  
How does this current mistrust in GINS antibodies for high-resolution microscopy affect the 
general validation of these antibodies, and the data presented in the rest of this thesis? Could 
it be that GINS antibodies are also not as specific as they appear in other immunological 
methods? I believe there is no doubt that GINS antibodies, which have been validated by 
siRNA knock-downs are absolutely specific for western blotting. In other words, I see no 
reason to doubt that the strongest band of the appropriate MW recognised by these validated 
antibodies is due to the interaction with the specific antigen. I also believe that the 
localisation of the GINS stain to the nucleus can be trusted, since it is supported by staining 
of the same cell type using unrelated GINS antibodies (Aparicio et al., 2009) and at least 
partially by the IP experiments in Figure 3.19, where I showed that GINS complex can be 
immunoprecipitated from nuclear extracts (note that I did not IP the cytoplasmic extract as 
well). Nuclear staining is also corroborated by the staining pattern observed in 
immunohistochemistry, where rSld5, rPsf3 and mSld5A/B antibodies stain nuclei of 
proliferating cells, but are absent from nuclei of non-proliferating differentiated cells 
(Figure 3.18 and Figure 5.2). This follows closely the staining pattern observed by the 
highly validated proliferation marker Mcm2 (Freeman et al., 1999). Since the rest of the 
immunostaining experiments presented in this thesis do not explore the localisation of GINS 
antibodies at a subnuclear level, remaining results are not affected. Nevertheless, great care 
should be taken when deriving conclusions about the intensity of the nuclear staining, 
especially in cells processed and visualised for confocal immunofluorescence microscopy. 
Could the paradox of GINS antibodies also affect the interpretation of data beyond the 
realms of this thesis? Why should we care about resolving this conundrum? GINS 
antibodies display a focal pattern, which is reminiscent of the focal pattern observed for 
MCM (Madine et al., 1995b), Cdc45 (Bauerschmidt et al., 2007) and various other nuclear 
proteins involved in DNA replication, such as ORC proteins (Prasanth et al., 2004). If it 
turns out that the GINS foci with at least some antibodies are due to an artefact, this raises 
an important question of which focal pattern can in fact be trusted and whether this affects 
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the interpretation of the MCM paradox. Furthermore, if at least a portion of the antibody 
staining or some of the antibodies turn out to be non-specific, this deserves some atention as 
a very exemplary cautionary tale of how suspicious one should be of the high-resolution 
immunofluorescence staining even by the cleanest of antibodies. Lastly, even if the staining 
turns out to be specific, this could increase our understanding of the experimental technique 
used to generate the confusing results. 
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Chapter 5 GINS proteins as candidate cancer 
markers 
Introduction 
Cancer is the second most common killer in the developed countries and the biggest cause 
of death worldwide (WHO, 2010). Finding the cure for cancer is the holy grail of cancer 
research, but is an extremely difficult task due to the diverse phenotype of malignant cells. 
Improving prevention and early detection is therefore a more realistic strategy for 
decreasing cancer deaths at the moment. Currently, the detection of many common types of 
cancer, including urological cancers, relies chiefly on subjects promptly reporting their 
symptoms (such as haematuria, pain when urinating and other types of discomfort during 
and after urination for genito-urinary tract cancers). Diagnosis before symptoms start would 
have a significant effect on patient prognosis, as has been illustrated for example through 
the introduction of breast and cervical cancer population screening (Lawrence et al., 2009, 
Peto et al., 2004).  
Bladder cancer (most commonly a transitional cell carcinoma) is Britain’s 6th commonest 
cancer overall and the 4th commonest cancer for men (Cancer Research UK, 2010). 
Prognosis is good if cancer is diagnosed in its early (pre-invasive) stage, with 80-90% 5-
year survival. However, many transitional cell carcinomas of the bladder frequently recur, 
which calls for close monitoring after the initial successful tumour treatment (Mufti & 
Singh, 1992). Furthermore, 20% bladder cancer patients in the UK present with an invasive 
bladder cancer. This significantly reduces their prognosis – only 1 in 2 or 1 in 4 people 
diagnosed with a T2- or T3-stage invasive bladder cancer, respectively, will still be alive 3 
years later (Cancer Research UK, 2010). There is therefore a great need for a sensitive 
screening tool, which would allow both early detection and frequent follow-up tests after the 
initial treatment. Recent reports suggest that such tools could be developed through 
detection of many genomic and proteomic markers (Shirodkar & Lokeshwar, 2009), notably 
the detection of nuclear matrix protein 22 (NMP22) in urine supernatants by ELISA 
(Jamshidian et al., 2008) or Mcm5 in urine sediments by DELFIA (Dissociation-Enhanced 
Lanthanide Fluorometric Immunoassay) (Stoeber et al., 2002), and the home haematuria 
dipstick analysis (Madeb & Messing, 2008). None of these tests has been proven reliable 
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enough to replace cytoscopy and/or cytology and the search for the optimal biomarker is 
still ongoing (Herman et al., 2008). 
Prostate cancer is now Britain’s most common male cancer – 24% of diagnosed male 
cancers are of prostate origin (Cancer Research UK, 2010). A major danger of prostate 
cancer is that it tends to spread into the bones rather than any other organ and the degree of 
the spread is sometimes independent of the tumour size (Cancer Research UK, 2010). If a 
patient presents with a metastatic prostate cancer, his 5-year prognosis is only 30%. Testing 
of the prostate-specific antigen (PSA) serum levels was introduced into the clinic almost 20 
years ago (Catalona et al., 1991) in the hope that it would offer a test that could be used for 
the detection of prostate cancer in the early stages. However, whilst being an excellent 
tissue-specific marker, PSA levels do not correlate very well with the cancer progression 
risk (Thompson et al., 2005). Despite tailoring the treatment to each individual and his 
specific risk factors beyond the PSA levels and promoting active surveillance and watchful 
waiting, today’s healthcare still has to treat 48 men in order to prevent one of them from 
dying of prostate cancer (Neal et al., 2009). Since treatment of prostate cancer can 
significantly reduce the quality of a patient’s life, a better prognostic prostate cancer marker 
would help to stratify patients into those that require treatment and those who do not.  
Cancer is a disease of aberrant cell proliferation, making cell cycle proteins an obvious 
choice for cancer markers (Tachibana et al., 2005). Whilst not specific to just cancer cells 
(they mark every proliferating cell), they are at the same time not organ-specific. This can 
circumvent the need to either understand the intricate, very dynamic and heterogeneous 
biochemical processes in the dysplastic and neoplastic cells or devise top-down approaches 
to biomarker discovery, depending on the cancer type, stage and method of detection. 
Although a range of proliferation markers including Cdc45 (Pollok et al., 2007), Cdc6 
(Williams et al., 1998) and PCNA (Chan et al., 1983) have been characterised as 
proliferation markers, MCM proteins (especially Mcm2 and Mcm5) offer significant 
advantages owing to their extensive clinical evaluation and consistently superior labelling 
index to the traditional ‘proliferation’ markers such as Ki67 (Wharton et al., 2001, Schrader 
et al., 2005, Szelachowska et al., 2006). Over the last 12 years MCM antibodies have been 
evaluated for the non-invasive detection of several cancer types with varying but mostly 
successful outcomes (Williams et al., 1998, Scarpini et al., 2008, White et al., 2009, 
Chatrath et al., 2006, Scott et al., 2006). Some, chiefly the improved cervical smear testing, 
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are now undergoing advanced clinical trials. Based on its excellent track record, Mcm2 is 
now a main component of a commercial antibody cocktail ProExC (BD Biosciences), which 
has become the Mcm2-based proliferation reagent of choice over the past couple of years 
(Shroyer et al., 2006, Badr et al., 2008).  
Given the molecular interaction between GINS, MCM and Cdc45, I wanted to test if GINS 
could be useful markers for cancer as well. In this chapter, I report that GINS subunits are 
downregulated when cells enter quiescence or differentiation programmes with roughly the 
same kinetics as Mcm2. Staining of normal malignant human tissue sections indicates that 
the labelling index of Sld5 is as good as that of Mcm2. The second part of the chapter 
focuses on testing to see if Sld5 could offer any advantages over Mcm2. These efforts had a 
strong commercial drive due to the filing of a patent at the start of the second year of my 
doctoral research. I was able to determine that Sld5 protein shows superior stability when 
incubated in urine, especially at body temperature. This led to the comparison of Mcm2 and 
Sld5’s performance in cancer detection methods that rely on isolation of the material from 
harsh extracellular environments such as urine and faeces. I found that Sld5 might offer 
qualitative and perhaps quantitative advantages over Mcm2, including ProExC, for the 
detection of malignant colonocytes retrieved from stool of colorectal cancer patients and 
malignant cells retrieved from urine of prostate and bladder cancer patients. This deserves 
further evaluation using immunocytology with mSld5A antibody. I also discuss further 
planned experiments, chiefly the development of an Sld5 ELISA to test if the protein can be 
detected in the urine supernatants.  
 
Results 
5.1 Sld5 protein is downregulated in quiescence with similar 
kinetics to Mcm2 
GINS proteins are expressed at equal levels in all stages of the cell cycle (my unpublished 
observation and Aparicio et al., 2009). On the other hand, immunohistochemical staining of 
tissue sections for the purpose of antibody validation (Figure 3.18) has already indicated 
that Sld5 protein is down-regulated when cells exit the cell cycle and enter the 
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differentiation programme. This suggests that GINS proteins could be useful as markers of 
proliferating cells. To further examine the relationship between GINS proteins and the 
proliferation potential of cells, I next asked if GINS proteins are also downregulated when 
cells enter quiescence. To test this, WI38 human diploid fibroblast cells were driven into 
quiescence by contact inhibition. Whole-cell lysates were harvested at regular intervals after 
cells had stopped cycling and analysed by immunoblotting.  
Reduction in GINS protein levels was clearly visible even after 3 days in quiescence (Figure 
5.1). This is in agreement with the data subsequently published by Mendez and colleagues 
(Aparicio et al., 2009). Figure 5.1 also suggests that the kinetics of GINS reduction appears 
very similar to the Mcm2 profile. This data clarifies the published information (Aparicio et 
al., 2009) and places Sld5 protein in the same group as the MCMs when considering the 
kinetics of reduction in protein levels as cells enter quiescence. It would be interesting to 
test whether GINS, MCM (and Cdc45) also behave similarly when cells are triggered to 
restart the cell cycle, in particular which proteins get expressed and loaded onto the 
chromatin first. 
It is interesting to note that Sld5 and Mcm2 were both present at roughly a third of the 
original protein levels even after 23 days in quiescence (Figure 5.1). Previous reports 
describe Mcm2 protein levels falling to less than 1% of those detected in proliferating cells 
by day 14 of WI38 contact-inhibition (Stoeber et al., 2001). In my experiments, Sld5 and 
Mcm2 were undetectable only after maintaining a confluent culture for over 2 months 
(Figure 5.1, day 74). This discrepancy could be a result of (i) differences in the sensitivity of 
the antibodies used for immunoblotting (my signals were stronger), (ii) the passage number 
of WI38 culture or a small number of cells in my experiments remaining in the cycle, or (iii) 
possibly due to the perturbations to the monolayer when changing the medium. BrdU 
labelling of a quiescent WI38 culture grown on coverslips and immunostaining for Sld5 and 
Mcm2 could have shed further light on which reason(s) contributed to the observed effect. 
All in all, WI38 contact-inhibition experiments indicate that Sld5 and Mcm2 levels decline 
upon cells entering quiescence with comparable rates. The rate of decline in protein levels is 
slower than the previously published work (Stoeber et al., 2001) and the reasons behind this 
discrepancy could not be elucidated fully, but are also believed not to be essential to 
understand for the purposes of evaluating GINS proteins as proliferation markers (the main 
aim of this chapter). Since Sld5 protein levels decline at a similar rate to the Mcm2 protein, 
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and Mcm2 is an excellent proliferation marker (Coleman & Laskey, 2009), GINS proteins, 
which also score well in the WI38 contact-inhibition test, could also prove excellent 
proliferation markers.  
 
Figure 5.1 Sld5 protein is downregulated in quiescence (G0). WI38 human fibroblast cells were grown 
to confluence and maintained in the confluent state with frequent changes of the full medium. Total protein 
samples were harvested at regular intervals after the confluent culture was considered to have entered 
quiescence (day 0), judging by the lack of dividing cells and cell-free areas in the flask.  Immunoblotting of 
whole-cell lysates from two independent experiments.   
5.2 Sld5 and Psf3 mark proliferating cells in human tissue 
biopsies, including dysplasias and malignancies 
Data presented so far (in Figure 5.1 and Figure 3.18) strongly suggests that GINS subunits 
could be used as markers for proliferation. I next used purified rabbit antibodies to stain 
sections from a range of normal and malignant human tissues (bladder, cervix, colon, 
prostate, kidney and skin) in collaboration with CR Scarpini and N Coleman. CR Scarpini 
performed the staining and evaluated the slides. An excerpt from her extensive collection of 
data is included here (Figure 5.2) because it forms an essential part of this chapter.  
CG Scarpini readily observed a strong signal for Sld5 and Psf3 in the nuclei of cells of all 
the proliferative compartments, including morphologically recognisable dysplasias and 
malignancies (see Figure 5.2 for bladder and cervix). By visual estimation, the labelling 
index of Sld5 was very similar to Mcm2 in all tissues examined (foci of rSld5 positivity in 
the normal bladder, which do not agree with Mcm2 staining, are an artefact of antigen 
retrieval process and do not localise to nuclei). On the other hand, the labelling index of 
Psf3 was higher than both Mcm2 and Sld5 in the nuclei of: 
- Early differentiating cells (for example, note a number of Psf3-positive nuclei in the 
suprabasal layer of normal cervix and normal bladder, which were all negative for 
Sld5 and Mcm2, Figure 5.2);  
23 12 6 5
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- Some cell types not expected to be undergoing cell division (note numerous Psf3-
positive nuclei in the connective tissue of the normal cervix that are usually negative 
for Sld5 and Mcm2);  
- Malignant cells of the bladder but not of the cervix (note higher labelling index for 
Psf3 in malignant bladder and identical labelling indices for all three markers in the 
‘CIN3+SCC’ panels). 
This could be an over-representation, owing to the relatively stronger signal of the rPsf3 
antibody, which was developed under the same conditions as Mcm2 and rSld5 (relatively 
weaker antibodies). A weaker, shorter development may be necessary for better 
discrimination using the anti-Psf3 antibody. Alternatively, this could reflect realistic 
differences in expression patterns, implying that: 
(a) Psf3 protein degrades more slowly when cells exit the cell cycle; 
(b) Individual subunits are able to exist independently of the GINS tetramer, which may 
mean they also potentially perform non-overlapping functions; 
(c) Psf3 might be the marker of choice for bladder cancer owing to its higher labelling 
index compared to Sld5 and Mcm2.  
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Figure 5.2 Comparison of Sld5, Psf3 and Mcm2 staining in bladder and cervix (data by CG Scarpini). 
Immunohistochemical staining of paraffin-embedded biopsy sections using rabbit (rSld5, rPsf3) and mouse 
(Mcm2) antibodies specified on the left was performed by P Stacey. Brown peroxidase staining indicates the 
presence of bound antibody. Bladder biopsy was morphologically classified as containing a malignant and a 
normal section. Cervical malignancy was morphologically classified as a mixture of cervical intraepithelial 
neoplasia grade 3 (CIN3) and squamous cell carcinoma (SCC).  
I also tested whether Sld5 and Psf3 could be detected in the malignant colonocytes isolated 
from stool of a colorectal cancer patient. I studied a range of malignant colonocyte clumps, 
which were identified on the basis of their morphological features and the positive Mcm2 
stain. An example of such a colonocyte clump that spanned all the sections stained by the 
different antibodies is presented in Figure 5.3. The same group of cells stained positive with 
all the GINS antibodies tested. The quality of staining was not as good as for Mcm2, but it 
should be noted that the antigen retrieval and other immunohistochemical variables had 
been optimised for this Mcm2 antibody and not for GINS antibodies. The rPsf3 antibody 
could have been diluted further (cytoplasmic staining). In addition, rPsf3 stained some 
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Mcm2 and rSld5-negative inflammatory cells (data not shown). In the case of Mcm2, 
staining in inflammatory cells is weaker and can be titrated out by staining with a lower 
concentration of Mcm2 antibody (Coleman & Laskey, 2009). This suggests that the higher 
labelling index of Psf3 observed in tissue sections is more likely due to differences in the 
strength of staining, rather than due to real differences in expression patterns between Psf3 
and Sld5/Mcm2. This could be investigated further by immunofluorescence tissue staining 
of frozen tissue sections with Mcm2 and rSld5/rPsf3 at the same time, which would allow a 
more quantitative assessment of the extent of staining by the different markers.  
Taken together, tissue-labelling studies suggest that antibodies to GINS, like Mcm2 and 
other MCM proteins, hold promise as specific and sensitive proliferation markers for both 
histological and cytological biopsies from a wide range of human tissues. Our observations 
agree with recently published results for Psf1 staining in human tonsils (Aparicio et al., 
2009) and Psf3 staining in colon (Nagahama et al., 2010). In our studies, Sld5 staining 
pattern was particularly good, i.e. comparable to the Mcm2 signal. Nevertheless, Psf3 also 
deserves further validation as a proliferation marker, keeping in mind that its potentially 
higher labelling index in certain tissue types could either work positively to increase the 
sensitivity (dysplasias of the cervix and especially of the bladder could be detected sooner, 
for example) and/or negatively to increase the number of false positives (if cervical smear 
sampled from the suprabasal layer, which could happen if smear was sampled too deeply).  
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Figure 5.3 Comparison of Sld5, Psf3 and Mcm2 staining in a group of malignant colonocytes isolated 
from stool of a colorectal cancer patient (distal colorectal cancer). Cellular matter was isolated from stool and 
embedded into a plasma clot by E Ikelle. P Stacey stained consecutive sections of the clot by 
immunohistochemistry using the specified rabbit (rSld5, rPsf3) and mouse (Mcm2) antibodies at a range of 
dilutions, as shown. I analysed the slides with guidance from CG Scarpini. Labels rSld5.1, 2, 3 refer to 
consecutive elution volumes from the antibody purification column with rSld5.2 being the most concentrated 
according to the immunoblotting signal (data not shown). Brown peroxidase staining indicates the presence of 
bound antibody. Large clear area in panel rSld5A.1 (1:500) is due to an area of the sectioned clot becoming 
dislodged during processing and not due to negative staining. 
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5.3 Are GINS better cancer markers than the MCMs? 
Psf3 and especially Sld5 hold promise as proliferative markers of comparable quality to the 
MCMs. But can they offer anything that the well-established and clinically validated MCM 
markers cannot already provide? Mcm5 and especially Mcm2 have been very successfully 
validated as markers in a range of clinical samples including cervical smear (Mukherjee et 
al., 2007), anal neoplasia testing (Scarpini et al., 2008), minimally invasive testing for oral 
squamous cell carcinoma (Scott et al., 2006) and many others. Screening applications, 
which rely on isolating cellular material from harsh protease-rich extracellular environments 
such as faeces, have been less successful, possibly owing to the instability of the MCM 
proteins (C Scarpini and N Coleman, personal communication). In my expression studies 
(3.1), recombinant GINS displayed very good stability at 4ºC (no significant degradation 
even after 1 month, data not shown). This suggested that GINS proteins might potentially be 
more stable than the MCMs in biological specimens.    
I first tested this hypothesis with a ‘proof-of-principle’ assay of comparing resistance to 
trypsin digestion of Mcm2 and Sld5 from HeLa whole-cell lysates and estimating the rate of 
disappearance of the full-length protein bands by immunoblotting. It was found that Sld5 
proteolysis proceeded slowly, whereas Mcm2 protein underwent very rapid proteolysis 
(Figure 5.4). Mcm2 could not be detected either as full length or as a prominent degradation 
product upon addition of trypsin (Figure 5.4, see the left-most +Trypsin lane), even after 
prolonged exposure (data not shown). This can perhaps be explained by taking into account 
that both proteins contain equal number of trypsin canonical sites per unit length of primary 
sequence according to ExPASy Peptide Cutter (Gasteiger et al., 2003), and that therefore 
Mcm2, which is approximately 4-times longer and about 4-times as abundant in HeLa cells 
(Figure 4.1), would be predicted to get cleaved faster (ignoring any significant differences 
in the association constants between the two proteins and trypsin). However, providing the 
explanation does not decrease the value of this finding, i.e. Sld5 protein still appears to be 
more resistant to proteolysis than Mcm2 in cell extracts. 
Trypsin might not compare well to the range of proteases usually found in human urine or 
faeces, so this result had to be interpreted with some care. Nevertheless, the experiment 
provided the first stepping stone towards confirming the superior stability of Sld5 (as the 
seemingly most stable GINS subunit, judging from the recombinant experiments in section 
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3.1 above) compared to Mcm2, the most thoroughly characterised and most trusted cell 
cycle marker at the moment (Coleman & Laskey, 2009). At the same time, this experiment 
also secured the filing of a patent “GINS gene expression as marker for actively cycling 
cells and cell cycle phase” (Bell, 2006), on which I was named a non-inventive contributor. 
Psf3 was not protected by the claims of this patent owing to its widespread staining pattern 
in tissue sections examined (Figure 5.2). My further work therefore mainly focused on the 
validation of Sld5, which is the only subunit protected by the patent and for which I also had 
a reliable set of antibodies available since year 1 of my doctoral project (Figure 3.6). 
 
Figure 5.4 Sld5 from tissue culture extract is cleaved more slowly by trypsin than Mcm2. HeLa whole-
cell extracts (kind gift from CG Scarpini) were incubated with trypsin protease at room temperature. Samples 
were collected at 0h, 10min, 20min, 30min, 45min, 1h, and 1.5h. Reaction was inhibited (but not completely 
stopped) by adding 2x Laemmli loading buffer and freezing down the sample immediately. No trypsin control 
for the starting and end points was included (0h and 1.5h, respectively). Harvested samples were analysed by 
immunoblotting. Membrane was first probed with rSld5 antibody, then stripped and re-probed with Mcm2 
goat antibody. Debris over the first two ‘+Trypsin’ lanes of Mcm2 membrane was due to the stripping solution 
precipitating on the membrane and could have interfered with the detection of a faint Mcm2 signal in those 
two lanes, if present. 
5.4 Sld5 is more stable than Mcm2 in urine 
As an upgrade to the crude trypsin-sensitivity test (Figure 5.4), I next designed an in vitro 
assay with an aim of better mimicking the conditions experienced by cellular proteins in 
urine. I used two bladder cancer cell lines: grade 2 RT112 and grade 3 EJ28. EJ28 and 
RT112 lysates were diluted in a urine sample from a healthy volunteer for various lengths of 
time and at either 4ºC or 37ºC (Figure 5.5A). I confirmed that urine from the healthy 
volunteer did not contain detectable levels of Mcm2 or Sld5 protein before the addition of 
cell lysates (Figure 5.5B, ‘Urine’ lanes). To account for any differences in loading between 
time-points, I compared the ratio of intensities of Mcm2 and Sld5 signals in order to 
0h1.5h + Trypsin
Mcm2
rSld5
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determine their relative stabilities. At 37ºC, Sld5 was substantially more stable (compare 
later time points: 3 days for EJ28 and 22 h for RT112). At 4ºC, this difference was less 
pronounced. Nevertheless, by day 3 there was a slight shift in favour of Sld5 (Figure 5.5B, 
RT112: Sld5 signal is stronger at 3 days than at 4h at 4ºC, whereas the Mcm2 signal is 
weaker at 3 days than at 4h). This suggests that Sld5 might be more stable than Mcm2 when 
exposed to the urine milieu. 
 
 
 
 
 
 
 
Figure 5.5 Sld5 from cell lysates is more stable than Mcm2 when incubated in urine.  (A) Diagram 
representation of the first urine spiking experiment: asynchronously cycling EJ28 or RT112 bladder cancer 
cells were detergent-lysed and incubated in urine from a healthy volunteer at either 37ºC or 4ºC. Samples were 
harvested at regular intervals and concentrated by TCA precipitation before immunoblotting (B). ‘Urine’ = 
unspiked urine before the addition of cell lysates. Mcm2-immunogenic band of starred (*) molecular weight 
probably represents Mcm2 degradation product.  
To confirm my observations from the first urine spiking experiment in an experimental set 
up that is arguably more realistic, I next studied the behaviour of intact cells in urine. This 
experiment was designed to mirror the way in which a clinical urine sample would be 
collected and processed for the analysis of cellular Mcm2 protein by immunocytochemistry, 
except that I used immunoblotting to analyse the cellular protein levels. I also analysed the 
urine supernatants, which would normally be discarded. Samples were either incubated at 
37ºC (to mimic the conditions inside the bladder before the cells are shed and subsequently 
excreted), or they were incubated at 4ºC (to mimic the conditions after urine has been 
collected for analysis, but before it has been processed). 
As illustrated in Figure 5.6A, the second set of urine spiking experiments used EJ28 bladder 
cancer cells, which express Sld5 and Mcm2 to a higher level than RT112 (data not shown). 
In the three repeats of the experiment, EJ28 cells were incubated in urine samples from 
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different healthy volunteers. At each time point, cells were separated from the urine in 
which they were incubated. Similarly to the first urine spiking experiment, cellular Sld5 
again proved more stable when incubated at 37ºC (Figure 5.6B: Sld5 signal remains similar 
between days 2 and 4, whereas Mcm2 signal is substantially reduced; Figure 5.6D: compare 
the ratio of intensities of Mcm2 and Sld5 signal for 17h with that for 0h; Figure 5.6E). At 
4ºC, on the other hand, I observed no substantial differences in stability between Mcm2 and 
Sld5 (panels B, D and E). 
In summary, these blots suggest that cellular Mcm2 at 37ºC, equivalent to the exfoliated 
cancer cell whilst still in the bladder, degrades more rapidly than Sld5. Once excreted and 
stored at 4ºC, the degradation for Sld5 is still slower, but probably not significant for the 
length of time that clinical samples are usually stored at 4ºC before processing. 
Nevertheless, it could be that these differences become more pronounced when the urine 
proteases-to-protein ratio increases (it is probable that the number of Mcm2 and Sld5-
positive cells in the clinical samples are significantly lower than what was used in this 
experiment). 
The experimental set up in Figure 5.6A also allowed me to study the supernatant fraction of 
the urine samples, which would be usually discarded in the MCM clinical trials. I found that 
both proteins appear to be released into the urine milieu during sample incubation (Figure 
5.6C), perhaps due to partial cell lysis, which I observed under the light microscope when 
counting harvested cells (data not shown). Importantly, assuming that both proteins are 
released from the cells at the same time, Mcm2 underwent a more prominent and faster 
degradation than Sld5 (Figure 5.6C 37ºC: Mcm2 signal peaks at 9h whereas Sld5 signal 
peaks at 25h). This result can be complemented with the conclusions from the initial urine 
spiking experiment (Figure 5.5), where the assumption that both proteins are released from 
the cells at the same time does not have to be made. Taken together, results from Figure 
5.5B and Figure 5.6C confirm that free Sld5 protein is more stable than Mcm2 in the urine 
milieu.   
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Figure 5.6 Cellular Sld5 is more stable than Mcm2 when incubated in urine and also persists longer if 
released from cells into urine milieu.  (A) Diagram representation of the second urine spiking experiment: 
asynchronously cycling EJ28 bladder cancer cells were incubated in urine from healthy volunteers at either 
37ºC or 4ºC. Samples were harvested at regular intervals and separated into the pelletable and supernatant 
fractions. The cell number (“Cells loaded relative to 0h:”) was estimated before analysing the pelletable 
fraction by immunoblotting (B). Proteins from the supernatant fraction were first concentrated by TCA 
precipitation before immunoblotting (C). Extra immunogenic bands appearing in some Mcm2 strips are 
believed to be partially degraded species of Mcm2. They were also observed at a much fainter level in cells 
incubated at 4ºC (data not shown).  (D) and (E) Repeat of experiment from panel B using two different urine 
donors.  
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All in all, the urine spiking experiments strongly suggest that free Sld5 is more stable than 
free Mcm2 protein in the urine environment. Sld5 protein in cells isolated from urine 
samples might offer a similar advantage over the cellular Mcm2, at least for the period 
during which the cells are still at body temperature (i.e. inside the bladder).  
Importantly, whilst the experiments so far very strongly suggest that Sld5 is more stable 
than Mcm2, they do not confirm that this advantage is significant for cancer detection. For 
example, even if Mcm2 is partially degraded, its degradation products could still be 
immunogenic. Bearing this in mind, it could be informative to re-analyse the urine spiking 
experiments with a dot blot technique or, better still, by immunocytochemistry of cells 
incubated in urine using the same antibodies that are used for clinical trials. Nevertheless, 
this experiment would still not control for the potential differences between bladder cancer 
cell lines incubated in urine in vitro and real bladder cells shed from the bladder wall and 
excreted upon urination. For example, cells of the bladder wall are believed to be protected 
by a mucus layer (N Coleman, personal communication). Furthermore, it is not clear what 
length of exposure is biologically relevant. Given the limitations of any further in vitro 
experiments and the time pressure of patent deadlines, I next turned my attention to testing 
whether I could observe signs of superior stability of Sld5 protein over Mcm2 in the clinical 
samples.  
5.5 Evaluation of GINS stability in the clinical samples 
5.5.1 Sld5 as a colorectal cancer marker 
Given the indications from the early experiments that Sld5 is present in malignant 
colonocytes isolated from stool of a left-sided cancer patient (Figure 5.3), I initially 
explored the application of Sld5 as a tool for colorectal cancer detection and screening.  
I focused on the right-sided colorectal cancers (proximal to the splenic flexure), which are 
not reliably diagnosed using Mcm2 (Davies et al., 2002). I based the initial evaluation on a 
sample from the only available right-sided colorectal cancer patient at the time. AD Mills 
helped me with the interpretation of the immunostaining. We observed a weak nuclear 
staining for Mcm2 in malignant cells (Figure 5.7-i and iii). This was as expected, given that 
colonocytes isolated from this patient spent a long time travelling down the digestive tract in 
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the protease-rich environment before being isolated for analysis. Interestingly, the Sld5 
staining of the same nuclei generally appeared cleaner with less background and stronger 
nuclear intensity (Figure 5.7-i and iii). Neither marker stained the nuclei of morphologically 
distinct columnar epithelial cells (Figure 5.7-ii), as expected for markers of proliferating 
cells only. 
 
 
 
 
 
 
 
 
Figure 5.7  Sld5 strongly and specifically stains malignant colonocytes isolated from stool of a right-
sided colorectal cancer patient (images by AD Mills). Smear of isolated fixed cells was a kind gift from E 
Ikelle. I processed the smear for indirect immunofluorescence confocal microscopy using rabbit (rSld5) and 
mouse (Mcm2) antibodies. Based on their morphology, the two clumps of cells (i) and (iii) were classified as 
malignant colonocytes and (ii) were classed as columnar epithelial cells.    Scale bar: 20µm. 
AD Mills evaluated the qualitative conclusions from Figure 5.7 by an automated 
quantitative analysis using the Olympus ScanR system. We again observed no substantial 
difference in the number of positive nuclei, although the number of Sld5-positive nuclei was 
always slightly higher using several different analytical criteria (see Table 5-i for an 
example).  
Nuclei 498 
Positive nuclei (Mcm2 or Sld5 positive) 204 (41%) 
Mcm2 positive 171 (34%) 
Sld5 positive 173 (35%) 
Sld5 + / Mcm2 - 34 
Mcm2 + / Sld5 - 32 
Table 5-i Cells isolated from faeces of a right-sided colorectal cancer patient (Figure 5.7): summary of 
automated quantitative analysis using Olympus ScanR system (data by AD Mills).  
MergerSld5DNA Mcm2
(i)
(ii)
(iii)
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I was unable to evaluate further samples for this comparative mini-study owing to a change 
in sample processing in the effort to improve the retrieval of colonocytes as part of the main 
study (White et al., 2009). Unfortunately, this rendered final samples more difficult to 
analyse by immunofluorescence (data not shown).  
All in all, staining of the one available slide suggests that Sld5 does not offer a quantitative 
advantage over Mcm2 as an immunological marker of malignant colonocytes isolated from 
right-sided colorectal cancer patients. Nevertheless, Sld5 staining might possess qualitative 
advantages, such as improving the ease of sample analysis and removing borderline cases, 
especially when analysed by hand and/or by less sensitive and more common detection 
methods such as immunohistochemistry. With this in mind, it would be interesting to revisit 
the comparison of Mcm2, Sld5 and Psf3 staining in malignant colonocytes of proximal 
colorectal cancers using the experimental set up from Figure 5.3, especially now that I have 
characterised monoclonal Sld5 antibodies and Psf3 has been reported as a marker of colon 
carcinoma progression (Nagahama et al., 2010). 
5.5.2 Pilot study: Sld5 as a marker for male genito-urinary tract 
malignancies 
I next devised a study to test whether Sld5 could be used as a marker for male genito-
urinary tract malignancies through urinalysis. Urine spiking experiments (5.4) offered 
strong support for the superior stability of Sld5 compared to Mcm2 in urine. This might be 
especially useful for cytology-based detection of prostate cancer, where very high 
sensitivity is needed to achieve accurate detection of relatively few cells of prostate origin in 
the urine samples. Mcm2 has so far proven unreliable as a prostate cancer marker (CG 
Scarpini and N Coleman, personal communication). Owing to its superior stability, it is 
possible that Sld5 might perform better in this application. Testing this hypothesis was the 
first reason for setting up a pilot study. 
The pilot study was also designed to test if Sld5 could be used for liquid-based cancer 
detection. Experiments in 5.4 indicated that Mcm2 and especially Sld5 might be detectable 
in the urine supernatants (Figure 5.6C), an application which has so far not been extensively 
tested even for the MCMs. Arguably, cytology is more informative and definitive as a 
means of diagnosis, which is why it has so far been the method of choice, especially by 
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pathologists. However, quantitative liquid urinalysis offers advantages due to its speed, ease 
and lower cost of processing, making it more readily applicable as a frontline screening tool. 
Again, Sld5 would be especially suited for such an application owing to its superior 
stability. To satisfy both aims of the study, I decided to collect both cellular and supernatant 
fractions of urines from male patients with urogenital malignancies. 
5.5.2.1 Study design: cellular fraction 
Various aspects of the study design were carefully considered in advance of sample 
collection. 
Firstly, special care was taken to optimise the fixation method for immunofluorescence 
staining. By using a mixture of HeLa cells and normal cells isolated from a urine of a 
healthy volunteer, processed in parallel by both ThinPrep technology and the standard 
paraformaldehyde-based fixation method used for tissue culture cells (2.4.7) and stained for 
the same antibodies that were later used in the study, it was determined that the standard 
laboratory method produces a substantially brighter immunofluorescent signal (data not 
shown). I therefore decided to opt for the paraformaldehyde-based method, although 
ThinPrep technology might have been better at washing the urine sample before fixation 
and getting rid of salt/lipid precipitates that occasionally persisted during sample processing 
(in 9 out of 51 samples to date). 
Secondly, I considered what range of antibodies to use for the study. I planned to make 2 
coverslips per urine sample (unless the urine volume was less than 15mL), so that one 
coverslip could be analysed using rSld5 and the other one using mSld5A (longer-term 
reagent of choice). Using rSld5 allowed the simultaneous inclusion of mouse ProExC 
antibody, which would serve as a comparison to Mcm2 performance.  
Lastly, to better characterise any positive cells in prostate cancer patients, I also included a 
goat anti-PSA antibody. Initial tests confirmed that PSA antibody staining is broadly 
specific (colon HCT116 and bladder EJ28 cells were negative for PSA; see Figure 5.8). In a 
prostate cancer cell line VCaP, PSA staining ranged from a very diffuse cytoplasmic stain to 
a granular stain that occasionally overlapped with the nucleus, when very strong (Figure 
5.8). This staining pattern was used as a guide to judge the specificity of PSA staining in the 
clinical samples. 
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Figure 5.8 PSA staining is cytoplasmic, often granular and appears to be specific to the cell lines of 
prostate origin. VCaP prostate cancer cell line (A), EJ28 bladder cancer cell line and HCT116 colorectal 
carcinoma cell line (B) were grown on coverslips and processed for indirect immunofluorescence confocal 
microscopy with the indicated antibodies. Image collection and processing for the PSA signal was the same in 
both panels.    Scale bar: 50µm. 
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5.5.2.2 Study design: supernatant fraction 
The second aim of the study was to test whether it is possible to detect free protein in the 
urine supernatants. In an attempt to optimise the supernatant analysis ahead of the pilot 
study, I tested two methods of detection on a set of urine samples from prostate cancer 
patients that were recruited for a separate Mcm2 study (gift from CG Scarpini).  
The first method involved precipitating the proteins from urine samples of 18 patients and 2 
controls by TCA and analysing them by western blotting for the presence of Sld5 and 
Mcm2. Unfortunately, the results were inconclusive, since Mcm2 and Sld5 bands could not 
be detected due to high background of other precipitated proteins in the sample (data not 
shown). This could be because TCA was not efficient at precipitating the two proteins of 
interest, but is unlikely given that sufficient ‘carrier’ protein (i.e. other abundant species 
such as albumin and keratin) was present in the sample and that I have been able to 
precipitate these proteins by TCA in other experiments (Figure 5.5B, Figure 5.6C). The 
more likely reason for the inconclusive results is that both proteins might exist in 
substantially lower concentrations compared to other prominent proteins in the urine – even 
if their amounts are within the detection range for immunoblotting on a clean background.  
In hindsight, it would have been informative to repeat the experiment with a significantly 
smaller amount of protein loaded, since overloading the lanes in the interest of detecting 
trace amounts of Sld5 and Mcm2 could have also contributed to high background. 
Alternatively, it might have been helpful to remove abundant proteins before TCA 
precipitation (e.g. by using a commercially available albumin-removal kit). 
I next analysed the same set of urine samples by immunoprecipitation (IP) to increase the 
sensitivity, circumvent the need for TCA precipitation and separate the proteins of interest 
from the other proteins that are present in the urine sample. Immunoprecipitation was 
performed on five clinical urine samples from prostate cancer patients and a pair of controls: 
urine from a healthy volunteer and the same urine spiked with detergent-lysed EJ28 cells. 
Immunoprecipitation was performed using two antibodies: rSld5 and the industry-standard 
Mcm2 antibody that is used for detection of Mcm2 in bladder cancer samples (Mukherjee et 
al., 2001, Davies et al., 2002). Bound protein and antibody was eluted from the beads by 
adding Laemmli loading buffer. Eluates were analysed by immunoblotting (Figure 5.9) 
using different antibodies from the ones used for the immunoprecipitation itself. 
     
  155 
Unfortunately these antibodies were still from the same species (rabbit and mouse) because 
mouse monoclonal Sld5 antibodies were not available at that time. 
The initial analysis (Figure 5.9A) could not confirm whether Sld5 is present in the clinical 
samples due to significant amounts of background staining. Despite this background 
staining, it appeared very likely that Sld5 was immunoprecipitated from the spiked urine 
control (compare Sld5 signal in lanes 14 and 16, panel A; both lanes display similar 
intensity of background staining), confirming that the IP itself is working. Mcm2 analysis 
was easier because there was less background staining in the higher molecular weight 
portion of the gel. Mcm2 could not be efficiently detected in the clinical samples, although 
it was immunoprecipitated from the spiked control when using the Mcm2 antibody and to a 
lesser extent when using rSld5 antibody (starred lanes in panel A). This suggests that GINS-
MCM complex may still exist in the urine supernatant. If this was the case and the 
interaction between MCM and GINS persists in the urine, it would be expected that the 
GINS complex would also remain intact and would therefore be immunoprecipitated with 
the Sld5 antibody, as was found to be the case in the initial co-immunoprecipitation 
attempts (Figure 3.19). However, when I probed for the other GINS subunits, I was unable 
to detect a convincing signal (Figure 5.9A), although the analysis was again complicated by 
the presence of background staining, especially in the region of the expected migration of 
Psf3.   
High background is believed to be due to antibodies for IP not being cross-linked to the 
protein A beads and so also being present in the eluate. To determine with greater 
confidence whether Sld5 has been immunoprecipitated from the samples or not, I next 
repeated the immunoblotting analysis. This time, the membranes were initially probed only 
with the anti-rabbit secondary antibody (Figure 5.9B). From this, it was evident that the 
secondary antibody recognises a protein (possibly part of the Sld5 rabbit antibody light 
chain) that migrates very similarly to the Sld5 protein (compare signal at the level of the 
arrow in panel B). The two proteins could not be separated by running the same sample on a 
higher percentage acrylamide gel for longer (panel C). I therefore quantified all the Sld5-
size bands in panel C and compared the relative intensities to determine if there was any 
change in the pattern of intensities between the signal when probing with the secondary 
antibody only and the signal when probing with rSld5 antibody (and then the secondary 
antibody). The analysis assumed that there was no significant levels of Sld5 in the unspiked 
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control sample, so the relative intensity of that band was assumed to remain the same when 
probed with secondary antibody only or with rSld5 and the secondary antibody. The 
intensity of the unspiked control was therefore used to normalise the intensity of all the 
other bands. Using this assumption, it is clear that the signal in both the spiked and clinical 
urine samples is higher in rSld5B antibody IPs (panel D, compare the red and blue bar for 
each sample). The difference between the normalised signal when probing with the 
secondary antibody and the normalised signal when probing with rSld5 could indicate that 
there is some Sld5 present in those samples that show an increase in the signal. This applies 
to all samples in panel D, implying that Sld5 is present in all the clinical samples. However, 
this interpretation is further complicated by the observation that the addition of rSld5 
antibody also produces a smear of bands of variable intensity in the area between the 
antibody heavy chain and the expected migration point for Sld5 protein (see starred areas in 
panel B). It therefore cannot be excluded that at least some of the increase in signal is due to 
binding of the rSld5 to the smear of bands onto the gel. The identity of the smear of bands 
has not been determined, but is believed to be due to non-specific binding of urinary 
proteins to the protein A beads (data not shown).  
All in all, immunoprecipitation did not conclusively confirm the presence of Sld5 in the 
urine samples of prostate cancer patients, although I do conclude that intact Mcm2 is 
probably not present at detectable levels. Sld5 detection was made extremely difficult by the 
presence of background staining. Clearly, this made the method untenable for the analysis 
of urine samples in the urine study. Now that Sld5 mouse monoclonal antibodies are 
available, it would be informative to revisit these western blots using mSld5A. 
Nevertheless, even if this would solve the background problem, it would only serve as a 
proof-of-principle (or proof-of-presence of Sld5 in the urine) and would not suggest that IP 
is the method of choice for the analysis of the pilot study urine samples. Considering 
multiple shortcomings of the IP approach (long processing time which also affects stability 
of low concentration urinary markers, non-specific binding of urine samples to the beads, 
unsuitability of this technology to mass frontline screening, etc), my efforts would be better 
spent developing an ELISA method. 
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Figure 5.9 Immunoprecipitation attempts of Sld5 and Mcm2 from urine supernatants of five prostate 
cancer patients (gift from CG Scarpini) and a spiked/unspiked control.  (A) Urine samples were split in half 
and immunoprecipitated with either a rabbit Sld5 (rSld5B – alternative antibody to rSld5 used in the rest of the 
thesis) or Mcm2C, a mouse monoclonal Mcm2 antibody that is being commercialised for detection of Mcm2 
in urine. ‘PC’ denotes all the prostate cancer clinical samples, ‘C’ is the control (urine sample for a healthy 
volunteer) and ‘C+Lys’ is the same control urine sample spiked with detergent-lysed EJ28 cells. After 
extensive washing, the beads and any remaining bound proteins were resuspended in 1xLB and analysed by 
immunoblotting using the antibodies indicated on the left (Mcm2 was BM28 antibody) together with the initial 
EJ28 lysate used for spiking (‘Lys’) and whole-cell lysates of EJ28 asynchronously cycling cells (‘EJ28’). 
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Mcm2 doublet could only be detected in the ‘C+Lys’ eluates (see starred lanes).  (B) Repeat immunoblotting 
of the samples from (A), this time first probing the membrane with only the secondary antibody (HRP-labelled 
anti-rabbit) and then with rSld5 followed by the same secondary antibody. Starred areas (*) are believed to be 
due to cross-reactivity of the rSld5 antibody. Arrow denotes the band on the top membrane, which overlays 
with the Sld5-size band on the bottom membrane.  (C) Second repeat of the immunoblotting experiment for 
the purposes of quantification of the band intensity on a 15%(w/v) acrylamide gel with longer running. 
Immunoblotting was performed on a subset of samples (lysates of EJ28 cells used for spiking and eluates of 
IPs with the rSld5B antibody). As in panel B, membrane was first probed with only the secondary antibody 
(HRP-labelled anti-rabbit) and then with rSld5 followed by the same secondary antibody. Arrow denotes the 
band on the top membrane, which overlays with the Sld5-size band on the bottom membrane.  (D) 
Quantification of the images presented in panel C. Sld5-size band was quantified using ImageJ software. The 
intensity of the unspiked control band (‘C’) was used to normalise the signals by dividing all intensities by the 
intensity of ‘C’ band. Results of that operation are represented graphically in D. 
Given inconclusive results from the initial experiments described here, I have so far 
therefore been unable to design a good experimental set-up for analysing the supernatant 
fraction of the urine samples collected for the pilot study. Now that I have characterised 
good Sld5 mouse monoclonal antibodies, I will revisit this after submission of my thesis and 
optimise a sandwich ELISA. To date, I have therefore only been able to analyse the pilot 
study clinical samples by the cytological approach I outlined in section 5.5.2.1. These 
results are presented next. 
5.5.2.3 Preliminary results: Sld5 is present in the cellular fraction 
Urine samples were obtained from men attending the prostate and bladder cancer clinics at 
the Addenbrooke’s Hospital Cambridge with symptoms suggestive of prostate or bladder 
cancers, but before any treatment was started. Patient recruitment and sample collection was 
done by J Burge and colleagues at the clinic. Protease inhibitors were added to the urine 
samples immediately after collection; and care was taken to keep the samples on ice and 
process them as fast as possible, typically within 1h of the clinic closing time. To date, 50 
subjects have been recruited for the study. Of these 17 have been fully analysed by 
multiplex immunofluorescence by two independent observers (Table 5-ii). The remaining 
samples are awaiting the complete clinicopathologic details before the results can be fully 
evaluated. 
Of the subjects described in Table 5-ii, 8 were diagnosed by pathologists to have 
adenocarcinoma (prostate cancer), 4 transitional cell carcinomas (bladder cancer) and 3 
were determined to have benign lesions (no cancer). I also recruited further 2 subjects as 
bona fide healthy controls, who did not attend the examination in the clinic but were 
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considered healthy because of their age (26 and 31) and lack of symptoms of bladder or 
prostate cancer.  
Subject 
ID 
Clinic 
attended 
PSA 
[ng/mL] 
Histology 
grade 
Histology 
stage (TNM) 
Cancer type Sld5-based diagnosis 
(immunofluorescence) 
NM001 Prostate 10.6 G6 pT2   N0 Mx Adenocarcinoma +? (Few cells) 
NM002 Prostate 14.2 G10 pT3b N1 M0 Adenocarcinoma +  (Many cells; see Figure 5.10B1 and B2) 
NM003 Prostate 18.5 G7   T3   Nx Mx Adenocarcinoma +  (Many cells) 
NM004 Prostate 7.0 G7   T3a N0 Mx Adenocarcinoma +  (Many cells; frequent 
apoptotic nuclei; see Figure 5.10B3) 
NM005 Prostate 9.0 G6 pT2   Nx Mx Adenocarcinoma + 
NM006 Prostate 3.8 G6 pT1c Nx Mx Adenocarcinoma +?  (Few cells) 
NM007 Bladder 2.8 G2 pT2   Nx Mx TCC +? (Dirty slide) 
NM008 Bladder 0.85 G3 pT4a N1 M1 TCC + 
NM009 Bladder 0.8 G3 pTa   Nx Mx TCC +? (Dirty slide) 
NM010 Prostate 16.4 G7 pT1c N0 Mx Adenocarcinoma + 
NM012 Prostate 7.5 Benign Benign Benigna – 
NM013 Prostate 53 N.D.   T4   NxM1 Adenocarcinoma – d 
NM014 Bladder N/A G2 pT3a N0 Mx TCC + (see Figure 5.10A) 
NM015 Prostate 6.3 Benign Benign Benignb –?  (Few cells) 
NM016 Prostate 2.8 Benign Benign Benignc –?  (Few cells) 
NMcF N/A N/A N/A N/A Bona fide healthy –  (Many squamous epithelial 
cells due to female origin; see Figure 5.10C) 
NMcM N/A N/A N/A N/A Bona fide healthy – 
 
NMcF – healthy female volunteer (26 years old); NMcM – healthy male volunteer (31 years old). 
PSA – prostate-specific antigen; serum levels at the time of urine collection. TCC – transitional cell carcinoma. TNM – 
tumour-node-metastasis staging. N.D. – no biopsy done due to high PSA levels and other symptoms that confirm prostate 
cancer beyond doubt. 
 
a Same diagnosis using multi-core saturation biopsy 2 months later. 
b Same diagnosis using multi-core saturation biopsy 8 months later. 
c Same diagnosis using multi-core saturation biopsy 3 months later. 
d Significant cell loss during processing. 
 
Table 5-ii Clinicopathologic details of subjects providing urine samples. Histology grading for prostate 
cancer is a Gleason score 1-10; for bladder cancer on a scale of 1-3. Subject NM011 does not exist (numbering 
error at the clinic). Sld5-based diagnosis was determined by qualitatively assessing the number of Sld5-
positive nuclei by indirect immunofluorescence confocal microscopy (Figure 5.10). Presence of 3 or more 
Sld5-positive nuclei of the suspect morphology out of ~75 nuclei examined was classified as positive. 
Question mark next to the diagnosis denotes uncertainty due to small number of cells present on the slide (less 
than ~30 cells). 
I stained the cells isolated from the urine samples of these subjects for Sld5, Mcm2 and PSA 
by immunofluorescence microscopy. Analysis was performed by investigating 
approximately 75 cells per slide (focusing on the cells with suspect morphology and 
ignoring normal squamous epithelial cells) and scoring the nuclear staining of Sld5 and 
Mcm2. A sample was scored positive if there were at least 3 Sld5-positive nuclei present. A 
panel of typical nuclei observed is presented in Figure 5.10.  
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I observed a good agreement between Mcm2 and Sld5 staining in the nucleus, although 
Sld5 staining was generally substantially stronger. In many cases, Mcm2 positivity would 
have probably been missed if it were not for the presence of a stronger Sld5 stain to induce a 
careful examination of those nuclei for presence of Mcm2. The difference was especially 
noticeable when using ProExC as the Mcm2 antibody (Figure 5.10, compare Mcm2 signal 
in panels A and B), which could be because the commercially available ProExC antibody 
mix was optimised for immunocytochemical staining, and not immunofluorescence.  
Sld5-positive cells isolated from prostate cancer patients often displayed a prominent 
cytoplasmic PSA stain (Figure 5.10, B1 and B2), confirming the prostatic origin of the 
Sld5-positive cells. I occasionally observed a PSA-like granular signal in the cytoplasm of 
some of the Sld5-positive cells from bladder cancer patients as well (subject NM014, see 
panel A1), although the signal was often weaker or composed of fewer foci (compare PSA 
staining in NM014 and NM002). I did not detect any PSA staining in the EJ28 (Figure 
5.8B) and RT112 (data not shown) bladder cancer cell lines in my initial tests. Bladder 
cancer often spreads into the prostate, but this was not the case for patient NM014, 
according to the clinical information available. Based on this observation, special care was 
taken that only strong granular PSA staining was classified as cells of prostatic origin.  
All samples contained Sld5 and Mcm2 negative nuclei (see panel C and cells surrounding 
the positive nuclei in panel A), confirming the specificity of Sld5 and Mcm2 staining. Sld5 
and Mcm2 positive nuclei often displayed a stronger (see panel B1) or more reticulate (see 
panel A) DNA stain, as would be expected from cancer cells. Interestingly, some samples 
(e.g. NM002 and NM004, see panel B3) contained multiple fragmented nuclei, typical of 
apoptotic cells. 
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Figure 5.10 Sld5 stains malignant cells of prostate and bladder cancer patients. Indirect 
immunofluorescence confocal microscopy of representative cells retrieved from urine samples of bladder and 
prostate cancer patients, and healthy controls (see Table 5-ii for the clinicopathologic details). ‘Mcm2’ – either 
ProExC or BM28 antibody, as specified.    Scale bar: 10µm. 
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Samples were analysed by two independent observers (AD Mills and myself). Our scoring 
agreed for all the 17 samples the same, as presented in Table 5-ii. Agreement between 
cytology-based Sld5-based diagnosis and the standard biopsy pathological examination was 
good: only 1 out of 17 samples was misdiagnosed by Sld5 immunofluorescence (NM013). 
This was possibly due to insufficient cell recovery, as recorded in the sample database at the 
time of processing. It should be noted that there was a number of possibly unreliable 
diagnoses due to fewer than approx. 30 cells present on the slide. It is hoped that automated 
ScanR-based quantification, which I am optimising at the moment, will help to speed up the 
analysis of future samples, especially those with fewer numbers of cells on the slide (where 
exhaustive scanning of the coverslip is needed to obtain sufficient cell numbers).  
Taken together, the preliminary results of the cytological analysis of the pilot study indicate 
that Sld5 can be detected in the cells isolated from urine of prostate and bladder cancer 
patients but not in the cells from healthy controls. A more precise specificity and sensitivity 
of the marker will be determined once all 50 samples have been analysed. At first 
assessment, specificity appears to be 100% as there were no false-positives and sensitivity 
appears to be over 90% due to 1 false-negative diagnosis; with a cautionary note that these 
values are probably overestimates due to the underrepresentation of asymptomatic cases and 
healthy individuals in the study. Similarly to the assessment of malignant colonocyte 
staining in 5.5.1, Sld5 does not appear to offer a quantitative advantage over Mcm2 in the 
number of positive nuclei, but might ease the identification of positive nuclei owing to the 
increased strength of staining. This supports the in vitro observations presented above, 
which suggested that Sld5 is more stable than Mcm2 in urine samples (5.4).  
Based on these preliminary results, Sld5 holds promise as a urine-based marker of male 
genito-urinary cancers. Although Mcm2 is already established as a reliable marker for the 
cell-based detection method for bladder cancers (CG Scarpini and N Coleman, personal 
communication), there is as of yet no reliable cell-based marker for the detection of prostate 
cancer. Sld5 could fill this gap, subject to further validation and comparison using the more 
readily commercialisable mSld5A antibody on immunohistochemistry, which is the 
experimental method of choice for pathologists. What is more, the confirmed presence of 
Sld5 in cells isolated from urine further supports the hypothesis that Sld5 is released into the 
urine supernatant. This further justifies the plan to perform Sld5-ELISAs of urine 
supernatants collected during the course of this study upon submission of this thesis.  
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Discussion 
In this chapter, I describe the characterisation of GINS subunits Psf3 and Sld5 as 
proliferation markers and explore the possibility of using Sld5 for cancer detection. So, 
what does my work indicate about the quality of GINS proteins as proliferation markers and 
markers for cancer?  
Sld5 behaves very similarly to Mcm2 when cells enter quiescence (Figure 5.1) and displays 
a comparable staining pattern in tissue sections of normal, dysplastic and malignant origin 
in a range of tissues (Figure 3.18, Figure 5.2). This is not surprising, given the tight 
functional association of GINS and MCM complexes in the process of DNA replication 
(Moyer et al., 2006) and would suggest that Sld5 protein does not offer anything in the field 
of proliferation markers that the well-characterised MCM proteins cannot already offer. 
GINS proteins are also less abundant than MCM, although more abundant than Cdc45 
(Table 4-i), which has also been characterised as a proliferation marker (Pollok et al., 2007). 
One might therefore conclude that Sld5 protein could be classed as an equivalent 
proliferation marker to the MCMs if it was not for its superior stability. The real advantage 
of Sld5 is only revealed when considering exfoliated cells and their fragments in isolation, 
and not as part of a living tissue or a population of cultured cells ex vivo. In such situations 
(e.g. when cells are bathed in urine), Sld5 has the potential to outperform Mcm2 due to its 
superior stability. How significant this superior stability is for the purposes of cancer 
detection requires further validation. So far I have only validated Sld5 stability in vitro 
(Figure 5.4, Figure 5.5, Figure 5.6) and by small-scale ‘proof of principle’ studies using 
methods other than those preferred by pathologists (immunofluorescence staining of 
malignant colonocytes and malignant cells from urine specimens – Figure 5.7 and Figure 
5.10). Nevertheless, the initial results are promising at the qualitative level, which might 
well translate into a significantly improved sensitivity of detection, depending on the 
application and optimisation of antibody procedures.  
Some studies suggest that GINS subunits could be involved in oncogenesis (Obama et al., 
2005, Lau et al., 2007, Nagahama et al., 2010). Do my findings support this functional 
association? In our tissue staining experiments, GINS subunits, especially Sld5, displayed a 
staining pattern that mirrors Mcm2 staining (Figure 5.2). Mcm2 is a clear cell cycle marker 
with no implications in oncogenesis; evidence to the contrary is circumstantial and/or 
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restricted to animal models at best (Shima et al., 2007). Given the similarities in the staining 
pattern of Sld5 and Mcm2, our data argues against GINS subunits playing a role in such 
processes. Tumour cells express GINS proteins (e.g. Figure 5.2) and might even upregulate 
the protein (Aparicio et al., 2009) or mRNA levels (Obama et al., 2005, Thomassen et al., 
2009), but this could be a consequence rather than the cause of oncogenesis. Furthermore, 
the upregulation of protein levels could be a simple response to the increase in the cellular 
DNA levels in dysplastic and neoplastic cells, as has previously been shown to be the case 
for Mcm5 (Freeman et al., 1999).  
My evaluation of GINS antibodies as detection reagents for cancer has so far been focused 
on Sld5 owing to the inclusion of this subunit but not Psf3 in the patent claims (Bell, 2006) 
and the availability of mouse monoclonal antibodies (see section 3.2.2). However, the data 
presented in this chapter (see section 5.2) also indicates that Psf3 could offer 
complementary characteristics to Sld5. However, before Psf3 is further evaluated as a 
cancer marker, some care has to be taken to clarify whether the Psf3 expression pattern is 
significantly different from Sld5, or just a result of differences in antibody 
concentration/affinity or Psf3 stability, as discussed in section 5.2. Depletion of individual 
GINS subunits by siRNA results in concomitant reduction in the levels of other GINS 
proteins, as demonstrated in this thesis (Figure 3.17B) and by others (Aparicio et al., 2009). 
This would therefore suggest that GINS subunits do not exist in isolation. However, there 
are a couple of reports that argue otherwise. For example, differential expression of various 
GINS mRNA species has been observed in Xenopus laevis during embryonic development 
(Walter & Henry, 2004); although it should be noted that the authors did not correlate this 
with differential protein levels. In cardiac biology, the PSF3 gene locus (or ‘GINS3’) has 
been identified as a regulator of the QT interval in a zebrafish genetic screen (Milan et al., 
2009). Furthermore, two independent genome-wide association studies in humans suggest 
that this function of Psf3 is conserved in humans (Pfeufer et al., 2009, Newton-Cheh et al., 
2009). This might suggest that Psf3 functions in processes other than DNA replication in 
differentiated cells that no longer proliferate. However, it is possible that although Psf3 is an 
important determinant of the myocardium function, its effects may be temporarily restricted 
to the developmental stage, when myocardiac precursor cells are still in cycle and therefore 
likely to be expressing all GINS subunits. The literature does not exclude this possibility. 
All in all, the ability of Psf3 and other subunits to exist and function independently deserves 
further attention. This might also shed more light onto the seemingly incomplete 
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colocalisation of GINS subunits when examined by high-resolution confocal microscopy 
(see Figure 4.12). 
Apart from clarifying the expression pattern of Psf3 in relation to cell proliferation, the two 
most important priorities for further development of this work are: 
(1) Further validation of the promising results of Sld5 sensitivity and specificity for 
detection of prostate cancer by cytology of cells isolated from urine. This further 
validation should preferably employ the mSld5A and ProExC antibodies by 
immunohistochemistry to achieve the most relevant comparison. Validation could 
also be extended to include a comparison of mSld5A and Mcm2 in detecting 
malignant colonocytes from right-sided colorectal cancers (Figure 5.7). At the very 
least, positive findings from these validations could indicate that current industry 
standard proliferation marker reagents, such as the ProExC antibody, would benefit 
from the inclusion of mSld5A or equivalent antibodies in its cocktail.  
(2) Detection of free Sld5 protein in urine supernatants by a method suited to mass 
frontline screening, such as ELISA. Given the promising preliminary results of the 
pilot study (Sld5-positive cells are readily and specifically detected in urines of 
cancer patients), ELISA is the obvious next step. ELISA would draw together a 
wide range of reagents, experimental procedures and important findings made 
throughout the course of my doctoral research. Chiefly, I could capitalise on: 
a. The availability of highly characterised antibodies from two different 
species, at least one of which has already been confirmed to work for IP 
(Figure 3.19B); 
b. Ability to produce recombinant Sld5 protein (3.1) for optimisation studies 
and as a standard; 
c. The set of experiments in this final chapter, showing that Sld5 is present in 
the cells incubated in urine (Figure 5.10), that these cells release their content 
into the urine supernatant (Figure 5.6) and that the released Sld5 is more 
stable than Mcm2 (Figure 5.4, Figure 5.5), the current marker of choice for 
urine cytology (Stoeber et al., 2002).  
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If successful in optimising the ELISA and detecting Sld5 in the clinical samples, I hope to 
change the focus of my pilot study from a two-pronged approach of fractionating the 
samples into pelletable and supernatant fractions to collecting the sample for ELISA only. 
Freezing the samples without fractionation (possibly with the addition of a detergent) would 
aid cell lysis, thus releasing even more protein into the urine supernatant and would at the 
same time simplify the processing required upon sample collection, making this an ideal 
application to develop as a diagnostic (screening) tool. Sld5 ELISA, if successful, could be 
combined with a urine ELISA for microseminoprotein-beta (MSMB). This ELISA is 
currently being developed by HC Whitaker, DE Neal and colleagues at the Cancer Research 
Institute UK in Cambridge (Whitaker et al., 2010). The test is based on measuring the 
disappearance of MSMB protein upon the appearance of prostate cancer. Since Sld5 ELISA 
would measure the rise in the signal, the application of these two tests in parallel could 
significantly improve the reliability and sensitivity of the results. 
Returning to the key requirements for biomarkers in prostate and bladder cancer screening, 
as described in the introduction (page 135), is Sld5 well suited to meet the expectations?  
The benefits of a supernatant-based approach over cytology-based detection methods as a 
frontline procedure are numerous, including the ease of screening implementation, 
decreased requirement for specialist personnel and decreased cost. As such, a supernatant-
based ELISA method would be ideal to fill the gap for early bladder cancer detection and 
close monitoring post-treatment. In prostate cancer, the requirement is again for a method 
that allows frequent cheap monitoring of the risk population, but also for a marker with a 
higher prognostic value (i.e. marker that would differentiate between aggressive tumours 
and those that do not require aggressive treatment), as explained in the introduction. As 
such, the proliferative potential (which correlates with the expression levels of cell cycle 
proteins such as Sld5) could again add important information to the currently available PSA 
tests.  
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Chapter 6 General discussion and conclusions 
 
In this thesis, I have established a set of validated GINS antibody reagents and have used 
them to tackle two quite different biological questions: one was exploring the high-
resolution subnuclear localisation of the staining identified with the antibodies and the other 
one is the use of these antibodies in evaluating GINS proteins, chiefly Sld5, as markers for 
cancer detection. These two avenues of work also resulted in quite different levels of 
success: whilst Chapter 5 showed that Sld5 is a promising marker for cancer detection that 
deserves to be tested for use in ELISA-based detection of soluble Sld5 protein in urine 
samples, Chapter 4 could not address its aims entirely, given the insufficient colocalisation, 
as presented in Figure 4.12. Given that both chapters use the same antibody reagent, it is 
important to stress that the confusing results in Chapter 4 are thought very unlikely to affect 
the conclusions drawn from the data presented in Chapter 5, since the two chapters use the 
antibodies in very different ways (using different techniques or at a different scale of 
magnification). I therefore have full confidence in my conclusion from Chapter 5 that Sld5 
is specifically expressed in proliferating cells, as identified by immunohistochemistry 
(Figure 3.18, Figure 5.2), and that Sld5 is probably more stable in harsh extracellular 
environments, such as urine, as shown by immunoblotting (Figure 5.5 and Figure 5.6).  
The biggest overlap, technically, between Chapters 4 and 5 is the use of multiplex confocal 
microscopy to investigate the staining of Sld5 and Mcm2 in clinical samples (colonocytes 
isolated from stool and cells isolated from urine samples). Importantly, the 
immunofluorescence experiments in Chapter 5 use the same technique as those analysing 
the subnuclear localisation of GINS in Chapter 4, but in a different way. The assay in 
Chapter 5 is simply looking for the presence or absence of a nuclear stain. Having validated 
that the GINS antibodies recognise nuclei of cycling cells, but not those in quiescence 
(Figure 5.1) or having undergone differentiation (Figure 5.2). I am very confident that the 
staining presented in Figure 5.10 and Figure 5.7 is due to presence of Sld5 in those nuclei. 
The one cautionary note I would raise is that perhaps I cannot vouch for the intensity of the 
staining. Thus my comments that Sld5 stain was always easier to score, should perhaps be 
moderated until results can be corroborated by comparing the two antibodies (Mcm2 an 
     
  168 
Sld5) on comparable clinical samples by immunohistochemistry. Nevertheless, my 
comparison of the antibody immunofluorescence in tissue culture cells (Figure 5.8B) did not 
detect as marked a difference between the two antibodies as in the clinical samples. This 
suggests that the differences in intensities that I observed in the clinical samples are due to 
increased stability of Sld5 in those samples, a positive feature.   
Nevertheless, if there is something I had learnt during the progress of the research presented 
in Chapter 4, it is that one can never be too cautious. Despite the fact that I have so far been 
unable to provide a definitive conclusion to my observations in that chapter, the path which 
that project took was a useful one, albeit very frustrating at times. As a result of all the 
troubleshooting I had to do, I feel that this has really increased my understanding of the 
confocal microscopy and made me a lot more aware of the potential pitfalls of this 
technique and antibody procedures in general, and the ways in which data collection and 
processing can be optimised.  
The paradox of GINS antibody staining is extensively discussed at the end of Chapter 4, and 
there is not much that I feel I can add to that until some more work can be done to try to 
elucidate this conundrum. The only thing I would metnion is that during a recent review of 
the GINS genomic data available at NCBI, I discovered that there are now three human Psf3 
isoforms listed in the database (Figure 6.1). It remains to be determined whether alternative 
transcripts exist in the cell types and tissues that I investigated during my doctorate and 
whether that could explain some of the puzzling observations (is it, for example, possible 
that not all antibodies recognise the same isoform). Furthermore, alternative splicing of 
PSF1 has recently been reported in mice (Han et al., 2009), and is something that has not 
been explored, to my knowledge, in human cells. During the initial cloning of Psf3, I did 
amplify PCR bands of other sizes, one of which appeared very similar to the size expected 
of Psf3 isoform a mRNA (data not shown). However, the western blotting suggests that Psf3 
isoform b is the predominant protein form, since there are no other bands of equal intensity 
present on the western blot that could correspond to isoforms a and c (Figure 3.7C). 
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Psf3 isoform a GINS3 isoform a 28,644Da (mRNA has 4 exons) 
Psf3 isoform b GINS3 isoform b 24,404Da (mRNA missing exon 2) 
Psf3 isoform c GINS3 isoform c 15,524Da (mRNA missing exons 2 and 3) 
 
HsPsf3a  MSEAYFRVESGALGPEENFLSLDDILMSHEKLPVRTETAMPRLGAFFLERSAGAETDNAV 60 
HsPsf3c  MSEAYFRVESGALGPEENFLSLDDILMSHEKLPVRTETAMPRLGAFFLERSAGAETDNAV 60 
HsPsf3b  MSEAYFRVESGALGPEENFLSLDDILMSHEKLPVRTETAMPRLGAFFLERSAGAETDNAV 60 
         ************************************************************   
 
HsPsf3a  PQGFALLPRLECSGVIWLTAALTSQAPEILPPQPPMWLVLQGSKLELPLWLAKGLFDNKR 120 
HsPsf3c  PQ---------------------------------------------------------- 62 
HsPsf3b  PQG---------------------------------------SKLELPLWLAKGLFDNKR 81 
         **                                                           
 
HsPsf3a  RILSVELPKIYQEGWRTVFSADPNVVDLHKMGPHFYGFGSQLLHFDSPENADISQSLLQT 180 
HsPsf3c  -----------------------------------------------------------T 63 
HsPsf3b  RILSVELPKIYQEGWRTVFSADPNVVDLHKMGPHFYGFGSQLLHFDSPENADISQSLLQT 141 
                                                                    *   
 
HsPsf3a  FIGRFRRIMDSSQNAYNEDTSALVARLDEMERGLFQTGQKGLNDFQCWEKGQASQITASN 240 
HsPsf3c  FIGRFRRIMDSSQNAYNEDTSALVARLDEMERGLFQTGQKGLNDFQCWEKGQASQITASN 123 
HsPsf3b  FIGRFRRIMDSSQNAYNEDTSALVARLDEMERGLFQTGQKGLNDFQCWEKGQASQITASN 201 
         ************************************************************   
 
HsPsf3a  LVQNYKKRKFTDMED 255  
HsPsf3c  LVQNYKKRKFTDMED 138  
HsPsf3b  LVQNYKKRKFTDMED 216  
         ***************  
 
Figure 6.1 Comparison of the human Psf3 isoform a, b and c basic information and the alignment of the 
protein sequences. Sequences were aligned using ClustalW2 (Larkin et al., 2007). 
 
To finish on a positive note, my work has been very successful in the preliminary validation 
of GINS as proliferation markers that could one day have clinical significance. Beyond the 
directions that I have explored in my thesis, I am also looking for further ways to validate 
Sld5 as a cancer marker. For example, I have initiated a collaboration with Sir Walter 
Bodmer, with the aim of improving the diagnostic potential of circulating tumour cell 
(CTC) detection in blood. Our working hypothesis for this collaboration is that the increased 
presence of MCM or GINS positive CTCs would imply a more aggressive cancer with a 
higher chance of metastases.  
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